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Heme oxygenase (HO) is an enzyme that facilitates the oxidative breakdown of free 
heme into equi-molar concentrations of carbon monoxide (CO), the bile pigment 
biliverdin IX and free iron. These products have immuno-modulatory and anti-
oxidative properties, which may be useful in the treatment of diseases characterised 
by low-grade inflammation and oxidative stress, such as insulin resistance and 
hyperglycaemia in type 2 diabetes. In fact, HO-1 protein levels and carbon monoxide 
generation are down-regulated in murine models of obesity and type 2 diabetes. Two 
independent research teams have reported that pharmacological induction of HO 
activity by protoporphyrin-based compounds, such as hemin and cobalt (III) 
protoporphyrin IX chloride (CoPP), exerts anti-diabetic effects, including protection 
from weight gain, systemic inflammation and peripheral insulin resistance, in various 
experimental models of type 2 diabetes. However, the relative insolubility and 
instability of hemin in solution and the multiple side-effects of CoPP, including 
weight loss, preclude their use for the treatment of patients in clinic.  
 
Heme arginate (HA) is a stable and soluble composition of hemin and L-arginine 
(LA) in a solution containing propylene glycol, ethanol and water. Furthermore, HA 
is licensed for the treatment of acute porphyria in several European countries. 
Therefore, HA may potentially be used in clinical trials. The current PhD thesis tests 
the hypothesis that the heme component of HA ameliorates hyperglycaemia via 
induction of HO activity in the leptin receptor deficient db/db (db/db) mouse 
model of type 2 diabetes.   
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A preliminary in vivo study demonstrates that the heme but not the LA component of 
HA exerts an anti-hyperglycaemic effect in db/db mice. In a separate in vivo study, 
concomitant treatment of HA with stannous (IV) mesoporphyrin IX dichloride (SM), 
an inhibitor of HO activity, further improves the glycaemic control despite complete 
abrogation of the HA-mediated increase in HO activity in db/db mice. This result is 
in contrast to the above stated hypothesis, and demonstrates that the anti-
hyperglycaemic effect of HA is due to a HO activity independent mechanism. 
Furthermore, the ameliorative effect of HA and HA+SM treatment on 
hyperglycaemia in db/db mice coincides with a gain in body and visceral fat weight, 
a reduction in islet β-cell inflammation and the preservation of islet β-cell function. 
Subsequent in vitro experiments demonstrate that HA exerts anti-inflammatory 
effects by a HO activity independent mechanism in pro-inflammatory in vitro models 
such as in cytokine mix-stimulated MIN6 β-cells and in classically activated bone 
marrow derived macrophages (BMDMs).  
 
In conclusion, the current thesis demonstrates the novel finding that the heme 
component of HA can exert anti-inflammatory and anti-diabetic effects via a HO 
activity independent mechanism. Future work should focus on studies to test the 
hypothesis that the interaction of heme with the nuclear receptor Rev-erb-α is 
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1.1. DIABETES MELLITUS (DM) 
 
Diabetes mellitus (DM) can be described as ‘‘a metabolic disorder of multiple 
aetiology characterised by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, 
insulin action, or both’’ (Alberti et al., 1999). Insulin, a hormone secreted by 
pancreatic β-cells plays a vital role in regulating glucose homeostasis (Seino et al., 
2011). The development of DM is dependent on pathogenic processes which either 
cause loss of pancreatic β-cells resulting in consequent insulin deficiency, or promote 
resistance to insulin action in the insulin responsive organs (Gavin et al., 2002). 
 
1.1.1. HISTORICAL PERSPECTIVE OF DM 
 
DM has a remarkable history of discoveries spanning over 3500 years. The ancient 
Egyptians were the first to acknowledge and document the polyuric state associated 
with DM around 1550 BC. The term ‘‘Diabetes’’ itself was coined by Greek 
physician Aretaeus in the first century AD to describe a disease state with symptoms 
of polyuria, polydipsia and weight loss (Sanders, 2002). Later, English 
neuroanatomists Thomas Willis added the latin term ‘‘mellitus’’ to describe the 
sweet taste of diabetic urine in 1675. The first experimental evidence of the presence 
of excess glucose in urine of diabetic subjects was presented by Matthew Dobson in 
1776  (Sanders, 2002, Molnar, 2004). In 1889, Oskar Minkowski and Joseph von 
Mering, employed total extirpation of the pancreas in the dog in order to test the 
hypothesis that free-fatty acids (FFA) were vital for fat absorption, and unexpectedly 
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found that the pancreas was essential for blood sugar control. This remains one of the 
most significant discoveries of experimental medicine (Luft, 1989).  Over 30 years 
later, the collective effort of the Canadian research team of J.J.R. Macleod, F.G. 
Banting, Charles Best, J.B. Collip and Eli Lilly and Company led to the first 
successful clinical use of pancreatic insulin extract to treat diabetes (Banting et al., 
1922, Rosenfeld, 2002). In 1936, the first report distinguishing between the two 
distinct types of DM i.e. insulin-sensitive and insulin-insensitive was published in the 
Lancet (Himsworth, 1936) by the British scientist Sir Harold P. Himsworth. 
 
1.1.2. CLASSIFICATIO& SYSTEM FOR DM 
 
The first organised effort to address the chaotic nomenclature and classification of 
DM was made in 1979 by National Diabetes Data Group (NDDG). Subsequent 
reviews were made in 1980, 1985 and 1997 (Alberti et al., 1999) by the World 
Health Organisation (WHO). The current classification system is based on 
recommendations made by a joint review conducted by the WHO and the 
International Diabetes Federation (IDF) in 2005. There are three broad 
etiopathogenetic categories of classification: 
 
i. Type 1 diabetes (T1D): Previously known as insulin-dependent DM as the 
patients required routine insulin replacement therapy for survival (Gavin et al., 
2002). Type 1 diabetes arises due to destruction of β-cells or insulin either by 
auto-antibodies (auto-immune type 1 diabetes) or for other as yet unknown 
reasons (idiopathic type 1 diabetes), which results in absolute insulin deficiency 
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and leads to hyperglycaemia and ketoacidosis (Yoon and Jun, 2005, Notkins and 
Lernmark, 2001). The mechanisms promoting autoimmunity are poorly 
understood, but it is believed to be triggered by interactions between 
environmental and genetic susceptibility factors (Alberti et al., 1999). 
 
ii. Type 2 diabetes: Previously known as non-insulin dependent DM (NIDDM) as 
patients survived even without insulin replacement therapy (Gavin et al., 2002). 
Type 2 diabetes occurs due to the development of resistance to insulin action in 
peripheral organs and a relatively inadequate insulin secretion by β-cells 
(Lebovitz, 2002, Kahn et al., 2006). The aetiological factors are not well 
understood, however, obesity, high calorie diet and lack of physical activity are 
increasingly associated with the development of type 2 diabetes (Kahn and Flier, 
2000). As the focus of the current thesis is on type 2 diabetes, the 
pathophysiology of type 2 diabetes will be discussed in more detail in section 1.3. 
 
iii. Other specific type: DM arising due to specific aetiological causes which result 
in specific genetic and immunological defects leading to hyperglycaemia is 
clustered in this group. Cases of hyperglycaemia occurring during pregnancy 
(gestational DM), due to maturity-onset diabetes of young, damage to the 
exocrine pancreas, genetic mutations of insulin receptors and infection and 
chemical induced damage to islet β-cells constitute this group (Alberti et al., 




1.1.3. PREVALE&CE OF DM 
 
The western world, as well as developing countries, faces a paramount challenge 
posed by an increase in the prevalence of DM, as each year over 10 million new 
cases of DM are detected worldwide (Wild et al., 2004, Shaw et al., 2009). The 
percentage of death due to DM associated complications is alarmingly high, 9 to 18 
% in persons aged 35-64 years in the U.S.A., Europe and South-east Asia (Roglic et 
al., 2005). The Scottish diabetic survey conducted by the National Health Service 
(NHS) Scotland is reflective of the worldwide concern regarding the increase in the 
incidence of type 2 diabetes. There has been a steady increase in the incidence of 
type 2 diabetes from 1.5% to 4% of the Scottish population between 2001 and 2010 
(Figure 1.1; Source: NHS Scottish Diabetic Survey publications, 
http://www.diabetesinscotland.org.uk/Publications.aspx?catId=3). In the same period 
of time, the incidence of type 1 diabetes has remained below 0.5% of the population. 
 
 
Figure 1.1 Incidence of type 1 and 2 diabetes in Scotland between 2001 and 2010. 
Source: National Health Service (NHS), U.K. Scottish Diabetes Survey 
(http://www.diabetesinscotland.org.uk/Publications.aspx?catId=3). Data is crude 
percentage prevalence calculated based on the number of patients with type 1 and type 
2 diabetes who are registered on the national diabetes database. 
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1.1.4. COMPLICATIO&S OF DM 
 
The onset of DM can lead to the development of long-term vascular complications 
which contribute to the increased morbidity and mortality associated with DM. The 
network of arteries and capillaries responsible for constant blood supply to vital 
organs are severely put under stress by the injurious effects of pathophysiological 
concentrations of glucose in the blood (Fowler, 2008, Standl et al., 2011). Factors 
such as obesity, smoking, blood pressure and cholesterol levels increase the risk of 
vascular complication in DM (Van Gaal et al., 2006, Price et al., 1999, Fowler, 2008, 
Staessen, 2008). The vascular complications of DM are categorised into macro- and 
micro-vascular complications. 
 
1.1.4.1. MACRO-VASCULAR COMPLICATIO&S 
 
Large population studies have demonstrated a strong correlation between DM and 
cardiovascular disease (CVD) which remains the primary cause of mortality in 
people with DM (Ledru et al., 2001). The narrowing of the arterial walls, a 
pathophysiological feature of atherosclerosis is the hallmark of macrovascular 
complication that includes coronary and peripheral arterial diseases (Fowler, 2008). 
Immune cell infiltration, especially macrophages and T-lymphocytes, and their 
interaction with oxidised lipid molecules to form foam cells is a critical feature in 
generating atherosclerotic lesions that lead to thrombosis and organ infarction 
(Hansson, 2005).  
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The precise mechanisms by which diabetic conditions lead to atherosclerotic plaque 
formation in CVD are not well understood (Fowler, 2008). One would expect 
therapeutic interventions targeting hyperglycaemia to improve CVD outcome. 
However, reports from prospective studies such as the United Kingdom Prospective 
Diabetes Study (UKPDS) suggests otherwise, as no significant improvement in 
cardiovascular outcomes was noted in patients with type 2 diabetes on treatment with 
insulin or sulfonylureas (Turner et al., 1998). Hence, treatments exclusively targeting 
hyperglycaemia may be inadequate for reducing atherosclerotic plaque formation. 
 
One potential mechanism by which hyperglycaemia may link to endothelial 
dysfunction is via endothelium-derived nitric oxide (NO). In normoglycaemia NO 
has vasoprotective properties: it promotes dilatation of blood vessels and inhibits 
oxidation of low density lipoprotein (LDL) cholesterol, platelet aggregation and 
proliferation of vascular smooth muscle cells (Forstermann and Munzel, 2006, 
Forstermann, 2008). However, hyperglycaemia-induced free radical production and 
reactive oxygen species (ROS) formation may abrogate the vasoprotective actions of 
NO via oxidative inactivation of NO by superoxide (O2
.) and the consequent 
formation of peroxynitrite (Peluffo and Radi, 2007). 
 
1.1.4.2. MICRO-VASCULAR COMPLICATIO&S 
 
Gluco-toxicity mediated damage of small blood vessels lead to microangiopathy-
related complications including diabetic retinopathy, diabetic neuropathy and 
diabetic nephropathy. The duration and severity of gluco-toxicity increases the risk 
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of diabetic retinopathy and neuropathy (Fowler, 2008). Diabetic patients with micro-
albuminuria (defined as excretion of albumin at a rate of 30-299mg/24 hours) are at a 
greater risk of diabetic nephropathy which is the leading cause of renal failure and 
associated mortality in United States (Dronavalli et al., 2008).  
 
Gluco-toxicity mediated dysfunctions of the endothelial cell lining of blood 
capillaries are primarily responsible for micro-vascular complications. Endothelial 
cell damage in micro-vascular diseases is closely associated with numerous 
molecular signalling pathways: protein kinase C (PKC) activation, advanced 
glycation end product (AGE) production, an increase in the sorbitol-aldose reductase 
(polyol) pathway and hexosamine pathway flux (Vasavada and Agarwal, 2005). 
Hyperglycaemia stimulated ROS production by the mitochondrial electron chain has 
been implicated in endothelial cell damage (Reusch, 2003). Elevated ROS 
production in the endothelial cells mediate DNA strand breaks and subsequent 
activation of Poly (ADP-ribose) polymerase (PARP) that facilitates inactivation of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an important enzyme of 
glycolytic pathway necessary for optimal glucose metabolism. Inhibition of GAPDH 
activity shunts glucose into the polyol pathway and leads to activation of PKC by 
diacylglycerol and stimulation of AGE production (Figure 1.2) (Nishikawa et al., 
2000, Du et al., 2003).  
 
There is also evidence of a pro-inflammatory response in micro-vascular 
complication. ROS generation has been reported to increase transcription activity of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in endothelial 
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cells (Nishikawa et al., 2000, Reusch, 2003). A recent study in the db/db mouse 
model of diabetic nephropathy has shown correlation between increased macrophage 
infiltration in the kidney and hyperglycaemia, albuminuria, glomerular and tubular 




Figure 1.2 Diagrammatic representation of the gluco-toxicity mediated damage of 
the endothelial cells in the micro-vascular complications of DM. Elevated levels of 
blood glucose (hyperglycemia) increases the glucose and mitochondrial energy 
substrate flux resulting in an increase in generation of reactive oxygen species (ROS, 
O2
-) which can cause breakage of DNA strands and activate PARP. PARP inhibits 
GAPDH activity which activates signalling pathways such as the polyol and glucosamine 
flux, PKC and AGE that are associated with the pathophysiology of micro-vascular 
complications of DM. Abbreviations. GAPDH: Glyceraldehyde 3-phosphate 
dehydrogenase, DAG: Diacylglycerol, PKC: Protein kinase C, AGE: Advanced glycation 
end product, PARP: Poly (ADP-ribose) polymerase. Picture adapted from Reusch, 
J.E.B. 2003. Diabetes, microvascular complications, and cardiovascular complications: 
what is it about glucose. The Journal of Clinical Investigation 112 (7). Pg. 987. 
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1.1.5. CLI&ICAL MA&AGEME&T OF DM 
 
The worldwide increase in the incidence of DM presents a daunting task for health 
care management. Due to the chronic nature of the disorder, treatment must be 
targeted at maintaining glycaemic control and also preventing and treating 
macrovascular and microvascular complications. Insulin replacement therapy 
remains the mainstay treatment for type 1 diabetes, and this requires regular 
monitoring of blood glucose levels to ensure efficacy and avoid hypoglycaemic 
excursion (Gallen, 2004, Owens et al., 2001). Pancreas or islet β-cell transplantation 
is an alternative for treatment of type 1 diabetes, however, this requires the use of 
immuno-suppressants which can increase the life-long risk of a plethora of infectious 
agents and malignancies and there is a possibility of recurrence of the disease 
particularly with islet transplant (Reach, 2001, Vendrame et al., 2010). 
 
Research spanning decades has increased the present understanding of the molecular 
and cellular regulation of energy homeostasis but has not translated into therapeutic 
interventions. The clinical management of type 2 diabetes has been largely restricted 
to therapies involving insulin analogues and insulin secretagogues, like 
sulfonylureas, which promote insulin secretion from β-cells (Robertson et al., 2003, 
Sheehan, 2003). In addition, oral agents such as metformin [modulator of 5' 
adenosine monophosphate-activated protein kinase (AMPK)] and the 
thiazolidinedione group of compounds [nuclear receptor peroxisome proliferator-
activated receptors-gamma (PPAR-γ) agonist] reduce hepatic glucose production and 
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promote insulin sensitization in peripheral organs (Figure 1.3) (Zhou et al., 2001, 
Hawley et al., 2002, Maeda et al., 2001, Day, 1999, Cheng and Fantus, 2005).  
 
Chronic low-grade inflammation is a key component of the pathophysiology of 
obesity-associated type 2 diabetes (Donath and Shoelson, 2011) and represents an 
interesting target for therapeutic intervention. Indeed, trials employing interleukin-1β 
receptor antagonists (IL-1Ra) have already demonstrated the efficacy of this 




Figure 1.3 Diagrammatic representation of the target organs and action of anti-
hyperglycaemic agents in type 2 diabetes. Text in blue represents the action, text in 
green represents the anti-hyperglycemic agents, and green and red circles represent the 
mode of action of the agents. Abbreviations. FFA: Free fatty acid. Picture adapted 
from Cheng, A.Y.Y. and Fantus, I.G. 2005. Oral antihyperglycemic therapy for type 2 




1.2. I&SULI&: A& OVERVIEW 
 
Insulin, secreted by the β-cells residing in islet of Langerhans in the pancreas, is a 
key hormone regulating glucose homeostasis. Insulin secretion is tightly regulated by 
nutrient status and hormonal factors such as incretins secreted from gastrointestinal 
tract (Seino et al., 2011). Importantly, insulin action in peripheral insulin-sensitive 
organs, including muscle, liver and adipose tissue is indispensable for maintaining 
glycaemic control (Ferrannini, 1998).  
 
1.2.1. I&SULI& BIOSY&THESIS 
 
The expression of insulin gene is restricted to islet β-cells. A highly conserved 
insulin promoter region is present ~340 base pair upstream of the transcription 
initiation start site (Qiu et al., 2002). Transcription of insulin gene is regulated by 
transcription factors, including pancreatic and duodenal homeobox-1 (PDX-1), β-cell 
E-box transactivator (BETA)/NeuroD and RIPE3b1/MafA (Kim et al., 2012). 
Glucose mediates insulin gene expression by promoting PDX-1 and MafA binding to 
A3 and C1 transcription control elements, respectively (Poitout et al., 2006). 
 
Preproinsulin is the primary translation product of insulin gene. Preproinsulin, a 
precursor of the functional insulin polypeptide, is synthesised in the cytoplasm. 
Preproinsulin has a signal peptide, which confers inactivity to the preproinsulin 
polypeptide (Weiss, 2009). The interaction between the signal peptide of 
preproinsulin and the signal recognition particle on the endoplasmic reticulum (ER) 
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membrane facilitates translocation of preproinsulin into the lumen of ER. Proteolytic 
cleavage of the signal peptide from preproinsulin polypeptide in the lumen of ER 
produces proinsulin. Proinsulin undergoes post-translational modification to form 
three disulphide bonds vital for proinsulin stability (Harding and Ron, 2002, Kim et 
al., 2012). Proinsulin is delivered to the Golgi apparatus and gets packaged into 
clathrin-coated secretory granules (Orci et al., 1987). Peptidases cleave proinsulin 
into insulin and C-peptide. Insulin crystals are stored as hexamer molecule and are in 
inactive state (Orci et al., 1984). 
 
1.2.2. I&SULI& SECRETIO& 
 
Glucose-dependent insulin secretion by β-cells is facilitated by presence of channels 
that allow flow of ions, particularly potassium (K+) and calcium (Ca2+) ions, into and 
out of the cell. Glucose transporter 2 (GLUT2), a transmembrane carrier protein, acts 
as glucose sensor in islet β-cells and mediates glucose entry into the β-cells (Prentki 
and Nolan, 2006). Glucose undergoes phosphorylation by the rate-limiting enzyme 
glucokinase to generate glucose-6-phosphate (G-6-P), which consequently passes 
through the glycolytic pathway to form pyruvate. Pyruvate dehydrogenase 
metabolises pyruvate to generate acetyl-CoA which enters the tricarboxylic acid 
cycle to generate adenosine-5'-triphosphate (ATP). The increase in ATP/ADP 
(adenosine diphosphate) ratio results in closure of ATP-gated potassium channel 
(Jones and Persaud, 1998). The closure of potassium channel facilitates 
depolarisation of the cell due to an increase in positive charge with in the cell. 
Depolarisation of the cell results in activation of the voltage-gated calcium channel 
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(MacDonald and Rorsman, 2006, Ashcroft and Rorsman, 1989), leading to an influx 
of Ca2+ ions within the cell which promotes insulin secretory granules to fuse with 
the membrane and release hexamer insulin molecules by exocytosis (Figure 1.4). On 
release, inactive hexamer insulin molecule dissociates to produce the active 
monomeric form of insulin (Renström et al., 2008).   
 
Free fatty acids (FFA) play a key role in amplifying the glucose-stimulated insulin 
release (GSIS) from islet β-cells (Nolan et al., 2006). Two separate pathways are 
responsible for the FFA potentiating GSIS (Figure 1.4). The first pathway involves 
binding of FFA to GPR40, a G protein-coupled receptor present, expressed on the 
cell membrane of β-cells. The intracellular signalling activated by FFA binding to 
GPR40 promotes an increase in intracellular Ca2+ ions, consequently increasing 
exocytosis of insulin granules in the membrane (Itoh et al., 2003, Gromada, 2006). 
The second pathway involves activation of protein kinase C (PKC) due to an increase 
in long chain acyl-CoA. The increase in malonyl-CoA concentration within the β-
cells lead to inhibition of β-oxidation of long chain acyl-CoA (Nolan et al., 2006). As 
a result, long chain acyl-CoA is shunted into the fatty acid-triglyceride pathway 
which promotes insulin secretion by directly increasing exocytosis of insulin 





Figure 1.4 Diagrammatic representation of the insulin secretion by islet β-cells. 
GLUT2 facilitates entry for glucose into the cell where glucose is metabolised via 
glycolysis and the TCA cycle to produce ATP. The increase in the intracellular ATP/ADP 
ratio causes closure of the K+ATP channel resulting in depolarisation of the plasma 
membrane. This allows an influx of Ca2+ ions in the cytoplasm through the voltage-gated 
Ca2+ channel, facilitating release of insulin secretory granules by exocytosis. FFAs 
potentiate insulin release by directly activating GPR40 and through an increase in 
malonyl-CoA with a consequent increase in long chain acyl CoA which stimulates 
exocytosis of insulin granules either directly or by activating PKC. Abbreviations. FFA: 
Free fatty acid, FATP: Fatty acid transport protein, K+: Potassium ions, Ca2+: Calcium 
ions, PKC: Protein kinase C, TCA: Tricarboxylic acid, G-6-P: Glucose-6-phosphate. 
Picture adapted from Jones, P.M. and Persaud, S.J. 1998. Protein kinase, protein 
phosphorylation, and the regulation of insulin secretion from pancreatic β-cells. 
Endocrine Reviews 19 (4). Pg. 429. 
 
1.2.3. I&SULI& ACTIO& 
 
The insulin receptor is a tyrosine kinase transmembrane receptor (Pirola et al., 2004) 
composed of two alpha (α) and two beta (β) subunits, attached by disulfide bonds. 
Insulin binds to the extracellular α-subunit of the insulin receptor leading to 
conformational changes, facilitating ATP-binding to the intracellular β-subunits. 
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ATP-binding to β-subunits results in autophosphorylation of β-subunits which 
stimulates their kinase activity for intracellular substrates (Saltiel and Kahn, 2001, 
Kido et al., 2001).  
 
Insulin has pleiotropic effects (Figure 1.5) in the peripheral organs, such as 
modulating hepatic glucose production, glucose uptake by muscles and lipolysis in 
adipose tissue and liver (Ferrannini, 1998). Hence, an intact insulin secreting 
apparatus and physiological action of insulin are essential to maintain energy 





Figure 1.5 Diagrammatic representation of the pleiotropic effects of insulin that 
contribute to energy homeostasis. Elegant studies over the years have established 
insulin to have multiple functions in various organs such as to stimulate glucose uptake 
(Herman and Kahn, 2006), synthesize glycogen (Kasuga et al., 2003), inhibit lipolysis 
(Morimoto et al., 1998) and hepatic glucose production (HGP) (Girard, 2006) which 
contributes to maintenance of energy homeostasis. Picture adapted from Rosen, E.D. 
and Spiegelman, B.M. 2006. Adipocytes as regulators of energy balance and glucose 
homeostasis. Nature 444. Pg. 849. 
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1.3. PATHOPHYSIOLOGY OF TYPE 2 DIABETES 
 
The common pathophysiological features displayed in type 2 diabetes arise from 
multiple aetiological factors, including the development of peripheral insulin 
resistance and relatively insufficient secretion of insulin (Kahn et al., 2006).  
 
1.3.1. I&SULI& RESISTA&CE I& TYPE 2 DIABETES 
 
The discrete molecular mechanisms underlying the development of insulin resistance 
are still elusive. Obesity and a high energy diet are factors promoting insulin 
resistance (Kahn and Flier, 2000). Extensive research in this field over the last couple 
of decades has generated two key hypotheses to explain the molecular mechanisms 
responsible for obesity mediated insulin resistance, as is discussed below. 
 
1.3.1.1. ECTOPIC FAT/LIPID STORAGE PARADIGM 
 
The underlying mechanisms for ectopic deposition of lipids are proposed to be 
failure of fat cell formation and lipid oxidation (Heilbronn et al., 2004). The failure 
of adipocyte proliferation and differentiation limits the increase in adipose mass in 
type 2 diabetes. The finite ability of adipose tissue to expand and take up lipid, 
coupled with increased lipolysis due to insulin resistance in adipose tissue, leads to 
ectopic deposition of lipids in liver, skeletal muscle and pancreas (Szendroedi and 
Roden, 2009). Lipid deposition in the liver and muscle in obese individuals strongly 
correlates with the degree of insulin resistance (Goodpaster et al., 1997).  
 39 
Ectopic deposition of lipid in skeletal muscle and liver impairs the efficacy of insulin 
in stimulating glucose uptake in skeletal muscle (Boden and Shulman, 2002) and 
suppressing hepatic glucose production (Matsumoto et al., 2006). An increase in 
glucose metabolism in the muscle and liver elevates the concentration of malonyl-
CoA which inhibits transfer of free-fatty acids (FFAs) to the mitochondria for β-
oxidation (Winder and Hardie, 1996, Ruderman et al., 1999, Szendroedi and Roden, 
2009). The increase in the concentration of FFAs result in shunting of FFAs into the 
glycerol-lipid pathway to synthesise diacylglycerol (DAG), a lipid metabolite which 
can activate isoforms of protein kinase C (PKC) (Kelley and Mandarino, 2000, 
Holland et al., 2007). PKC activation has been implicated in impairment of insulin 
signalling in the muscle and liver via inhibition of the tyrosine kinase activity of the 
insulin receptor and inhibition of tyrosine phosphorylation of the insulin receptor 
substrate (IRS)-1 which are both required for insulin signalling (Figure 1.6) 
(Donnelly et al., 1994, Unger, 2003). Impaired insulin signalling in the muscle leads 
to inefficient glucose disposal in the muscle resulting in an increase in blood glucose 
levels.  
 
In liver, insulin mediates phosphorylation of transcription factor forkhead box O1 
(FoxO1) to prevent FoxO1 entry into the nucleus and subsequent expression of 
gluconeogenic genes, including phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G-6-P) (Matsumoto et al., 2006). The FoxO1 pathway 
becomes resistant to the effects of insulin in the leptin deficient ob/ob and 
lipodystrophic mouse models of type 2 diabetes (Shimomura et al., 2000). However, 
in these mouse models, the sterol regulatory element-binding protein 1c (SREBP-1c) 
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pathway which promotes insulin-dependent fatty acid and triglyceride biosynthesis 
does not become insensitive to insulin action (Horton et al., 2002). Hence, selective 
regulation of transcription factors FoxO1 and SREBP-1c by insulin in insulin-
resistant mice contributes to the classical triad of hyperglycaemia, hyperlipidaemia 




Figure 1.6 Diagrammatic representation of ectopic deposition of lipid in muscle 
and liver hypothesis. The model suggests an increase in oxidation of glucose because 
of increased glucose flux resulting from hyperglycemia. The increased glucose oxidation 
yields malonyl-CoA which impairs lipid oxidation and shunts lipid into the free fatty acid-
triglyceride cycle. The lipid intermediates activate the PKC and NF-κB pathways which 
can impair insulin signalling by inhibiting tyrosine activity of the IR and phosphorylation 
of IRS. Impairment of insulin signalling results in 1. Reduced glucose uptake by muscle, 
2. Increased hepatic glucose release and 3. Promote lipogenesis in the liver. Increased 
mitochondrial oxidation will promote ROS generation which can in turn impair the 
function of the mitochondria. These processes lead to significant increase in lipid 
concentration in the muscle and liver. Abbreviations. FFA: Free fatty acid, FATP: Fatty 
acid transporter protein, FABP: Fatty acid binding protein, PKC: Protein kinase C, NF-
κB: Nuclear factor kappa-light-chain-enhancer of activated B cells, IRS: Insulin receptor 
substrate, IR: Insulin receptor. Picture adapted from Szendroeidi, J. and Roden, M. 
2009. Ectopic lipids and organ function. Current Opinion in Lipidology 20. Pg 51. 
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1.3.1.2. E&DOCRI&E PARADIGM 
 
This emerged as an alternative hypothesis to explain insulin resistance alongside the  
ectopic fat deposition paradigm in the mid 1990s with the discovery that adipose 
tissue had endocrine functions (Friedman and Halaas, 1998). Adipose tissue was no 
longer viewed solely as an organ for storing energy reserve. The multiple bioactive 
peptides (popularly known as adipokines), including leptin and adiponectin released 
by adipose tissue, were demonstrated to have modulatory effects on energy 
homeostasis (Ronti et al., 2006). Leptin was the first molecule to be characterised 
extensively and has been shown to regulate satiety and energy expenditure 
(Barinaga, 1995, Myers et al., 2008). Adiponectin is the most abundant circulating 
adipokine and has received a great deal of attention because of its ability to promote 
insulin sensitisation in liver and muscle (Berg et al., 2001, Fruebis et al., 2001). The 
recognition of the difference in the secretory pattern of leptin and adiponectin in 
individuals with obesity, insulin resistance or type 2 diabetes, directed research 
towards translational benefits. The thiazolidinedione group of compounds are PPAR-
γ ligands and one of their mechanisms of action is to promote insulin sensitisation by 
increasing the circulatory levels of adiponectin (Day, 1999, Maeda et al., 2001). 
 
Adipose tissue has been shown to secrete inflammatory molecules, such as 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), which are significantly 
elevated in insulin resistance and type 2 diabetes. This observation has been largely 
responsible for proposing the existence of low-grade chronic inflammation in type 2 
diabetes. (Hotamisligil et al., 1993, Kern et al., 1995, Uysal et al., 1997).  
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S.&. Adipokine Metabolic effect References 
    
01 Leptin Promotes satiety, reduces insulin resistance, 
hepatic steatosis and improves hepatic insulin 
responsiveness. 
(Toyoshima et al., 2005, 
Petersen et al., 2002, 
Friedman and Halaas, 
1998) 
02 Adiponectin Promotes insulin sensitivity in liver and 
muscle through increased lipid oxidation. 
(Yamauchi et al., 2001, 
Yamauchi et al., 2003) 
03 TNF-α Impairs insulin signalling. Reduces 
adiponectin synthesis. Promotes lipolysis. 
(Hotamisligil et al., 1993, 
Hotamisligil et al., 1995, 
Saghizadeh et al., 1996) 
 
Table 1.1 Metabolic effects of some of the adipokines secreted by adipose tissue.  
 
1.3.2. β-CELL DYSFU&CTIO& I& TYPE 2 DIABETES 
 
The pancreatic islet β-cells respond to chronic fuel (glucose and lipid) overflow and 
insulin resistance by compensatory hypersecretion of insulin to achieve 
normoglycaemia. Longitudinal studies lend support to this observation as 
hyperinsulinaemia is often observed in insulin resistant volunteers despite a normal 
glycaemic level (Prentki and Nolan, 2006). The U.K. Prospective Diabetes Study 
group reported a progressive increase in hyperglycaemia in newly diagnosed patients 
with type 2 diabetic, over a period of 6 years which was associated with progressive 
loss of β-cell function (UKPDS, 1995). Hence, deterioration of islet β-cell function is 
crucial for the development of type 2 diabetes. However, the molecular determinants 
responsible for islet β-cell dysfunction are not well understood in type 2 diabetes.  
 
There are several lines of evidence that implicate glucolipotoxicity and inflammatory 
mediators in promoting islet β-cell dysfunction and damage in vitro (Donath et al., 
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2005, Donath et al., 2009). However, the underlying mechanisms responsible for 
islet β-cell dysfunction in animal models or in humans are still elusive. Key 
molecular determinants that are believed to contribute in islet β-cell dysfunction are 
discussed below, except for inflammation, which is will be discussed in section 1.4.3. 
 
1.3.2.1. SPECIES A&D GE&ETIC FACTOR 
 
The genetic composition of a particular species is of importance in determining the 
propensity for islet β-cell dysfunction. For example, leptin receptor deficiency results 
in severe β-cell dysfunction and profound hyperglycaemia on the C57BL/KsJ, but 
not on the C57BL/6J background, in which the hyperglycaemia is more modest and 
insulin levels are robustly preserved (Hummel et al., 1972, Leiter et al., 1981). Other 
evidence is derived from the ex vivo culture of islets from various species under 
varying concentrations of glucose to determine their susceptibility to glucotoxicity. 
Islets isolated from human and Psammomys obesus (sand rat) are susceptible to 
apoptosis and exhibit defective insulin release when cultured in a high glucose 
medium (Federici et al., 2001, Kaiser et al., 2005), whereas, the islets isolated from 




The degree of β-cell susceptibility to glucotoxicity varies between species. Culture of 
human islets in a high glucose concentration (33mM) resulted in a marked increase 
in apoptosis. However, β-cells from islets of obese (ob/ob) mice were relatively 
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resistant to apoptosis at a pathophysiological concentration of 11mM of glucose 
(Federici et al., 2001, Efanova et al., 1998).  
 
The evidence for an isolated effect of lipotoxicity in promoting β-cell toxicity 
remains inconclusive. β-cells should be susceptible to an increase in ROS induced by 
a high mitochondrial lipid flux as they have low levels of ROS-detoxifying enzymes 
(Laybutt et al., 2002).  However, ex vivo culture of islets isolated from Zucker fatty 
rats demonstrated that β-cells were relatively protected from hyperlipidaemia and 
stimulated insulin secretion (Nolan et al., 2006, Haber et al., 2003).  
 
The evidence for the toxicity of glucose and lipids (glucolipotoxicity) in combination 
are much stronger. Extensive studies with pharmacological inducers and inhibitors of 
lipid oxidation demonstrated that lipotoxicity in the insulinoma INS 832/13 β-cell 
line was due to an increase in glucose oxidation combined with accumulation of 
complex lipid molecules, some of which are cytotoxic (El-Assaad et al., 2003, 
Prentki and Nolan, 2006). The presence of islet steatosis (lipid retention) and reduced 
insulin gene expression in hyperglycaemic Zucker diabetic rats but not in Zucker 
fatty rats (Lee et al., 1994, Harmon et al., 2001) lends further support to the fact that 







1.4. I&FLAMMATIO& I& TYPE 2 DIABETES 
 
Inflammation is a well orchestrated response of the host to restore homeostasis 
following injury. Initiation, progression and resolution are key stages of 
inflammation that are tightly intertwined with the innate immune system (Tracy, 
2006, Henson, 2005). The dynamic process of inflammation involves a complex 
interaction between resident cells and circulatory immune cells mediated by the 
release of soluble proteins such as damage associated molecular pattern molecules 
(DAMPs) by resident cells and cytokines by immune cells. The inflammatory 
response at the site of injury is necessary to orchestrate the wound healing process 
(Eming et al., 2007). However ongoing inflammation for a prolonged period of time 
can have deleterious effects on the host tissues or organs due to the cytotoxic effects 
of substances released from immune cells (Wellen and Hotamisligil, 2005). Low-
grade chronic inflammatory processes have been implicated in various disease states, 
including obesity and type 2 diabetes, where inflammation is believed to be a cause 
as well as a consequence of the disorder (Hotamisligil, 2006, Kahn et al., 2006).  
 
Anti-inflammatory mediators such as salsalate and anakinra target pro-inflammatory 
pathways and facilitate NF-κB inhibition and interleukin-1 receptor (IL-1R) 
blockade, respectively. These compounds have shown encouraging anti-diabetic 
efficacy in clinical trials (Larsen et al., 2007, Fleischman et al., 2008). This has led to 
an increase in interest in the scientific community to pursue inflammation as a 
therapeutic target for type 2 diabetes. 
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1.4.1. OBESITY: A& I&FLAMMATORY DISORDER 
 
Obesity is a risk factor for the metabolic syndrome and type 2 diabetes, and the obese 
state is also recognised as a chronic inflammatory disorder. The link between 
inflammation and a metabolic disorder is perhaps not surprising from an evolutionary 
perspective. Metabolic and immune responses are key factors determining survival 
when species are challenged with nutrient restriction and infective organisms during 
natural calamities such as famine and epidemic out-breaks (Hotamisligil, 2006). In 
fact, the Drosophila fat body which is equivalent to human adipose tissue has been 
reported to incorporate mammalian homologues of both the liver and the immune 
system which demonstrates the existence of link between the functional units of the 
metabolic and immune systems (Søndergaard, 1993). The concurrent aberration of 
metabolic and immune responses in obesity further strengthens the link between 
these two responses. 
 
The first experimental evidence of the presence of a low-grade chronic inflammation 
in obesity came with the discovery of increased expression of the pro-inflammatory 
mediator, TNF-α, in visceral fat of humans and in experimental models of obesity 
(Hotamisligil et al., 1993, Kern et al., 1995, Hotamisligil et al., 1995). 
Simultaneously, adipose tissue was discovered to have endocrine functions, as 
adipocytes were found to secrete a large variety of soluble factors, including 
cytokines, which may be responsible for eliciting pro-inflammatory responses 
(Barinaga, 1995, Heilbronn et al., 2004). Notably, adipocytes express toll-like 
 47 
receptors (TLRs), like macrophages, and are activated by nutrients such as fatty 
acids, promoting inflammation in adipose tissue (Song et al., 2006, Shi et al., 2006). 
 
The underlying mechanisms responsible for generating inflammation in obesity are 
not well understood. However, adipocyte hypertrophy is believed to be responsible 
for the initiation of inflammation (Figure 1.7). The adipocytes are significantly 
enlarged (hypertrophy), which may promote microhypoxia (Hosogai et al., 2007). 
Hypoxia in adipocytes has been shown to activate the c-Jun N-terminal kinase (JNK) 
and NF-κB pathways, which induce chemokine release and recruitment of 
macrophages to remove the cellular debris resulting from adipocyte death (Ye et al., 
2007). However, a prolonged autocrine and paracrine inflammatory engagement 
between the  macrophages and adipocytes is established, which leads to further 
adipocyte injury (Figure 1.7) (Cinti et al., 2005). Relevant studies have established 
that the JNK and NF-κB pathways have a direct inhibitory effect on the insulin 
signaling cascade too (Schenk et al., 2008).  
 
Macrophage accumulation in adipose tissue is a characteristic feature of obesity. 
Extensive gene profiling in white adipose tissues from various rodent models of 
obesity and type 2 diabetes demonstrated elevated gene expression of macrophage 
chemo-attractants including monocyte chemo-attractant protein-1 (MCP-1) and 
macrophage inflammatory protein-1 (MIP-1) (Xu et al., 2003). Macrophages isolated 
from the adipose tissue of obese mice demonstrate a phenotypic switch from an 
alternately activated (anti-inflammatory) to classically activated (pro-inflammatory) 




Figure 1.7 Diagrammatic representation of the initiation of inflammation in the 
adipose tissue in obesity. An increase in energy influx due to high intake of energy-
rich diet leads to an increase in adipocyte size resulting in microhypoxia. Microhypoxia 
has been reported to initiate inflammation through activation of the JNK and NF-κB 
pathways resulting in release of pro-inflammatory cytokines such as MCP-1, IL-8 and 
TNF-α which promote macrophage recruitment and activation in adipose tissue. The 
microhypoxia and inflammatory response results in adipocyte death and further 
recruitment of macrophages, leading to a vicious pro-inflammatory chain reaction. 
Abbreviations. JNK: c-Jun N-terminal kinase, NF-κB: Nuclear factor kappa-light-chain-
enhancer of activated B cells, TNF-α: Tumor necrosis factor-α, MCP-1: Monocyte 
chemo-attractant protein-1, IL-8: Interleukin-8 (chemokine KC). Picture adapted from 
Schenk, S. et al 2008. Personal perspective. Insulin sensitivity: modulation by nutrients 
and inflammation. The Journal of Clinical Investigation 118 (9). Pg. 2996. 
 
It is believed that inflammation in adipose tissue impairs insulin signalling and hence 
promotes lipolysis. The pro-inflammatory response and increase in lipolysis in the 
adipose tissue leads to the release of pro-inflammatory mediators and free fatty acids 
into the circulation, resulting in ectopic deposition of lipid in muscle and liver, which 
promotes insulin resistance (Figure 1.8) (Hotamisligil, 2006, Shoelson et al., 2006, 




Figure 1.8 Diagrammatic representation of inflammation promoting insulin 
resistance and hyperglycaemia. Obesity associated inflammation in adipose tissue 
with recruitment of macrophages promote lipolysis (NEFA/FFA secretion) and increased 
secretion of pro-inflammatory mediators such as TNF-α, IL-6, MCP-1 and IL-8 into the 
circulation. The ectopic lipid deposition in liver and fat and possible exposure to 
inflammatory mediators impairs insulin action which leads to development of 
hyperglycaemia. Abbreviations. TNF-α: Tumor necrosis factor-α, MCP-1: Monocyte 
chemo-attractant protein-1, NEFA: Non-esterified fatty acid (also called FFA; free fatty 
acid), HGP: Hepatic glucose production. Picture adapted from Gaal, L.F.V. et al 2006. 










1.4.2. ROLE OF I&FLAMMATIO& I& DEVELOPME&T OF 
PERIPHERAL I&SULI& RESISTA&CE 
 
Obesity-induced low-grade chronic inflammation in the peripheral organs is 
associated with the development of insulin resistance. An early study demonstrated 
that TNF-α neutralization in obese insulin-resistant mice resulted in a profound 
improvement in glucose uptake into muscle (Hotamisligil et al., 1993). Interleukin-
1β (IL-1β) treatment has been reported to increase insulin resistance in human 
adipocytes by impairing insulin signaling through ERK-dependent transcription and 
non-ERK dependent port-translational modification of IRS-1 (Jager et al., 2007).  
The role of IL-6 in insulin resistance is not clear, as IL-6 production in visceral fat is 
high and is associated with insulin resistance in humans (Fontana et al., 2007). 
Furthermore, IL-6 knock-out mice have been reported to have improved insulin 
sensitivity (Tilg and Moschen, 2008). However, IL-6 is a potent inducer of AMPK 
and lipid oxidation, both of which should have an anti-diabetic effect (Febbraio, 
2007). 
 
Strong evidence links the pathways responsible for inflammatory responses and 
insulin signaling. JNK, which belongs to the serine/threonine kinase family, 
primarily mediates inflammatory responses by regulating transcriptional control of 
activation protein-1 (AP-1) (Davis, 2000, Shoelson et al., 2006). JNK is activated in 
liver, muscle and adipose tissue during obesity, potentially via endoplasmic 
reticulum (ER) stress, as well as increased levels of cytokines and free fatty acids 
(Figure 1.9). Interestingly, loss of JNK1 in experimental models of obesity has been 
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reported to ameliorate insulin resistance (Hirosumi et al., 2002, Wellen and 
Hotamisligil, 2005, Nakatani et al., 2004). Relevant studies aimed at studying the 
molecular link between JNK and insulin signaling in different organs have found that 
JNK activation causes phosphorylation of insulin receptor substrate-1 (IRS-1) at 
serine 307 residue, which impairs signaling between the insulin receptor (IR) and 
IRS-1 (Aguirre et al., 2002). Increased levels of lipid intermediates, such as 
diacylglycerol (DAG) and ceramide, during lipid infusion result in protein kinase C-θ 
(PKC-θ)-dependent phosphorylation of IRS-1 at Ser307 (Yu et al., 2002). A recent 
study demonstrated that removal of JNK1 specifically from hematopoietic cells had 
no impact on obesity, but protected mice from high-fat diet-mediated insulin 
resistance (Solinas et al., 2007, Solinas and Karin, 2010).   
 
The NF-κB pathway is also implicated in insulin resistance, as salicylates reverse 
hyperglycaemia and hyperlipidaemia in ob/ob mice via inhibition of the NF-κB 
pathway (Yuan et al., 2001, Yin et al., 1998). Inhibitor of kappa B kinase (IKK) can 
impair insulin signalling, either through direct serine 307 phosphorylation of IRS-1, 
or via transcriptional activation of NF-κB, which results in secretion of cytokines 
such as TNF-α (Figure 1.9) (Wellen and Hotamisligil, 2005, Schenk et al., 2008). In 
addition, TNF-α-mediated signaling has been reported to phosphorylate IRS-1 at 





Figure 1.9 Diagrammatic representation of the molecular signaling pathways 
orchestrating an inflammatory response and insulin resistance in peripheral 
organs. Increased influx of glucose and lipids in type 2 diabetes can initiate 
inflammatory pathways such as JNK, IKK/NF-Κb, and PKC through increased 
production of mitochondrial ROS, accumulation of lipid intermediates such as DAG and 
ceramide or elevated ER stress. These pathways can also inhibit IRS-1/2 and impair 
insulin signaling. Abbreviations. ER: Endoplasmic reticulum, DAG: Diacyl glycerol, 
ROS: Reactive oxygen species, PKC:  Protein kinase C, JNK: c-Jun N-terminal kinase, 
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells, IRS: Insulin 
receptor substrate, IR: Insulin receptor, IKK: Inhibitor of kappa B kinase, AP-1: Activator 
protein-1, TNF-α: Tumor necrosis factor-α, MCP-1: Monocyte chemo-attractant protein-
1, MIP-1: Macrophage inflammatory protein-1. Picture adapted from Wellen, K.E. and 
Hostamisligil, G.S. 2005. Inflammation, stress and diabetes. The Journal of Clinical 
Investigation 115 (5). Pg. 1116. 
 
1.4.3. I&FLAMMATIO& I& ISLET β-CELL DYSFU&CTIO& 
 
Glucolipotoxicity, oxidative stress, endoplasmic reticulum stress and mitochondrial 
dysfunction cause malfunction of islet β-cells in type 2 diabetes. A unifying 
mechanism to explain islet β-cell dysfunction for each of the above mechanisms may 
be inflammation because they all elicit a pro-inflammatory response (Donath et al., 
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2005). Gene expression profiling of islets from Goto-Kakizaki (GK) rats, which is a 
model of type 2 diabetes, demonstrated over-expression of >70 genes compared to 
non-diabetic rats, of which 34% belonged to the immune/inflammatory response 
families (Homo-Delarche et al., 2006). In another study, increased islet gene 
expression of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines 
(Chemokine KC, MCP-1, MIP-1) were reported in GK rats (Ehses et al., 2009). Islet 
macrophage infiltration has been reported in various experimental models of type 2 
diabetes including GK rats, high-fat fed C57BL/6J, leptin deficient ob/ob and leptin 
receptor deficient db/db mice (Ehses et al., 2007b). Hence, there is increasing 
evidence linking the existence of islet inflammation in type 2 diabetes. 
 
1.4.3.1. IL-1 PATHWAY AS A SE&SOR OF METABOLIC STRESS 
 
Gene profiling studies on islets from human donors with type 2 diabetes has 
demonstrated increased expression of the IL-1β gene. Ex vivo culture of human islets 
at high concentration of glucose results in islet β-cell death and the underlying 
mechanism for β-cell apoptosis was increased expression of the pro-apoptotic 
receptor FAS on β-cells. This process is further enhanced by glucose-stimulated 
release of IL-1β (Maedler et al., 2001, Schumann et al., 2007, Donath and Shoelson, 
2011). The concept of the IL-1 system as a sensor of metabolic stress in β-cell is 
based on a model where glucose is believed to activate inflammasomes which cleave 
the inactive pro-IL-1β produced by the free fatty acid (FFA)-toll-like receptor (TLR)-
NF-κB pathway into active IL-1β. Secreted IL-1β further stimulates the NF-κB 
pathway through IL-1 receptor (IL-1R) signaling to produce chemo-attractants such 
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as IL-8 and MCP-1 which recruit immune cells such as macrophages into islets 
(Figure 1.10) (Donath and Shoelson, 2011, Martinon et al., 2002). The model 
receives support from multiple observations including  
 
 The islet β-cells respond to a transient rise in glucose via activation of the NF-κB 
pathway to promote insulin release and β-cell proliferation (Maedler et al., 2002, 
Bernal-Mizrachi et al., 2002). 
 FFA increase IL-1β expression in islets via TLR-2/4, a receptor cascade involved 
in mediating the pro-inflammatory response to lipopolysaccharide (Beutler, 2004, 
Lee et al., 2001, Haversen et al., 2009, Ehses et al., 2010).  
 The combination of glucose and FFA induces higher cytokine production than 
FFA alone (Boni-Schnetzler et al., 2009).  
 
The interaction of the cytokine IL-1β with the IL-1R receptor is tightly regulated by 
the presence of another molecule named IL-1 receptor antagonist (IL-1Ra) which 
binds to the IL-1R receptor and blocks IL-1β interacting with the IL-1R (Donath et 
al., 2005). In islets cultured from type 2 diabetic GK rats, the addition of IL-1Ra has 
been reported to suppress the gene expression of chemokines such as chemokine KC, 
MCP-1 and MIP-1 demonstrating IL-1 activity to be partially responsible for the pro-
inflammatory response in islets in type 2 diabetes. Treatment of GK rats with IL-1Ra  
led to a significant improvement in peripheral insulin sensitivity, a decrease in pro-
insulin to insulin ratio, a reduction in islet immune cell infiltration and chemokine 
gene expression in the pancreatic islets (Ehses et al., 2009). An IL-1R activity 
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blocker named anakinra has been reported to have anti-diabetic efficacy in patients 





Figure 1.10 Interleukin-1β induced inflammation and apoptosis in islets of patients 
with type 2 diabetes. A model based on ex vivo studies involving islets from patients 
with type 2 diabetes. Glucose can activate pro-apoptotic caspase-1 via the 
inflammasome. Inactive pro-IL-1β generated by lipids via TLR/NF-κB pathway is then 
cleaved by activated caspase-1, generating active IL-1β which can stimulate the NF-κB 
pathway to produce pro-inflammatory chemo-attractants that promote macrophage 
infiltration. Abbreviations. TLR: Toll-like receptors, MCP-1: Monocyte chemo-attractant 
protein-1, MIP: Macrophage inflammatory protein, IL-1: Interleukin 1, IL-1R: Interleukin-1 
receptor. Picture adapted from Donath, M.Y. and Shoelson, S.E. 2011. Type 2 








1.4.3.2. THE ROLE OF &ITRIC OXIDE I& ISLET I&FLAMMATIO& 
 
Nitric oxide (NO)  has been implicated in islet β-cell dysfunction and destruction 
primarily in type 1 diabetes (Spinas, 1999). Ex vivo culture of rodent islets with a 
cytokine cocktail of IL-1β in presence of either interferon-gamma (IFN-γ) or TNF-α, 
or both, reduces β-cell secretion of insulin. This can be reversed by treatment with 
nitric oxide synthase (NOS) inhibitors (Corbett and McDaniel, 1995, Thomas et al., 
2002). The role of NO as a pathogenic mediator in human islets is less well 
established (Spinas, 1999).  
 
In the last decade, an increase in gene and protein expression of inducible isoform of 
NOS (iNOS) has been reported in islets of rodent models of type 2 diabetes including 
GK and ZDF rats (Salehi et al., 2008, Chentouf et al., 2011). Treatment with NOS 
inhibitors has been reported to rescue islet β-cell insulin secretion from the 
deleterious effects of NO (Kato et al., 2003, Corbett and McDaniel, 1995, Thomas et 
al., 2002). However, while ex vivo culture of islets isolated from diabetic rodents has 
demonstrated an increase in iNOS expression, a similar effect was not observed in 
patients with type 2 diabetes (Donath et al., 2009). Hence, there may be different 
mechanisms responsible for the β-cell dysfunction in humans compared with rodents.  
 
Ex vivo culture of rodent islets with either a cytokine mix or lipid increases NO 
production and iNOS expression (Oprescu et al., 2007, Corbett and McDaniel, 1995). 
It is widely believed that macrophages and endothelial cells are the primary source of 
NO in the islets. Culture of both cell-types under different conditions, such as 
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increased glucose and lipid concentration has resulted in a pro-inflammatory 
response that includes NO production (Figure 1.11) (Koliwad et al., 2010, Yan et al., 
2006). A recent study has reported that an NO donor reduces IRS-2 protein 
expression via proteosome-dependent degradation of the IRS-2 protein (Tanioka et 
al., 2011). Thus, there is an acceptance of a role of iNOS and NO in islet β-cell 
dysfunction in rodents. However, the existence of an interaction between different 
cell-types within an islet to facilitate NO generation has yet to be established in vivo. 
 
 
Figure 1.11 Interaction between β-cells and macrophages within islet to promote 
inflammation in type 2 diabetes. Increased glucose and lipid concentration can 
activate β-cells and macrophages to produce cytokines via the JNK and NF-κB 
pathways. The cytokines produced by β-cells can further activate adjacent β-cells and 
immune cells such as macrophages through autocrine and paracrine signaling. The 
activated macrophages infiltrating the islets can produce pro-inflammatory cytokines 
(and NO in rodents) to further damage β-cells. Abbreviations. NO: Nitric oxide, MCP-1: 
Monocyte chemo-attractant protein-1, IL-1: Interleukin 1. Picture adapted from Donath, 
M.Y. and Shoelson, S.E. 2011. Type 2 diabetes as an inflammatory disease. Nature 
Reviews Immunology 11. Pg. 100. 
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1.5. HEME OXYGE&ASE SYSTEM 
 
Heme is a complex of ferrous iron and protoporphyrin IX and is a prosthetic group in 
several proteins including haemoglobin, myoglobin, nicotinamide adenine 
dinucleotide phosphate oxidase (NADPH oxidase), microsomal and mitochondrial 
cytochromes. The heme prosthetic group regulates key biological functions of 
proteins by facilitating oxygen transport and the electron transfer required for bio-
chemical reactions. However, accumulation of free heme has cytotoxic effects on 
cells and tissues (Furuyama et al., 2007, Tsiftsoglou et al., 2006). 
 
The intracellular level of heme is tightly regulated. The heme biosynthetic pathway is 
essentially a 7 step process for synthesis of the protoporphyrin structure, followed by 
a terminal step where ferrous iron is inserted into the protoporphyrin ring to form 
heme (Figure 1.12). Each step is facilitated by a different enzyme. The first step of 
heme biosynthesis involves condensation of the amino acid, glycine, with succinyl-
coenzyme A (succinyl-CoA), an intermediate in the citric acid cycle. This is 
catalysed by 5-aminolevulinate synthase (ALAS), which is the rate-limiting enzyme 
in heme biosynthesis (Furuyama et al., 2007, Ajioka et al., 2006).  
 
 
The heme oxygenase (HO) system is the most effective mechanism for oxidative 
catabolism of free heme. Heme breakdown by HO produces equi molar amounts of 
carbon monoxide (CO), the bile pigment biliverdin IX and free iron (Figure 1.13). 
Biliverdin reductase immediately converts biliverdin IX into bilirubin IX. The free 
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iron is readily sequestered by ferritin which is the primary form of iron storage in the 




Figure 1.12 Diagrammatic representation of heme biosynthetic pathway in 
mammals. Picture adapted from Furuyama, K., Kaneko, K. and Vargas V., P.D. 2007. 
Heme as a magnificent molecule with multiple missions: Heme determines its own fate 
and governs cellular homeostasis. Tohoku J. Exp. Med. 213. Pg. 2. 
 
The two major isoforms of HO system are microsomal HO-1, an inducible isoform, 
and constitutive HO-2 isoform. HO-1 is a 32 kilo dalton (kDa) protein which is 
induced by a wide range of stimuli, including heme and non-heme based molecules, 
such as cytokines, endotoxins, ultra-violet radiation, oxidants, and heavy metal 
compounds (Abraham and Kappas, 2008). The enzymatic process of heme 
degradation was first reported in the 1960s by the Schmitt group (Tenhunen et al., 
1968, Tenhunen et al., 1969). The initial excitement with discovery of HO enzyme 
was due the belief that HO was a new member of the cytochrome P450 group. 
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However, subsequent research showed a disparity in the organ distribution of HO 
and cytochrome P450 (Abraham and Kappas, 2008). A decade later, induction of the 
HO enzyme in the liver by cobalt in a cytochrome P450 independent fashion 





Figure 1.13 Diagrammatic representation of heme oxygenase-1 (HO-1) in 
mammals. Picture adapted from Abraham, N.G. and Kappas, A. 2008. 
Pharmacological and clinical aspects of heme oxygenase. Pharmacological Reviews 60 
(1). Pg. 82. 
 
The vitality of HO-1 in tissue homeostasis is best emphasized by the unfortunate case 
of an individual who had HO-1 deficiency, the only case reported in the literature. 
The individual suffered from growth failure, leukocytosis, tissue iron deposition and 
anaemia before dying prematurely at 7 years of age (Morse and Choi, 2002, Yachie 
and Toma, 1999). 
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1.5.1. PHARMACOLOGICAL I&DUCTIO& OF HEME OXYGE&ASE 
 
A large proportion of the research in the HO field relies on pharmacological 
induction and inhibition of HO activity using metallo-porphyrins (Figure 1.14). 
Hemin (ferrous protoporphyrin IX) and cobalt protoporphyrin IX are routinely used 
to induce HO activity, whereas chromium and stannous mesoporphyrin IX have been 
used for competitive inhibition of HO activity (Abraham and Kappas, 2008). 
 
 
Figure 1.14 Routinely used metallo-porphyrins for modulating HO activity in 
experimental and cell culture models of diseases.  
Pictures taken from Frontier Scientific, Logan, U.S. website.  
 
However, metallo-porphyrins have been reported to have effects which are 
independent on HO activity including those listed below: 
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 Anti-apoptotic effect: Cobalt, tin or zinc protoporphyrins have been reported to 
directly inhibit caspase-3 activity. The porphyrin structure was demonstrated to 
occupy the active site of caspase-3 through molecular modeling studies 
(Blumenthal et al., 2005). 
 Inhibition of other enzymatic activity: Zinc- and tin-based porphyrin 
compounds inhibit nitric oxide synthase (NOS) and soluble guanylyl cyclase 
(sGC) activity in cell culture models. Minimum interference in NOS and sGC 
activity has been reported with chromium mesoporphyrin (Appleton et al., 1999, 
Grundemar and Ny, 1997).    
 Anti-oxidant potential: Manganese- and iron-based metallo-porphyrin 
compounds have been used as mimetics of superoxide dismutase (SOD), a potent 
anti-oxidative enzyme which protects from the cytotoxic effect of ROS (Patel and 
Day, 1999). 
 
The metallo-porphyrins remain the most common method of modulating HO activity 
despite their numerous off-target effects. Homozygous HO-1 knock-out (HO-1-/-) 
mice are a more incisive tool to demonstrate the effect of HO-1 deficiency. However, 
given the key role of HO-1 in heme degradation and as an anti-oxidant, it is perhaps 
not surprising that they have reduced viability and are therefore difficult to breed. 
Indeed, HO-1 homozygous knock-out mice are infertile and the rate of generation of 
live HO-1-/- offspring from breeding HO-1+/- mice is 1 in 4 (Poss and Tonegawa, 
1997), indicating substantial loss of life in vivo. Given the difficulties in generating 
HO-1-/- mice, it is likely that pharmacological modulators of HO activity will 
continue to be used, despite their limitations. 
 63 
1.5.2. A&TI-I&FLAMMATORY POTE&TIAL OF HO-1 
 
Induction of HO activity has cytoprotective effects in various inflammatory animal 
models. However, the underlying mechanisms are not well understood. Clearance of 
the pro-oxidant heme and the anti-inflammatory and anti-oxidant properties of the 
products of heme catabolism are possible reasons for HO-1 being cytoprotective 
(Nath, 2006). 
 
CO is a diatomic gas molecule best known to operate as a signaling molecule in 
biological systems. CO signals by either stimulating soluble guanylate cyclase (sGC) 
(Morita et al., 1995, Morita and Kourembanas, 1995) or activating mitogen-activated 
protein kinases (MAPK) (Otterbein et al., 2003, Otterbein et al., 2000). In vivo and in 
vitro studies have implicated p38MAPK activation to be a key mechanism for the 
cytoprotective effect achieved with HO-1 induction and CO. Lipopolysaccharide 
(LPS) treatment in the  presence of CO led to elevated interleukin-10 (IL-10) 
expression and decreased TNF-α (Ryter et al., 2002, Otterbein et al., 2000).  
 
Biliverdin and bilirubin, long considered as waste products have recently been 
viewed to have potent anti-oxidant properties. Their functional ability to scavenge 
ROS, thereby reducing the oxidation related stress and cellular damage, is beneficial 
for tissue homeostasis (Maines and Gibbs, 2005, Maines, 2005). Recently biliverdin 
reductase has been demonstrated to present on the external plasma membrane of 
macrophages and other cell-types (Wegiel et al., 2009). Tyrosine phosphorylation of 
biliverdin reductase, which occurs during conversion of biliverdin to bilirubin has 
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been implicated in activation of phosphatidylinositol 3-kinase (PI3K) and Akt which 
may confer an anti-inflammatory effect in LPS activated macrophages (Wegiel et al., 
2009). The activation of PI3K and Akt may also be responsible for the protection that 
HO confers against hypoxia and oxidative stress (Pachori et al., 2007, Worou et al., 
2011). 
 
Another heme catabolic product, free iron, is known to generate ROS. However, HO-
1 up-regulation also results in ferritin synthesis, which sequesters the free iron 
released, thereby ensuring cytoprotection from the deleterious effects of free iron  
(Pae, 2008). 
 
S.& Agent Cell-type Mechanism Reference 
     
01 Carbon monoxide (CO) Macrophages ↑ p38MAPK (Otterbein et al., 2000) 
02 CO releasing molecules Macrophages ↑ CO  (Sawle et al., 2005) 
03 Biliverdin reductase Macrophages ↑ PI3K-Akt-IL-10 (Wegiel et al., 2009) 
04 IL-10 Macrophages ↑ p38MAPK (Lee and Chau, 2002) 
05 15d-PGJ2 Macrophages ↑ p38
MAPK (Lee et al., 2003) 
06 Hemin Macrophage 
foam cells 
↑ IL-10 (Ma et al., 2007) 
07 Apoptotic cell supernatant Macrophages ↑ Adenosine 
receptor A2A 
(Weis et al., 2009) 
 
Table 1.2 List of molecules which are either derived from (1-3) or induce the heme 
oxygenase (HO) pathway (4-7) and demonstrate anti-inflammatory effect in 
classically activated macrophages. Abbreviations. 15d-PGJ2: 15-Deoxy-12, 14-






1.5.3. A&TI-DIABETIC EFFECTS OF HO-1 
 
Systemic administration of HO-1 inducers in rodent models of type 2 diabetes has 
been shown to ameliorate obesity, peripheral insulin resistance and hyperglycaemia 
(Li et al., 2008). The anti-diabetic efficacy of various HO activity inducers such as 
hemin, cobalt (III) protoporphyrin IX chloride (CoPP) and curcumin has been 
extensively studied in rodent models of insulin resistance including leptin deficient 
ob/ob mice, high-fed diet fed C57BL/6J mice, non-obese insulin resistant Goto-
Kakizaki (GK) rats and Zucker fatty (Zucker fa/fa) rats (Ndisang and Jadhav, 2009, 
Ndisang et al., 2009b, Weisberg et al., 2008, Kim et al., 2008, Li et al., 2008).  
 
N.G. Abraham’s research group based in New York Medical College has specifically 
studied the effect of the HO activity inducer CoPP in obesity and insulin resistance. 
They were the first to report that induction of HO activity by CoPP has an anti-
inflammatory effect in obese mice which improve insulin sensitivity in peripheral 
organs. Intraperitoneal administration of CoPP once a week for six weeks in the 
ob/ob mice increased serum adiponectin, decreased body weight, plasma IL-6 and 
TNF-α levels and improve glucose and insulin sensitivity (Li et al., 2008). Reduced 
insulin resistance along with decreased visceral and adipose tissue volume were 
reported in similar studies with an identical treatment schedule of CoPP in the 
Zucker diabetic fatty (ZDF) rat and Zucker fa/fa model of type 2 diabetes (Nicolai et 
al., 2009, Kim et al., 2008). Importantly these studies demonstrated induction of HO 
activity to be responsible for the beneficial effects of CoPP as co-treatment with the 
HO activity inhibitor stannous (tin) mesoporphyrin IX (SnMP or, SM) abolished the 
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beneficial effects of CoPP (Kim et al., 2008, Li et al., 2008). The authors of these 
reports have proposed induction of a HO/adiponectin axis as the central mechanism 
for the efficacy of CoPP.  The increase in HO activity with CoPP results in weight 
loss, a decrease in inflammation and remodelling of adipose tissue characterised by 
smaller adipocytes with less macrophage infiltration and greater adiponectin 
production. There was also an increase in phosphorylation of AMPK in skeletal 
muscle (Nicolai et al., 2009, Kim et al., 2008, Li et al., 2008). Adiponectin and 
AMPK are widely accepted to promote insulin sensitivity through their action in 
peripheral tissues. 
 






    
(Li et al., 2008) ob/ob mouse CoPP  
3mg/kg i.p., 1x/week 
6 weeks 
SM 
20mg/kg i.p., 3x/week 
6 weeks  
(Kim et al., 2008) Zucker obese rat CoPP  
2mg/kg i.p., 1x/week 
6 weeks 
SM 
5mg/kg i.p., 3x/week 
6 weeks  









Table 1.3 List of studies and dosage of HO activity inducer and inhibitor used in 
rodent models of type 2 diabetes by Abraham’s research group.  
Abbreviation. i.p.- intra-peritoneal administration. 
 
In 2009, J.F. Ndisang and co-workers published three research studies in which 
hemin administration in the ZDF and non-obese GK rat models of type 2 diabetes 
was demonstrated to efficiently reduce hyperglycaemia by promoting peripheral 
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insulin sensitivity. The beneficial effects of hemin were reversed by co-treatment 
with the HO activity inhibitor chromium (III) mesoporphyrin IX chloride (CrMP). 
Hemin treatment significantly reduced peripheral insulin resistance and improved 
glucose sensitivity by promoting weight loss and increasing serum adiponectin 
levels. The extensive characterization of the effect of hemin in soleus muscle 
demonstrated a reduction in mRNA expression of AP-1, NF-κB and JNK as well as 
restoration of the protein levels of AMPK and GLUT4. Hence, hemin administration 
was observed to have pleotropic effects which contributed towards its anti-diabetic 
efficacy in these studies (Ndisang and Jadhav, 2009, Ndisang et al., 2009b, Ndisang 
et al., 2009a).  
 













30mg/kg i.p., daily 
6 weeks 
CrMP 
4µmol/kg i.p., daily  
6 weeks  





30mg/kg i.p., daily 
5 weeks 
 Not used 






30mg/kg i.p., daily 
4 weeks 
CrMP 
4µmol/kg i.p., daily  
4 weeks  
 
Table 1.4 List of studies and dosage of HO activity inducer and inhibitor used in 
rodent models of type 2 diabetes by Ndisang’s research group.  




There have been a few studies reporting an anti-diabetic effect of curcumin, which is 
an inducer of HO-1 (McNally et al., 2007). Curcumin supplementation for 6 weeks 
(semi-synthetic diet with 0.2g/kg curcumin) in leptin receptor deficient db/db mice 
significantly reduced serum lipid levels, normalized hepatic anti-oxidant levels, 
increased hepatic glycogen storage, decreased hepatic β-oxidation and ameliorated 
hyperglycaemia (Seo et al., 2008). In another study, curcumin supplementation over 
a period of 40-60 days reduced hyperglycemia in the ob/ob and diet induced obesity 
(DIO) murine model of insulin resistance and type 2 diabetes by promoting an 
increase in serum adiponectin levels, weight loss and reducing macrophage 













Figure 1.15 Published anti-diabetic effect of metallo-porphyrin-based inducers of 
HO activity. Studies with HO inducers have reported an increase in adiponectin to have 
an insulin sensitizing effect. The restoration of AMPK levels in muscle may be due to an 
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1.5.4. HEME: A LIGA&D OF REV-ERB A&D ROLE I& METABOLIC 
A&D I&FLAMMATORY PROCESSES 
 
The nuclear receptor Rev-erb is a potent repressor of gene transcription. Rev-erb 
mediates repression of gene transcription through its interaction with the nuclear 
receptor corepressor (NCoR)-histone deacetylase-3 (HDAC3) complex (Yin et al., 
2010).  
 
Heme is a ligand for Rev-erb (Yin et al., 2010) and it suppresses the mRNA levels of 
gluconeogenic genes including phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G-6-P) in a hepatic cell line by stabilising binding of the 
NCoR-HDAC3 co-repressor complex to Rev-erbα (Figure 1.16) (Yin et al., 2007). 
Furthermore, Rev-erbα potentiates adipogenesis, as both a rise in the intracellular 
heme concentration and treatment with exogenous Rev-erbα ligands have been 
reported to induce adipocyte differentiation in 3T3-L1 cells (Kumar et al., 2010).  
 
The NCoR-HDAC3 co-repressor complex has been implicated in repression of some 
pro-inflammatory genes including iNOS too. LPS stimulation of murine 
macrophages releases the NCoR-HDAC3 co-repressor complex from the iNOS 
promoter and induces iNOS gene expression (Pascual et al., 2005). PPAR-γ agonists 
increase the stability of a PPAR-γ-NCoR-HDAC3 complex on the iNOS promoter, 
preventing release of the NCoR-HDAC3 co-repressor complex from the iNOS 
promoter and hence iNOS expression (Pascual et al., 2005). However, whether heme 
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can act as a Rev-erb ligand to inhibit LPS-induced iNOS expression (Figure 1.16) 





Figure 1.16 Heme dependent Rev-erb mediated metabolic and inflammatory 
processes. Heme binds to Rev-erbα to recruit NCoR-HDAC3 co-repressor complex on 
the promoter of PEPCK and G-6-P and inhibit the gene expression of PEPCK and G-6-P 
in hepatocyte cell line. Whether it can also inhibit pro-inflammatory gene expression by a 
similar mechanism has yet to be explained. Abbreviations. BS: Binding site, NCoR: 
Nuclear receptor corepressor, HDAC3: Histone deacetylases-3, PEPCK: 
Phosphoenolpyruvate carboxykinase, G-6-P: Glucose-6-phosphatase. Picture adapted 
from Yin, L., Wu, N. and Lazar, M.A. 2010. Nuclear receptor Rev-erbα: a heme receptor 
that coordinates circadian rhythm and metabolism. Nuclear Receptor Signaling 8. Pg.3.   
 
Two recent publications describe the role of Rev-erb in the regulation of circadian 
behaviour and metabolism (Solt et al., 2012b, Cho et al., 2012b). T.P. Burris and co-
workers have shown that two synthetic Rev-erb agonists, named SR9011 and 
SR9009, modulate the expression of key metabolic genes in the liver, skeletal muscle 
and adipose tissue, resulting in enhanced energy expenditure, a reduction in body 
weight and fat mass and a marked improvement in hyperlipidaemia and 
hyperglycaemia in the high fat diet model of type 2 diabetes. (Solt et al., 2012b). 
R.M. Evans and co-workers report an increase in circulatory glucose and triglyceride 
levels in tamoxifen-induced Rev-erb double knockout (Rev-erb α-/- and β-/-) C57BL/6 
mice compared to wild-type mice, suggesting that the presence of functional Rev-erb 
isoforms is critical for maintenance of energy homeostasis (Cho et al., 2012b).  
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1.6. &ITRIC OXIDE: A& OVERVIEW 
 
Nitric oxide synthases (NOS) are flavo-hemoproteins which regulate the synthesis of 
nitric oxide (NO) (Alderton et al., 2001). NO is a short-lived free radical which can 
diffuse freely between cells and mediates its action in an autocrine and paracrine 
fashion (Aktan, 2004, Lowenstein and Padalko, 2004). NO acts as a signalling 
molecule to facilitate biological functions, such as vasodilatation, neurotransmission 
but it may also promote cytotoxicity (Hibbs et al., 1987, Palmer et al., 1987).  
 
1.6.1. STRUCTURE OF &ITRIC OXIDE SY&THASE 
 
Each monomer of the NOS enzyme constitutes of two major domains, a C-terminal 
reductase domain and an N-terminal oxygenase domain. The C-terminal reductase 
domain has a binding site each for cofactors, nicotinamide adenine dinucleotide 
phosphate (NADPH), flavin adenine dinucleotide (FAD) and flavin mononucleotide 
(FMN) (Bredt et al., 1991). The N-terminal oxygenase domain possessesbinding sites 
for cofactors, including, heme and tetrahydrobiopterin (BH4) and also for its 
substrate, L-arginine. In the reductase domain, the flavin cofactors, FAD and FMN, 
facilitate electron transfer from NADPH to heme. The oxygenase domain acts as the 
active site for synthesis of NO (Crane et al., 1998). NOS are activated following 
homodimer formation, which is facilitated by the oxygenase domain (Figure 1.17) 
(Andrew and Mayer, 1999, Alderton et al., 2001). In the final step of the dimerisation 
process, stable incorporation of BH4 facilitates the dimerisation of NOS monomers, 
which have both a reductase and a heme-binding domain (Baek et al., 1993). The two 
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domains of the NOS monomer are linked by a calmodulin (CaM) recognition site. 
Binding of CaM, a calcium-binding messenger protein, to the CaM recognition site 
in the NOS monomer plays a critical role by potentiating electron transfer from the 




Figure 1.17 Structure and reaction catalysed by nitric oxide synthase (NOS). 
Electrons generated by oxidation of NADPH in the reductase domain, reache heme 
present in the oxygenase domain, via flavin cofactors including FAD and FMN, to 
facilitate a reaction between L-arginine and O2 to synthesise citrulline and NO. 
Abbreviations. NADPH, NADP+: Nicotinamide adenine dinucleotide phosphate ± 
hydrogen ion, FAD: Flavin adenine dinucleotide, FMN: Flavin mononucleotide, e-: 
Electron, BH4: tetrahydrobiopterin, Fe: Heme, CaM: Calmodulin, O2: Oxygen, NO: Nitric 
oxide. Picture adapted from Alderton, W.K., Cooper, C.E., and Knowles, R.G. 2001. 
Nitric oxide synthases: structure, function and inhibition. Biochem J 357. Pg.594.   
 
1.6.2. ISOFORMS OF &ITRIC OXIDE SY&THASE 
 
Three distinct isoforms of NOS have been identified and they differ in their 
localisation and regulation (Table 1.5). The two constitutive isoforms, endothelial 
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NOS (eNOS) and neuronal NOS (nNOS), are dependent on calcium (Ca2+) for their 
functionality (Feng, 2012). Both, eNOS and nNOS are expressed as an inactive 
monomer form. The increase in intracellular Ca2+ concentration initiates CaM 
binding to inactive eNOS and nNOS monomers, potentiating formation of active 
homodimers (Stuehr, 1999). In contrast, activity of the inducible NOS (iNOS) 
isoform, is independent of the increase in intracellular Ca2+ concentration because 
CaM binds to iNOS at physiological concentration of Ca2+ (Cho et al., 1992). Hence, 
permanent binding of CaM to iNOS potentiates constant dimerisation and 
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Table 1.5 List of isoforms of nitric oxide synthase and their distinctive feature, 
subcellular localisation and tissue expression.  







1.6.3. REACTIO&S CATALYSED BY &ITRIC OXIDE SY&THASE 
 
NOS facilitate synthesis of NO under physiological conditions (Kwon et al., 1990). 
However, NOS can also cause the synthesis of superoxides in absence of L-arginine 
(List et al., 1997). Both reactions are discussed below in detail. 
 
1.6.3.1. &ITRIC OXIDE SY&THESIS 
 
The primary function of the NOS homodimer is to synthesise NO. The reaction 
between the substrates, L-arginine, NADPH and O2 results in formation of L-
citrulline and NO (Figure 1.17) (Kwon et al., 1990). NO synthesis is a two-step 
process. The first step involves the hydroxylation of L-arginine to form an 
intermediate, NG-hydroxy-L-arginine (NOHLA). In the second step, electron 
oxidation of NOHLA produces L-citrulline and NO (Stuehr et al., 1991). The 
complete reaction consumes 1.5 moles of NADPH and 2 moles of O2 (Feng, 2012).   
 
1.6.3.2. SUPEROXIDE SY&THESIS 
 
NOS are capable of synthesising superoxide (O2
-), particularly in the absence or at 
low concentrations of L-arginine (List et al., 1997). L-arginine is the only 
physiological donor of nitrogen for NOS mediated synthesis of NO. In the absence of 
L-arginine, uncoupled reduction of oxygen leads to the production of superoxide and 
hydrogen peroxide (Morris and Billiar, 1994). The uncoupled reduction of oxygen is 
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dependent on the rate of NADPH oxidation achieved by transfer of electrons from 
NADPH to heme (Andrew and Mayer, 1999). 
 
1.6.4. METABOLITES OF &ITRIC OXIDE 
 
Nitrite (NO2
-) and nitrate (NO3
-) are metabolites of NO. NO reacts with molecular 
oxygen to produce nitrite (Kelm, 1999), a stable metabolite that has also been 
recognised to act as a biological signalling molecule (Bryan et al., 2005). The 
cytotoxicity of NO is chiefly due to the formation of peroxynitrite (ONOO-), an 
unstable structural isomer of nitrate, resulting from a reaction between NO and 
superoxide (Pacher et al., 2007). Peroxynitrite reacts with transition metal centres 
and amino acids to modify protein structure and function (Boccini and Herold, 2004, 
Radi et al., 1991b), initiates lipid peroxidation to cause degeneration of lipids in the 
membrane (Radi et al., 1991a) and mediates oxidative modifications in nucleobases 











1.7. HEME ARGI&ATE 
 
Heme arginate (HA) is a stable and soluble composition of hemin, isolated from 
human blood, and L-arginine in a solution containing propylene glycol, ethanol and 
water (Smirnov et al., 2000). HA was first prepared and tested by Tenhunen and co-
workers in Finland, to improve on hematin solutions (Tenhunen et al., 1987), which 
have a tendency to form heme aggregates and degrade (Goetsch and Bissell, 1986). 
Hematin infusion inhibits coagulation by inactivating thrombin and forming 
complexes with coagulation factors (Jones, 1986). HA unlike hematin, is stable for 
over 2 years if stored at 6oC (Tenhunen et al., 1987) and does not cause significant 
changes in coagulation and fibrinolysis parameters in healthy human volunteers 
(Volin et al., 1988). Importantly, HA has been reported to act as a substrate for heme 
oxygenase and displays anti-porphyrogenic properties in experimental porphyria and 
in humans (Tenhunen et al., 1987, Mustajoki and Nordmann, 1993). 
 
1.7.1. PHARMACOKI&ETICS OF HEME ARGI&ATE 
 
The pharmacokinetics of HA in human volunteers were reported by Tokolo et al in 
1986, where 4 healthy volunteers and 4 asymptomatic patients with porphyria 
received a single intravenous dose of 3 mg/kg of HA (Tokola et al., 1986). No 
significant changes in pharmacokinetics were observed between the two groups. 
Hence, the authors of the research article have presented mean values for 
pharmacokinetic parameters (Table) from all 8 volunteers (Tokola et al., 1986). 
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Parameter Description  Values 
   
Elimination half-
life (t1/2) 
Represents time required for the drug to reach half 
of its original concentration. 
10.8 ± 1.6 hours 
Total plasma 
clearance (Cl) 
Represents volume of plasma cleared of the drug 
per unit time. 
3.7 ± 1.2 ml/min 
Volume of 
distribution (VD) 
Represents volume needed for immediate 
distribution of the drug after intravenous injection. 
3.4 ± 0.9 l 
 
Table 1.6 Pharmacokinetic parameters determined for HA in 8 human volunteers. 




Porphyrias are a genetically heterogenous group of diseases resulting from mutations 
in the genes which encode enzymes that mediate heme biosynthesis (Foran and Ãbel, 
2003). These defects lead to accumulation of toxic intermediates from the heme 
biosynthesis pathway. Porphyrias are clinically classified into acute or non-acute 
forms based on the occurrence of life-threatening acute neurological attacks 
(Poblete-Gutiérrez et al., 2006). Acute intermittent porphyria (AIP) is the most 
common acute porphyria arising due to the autosomal dominant inheritance of a 
defect in porphobilinogen deaminase (PBGD) enzyme (Kauppinen and von und zu 
Fraunberg, 2002) which facilitates synthesis of hydroxymethylbiline, the third 
enzyme in the heme biosynthetic pathway (Figure 1.12) (Furuyama et al., 2007). 
Symptoms of AIP include abdominal pain, constipation, mental disturbances, 
convulsions, fever, and respiratory paralysis that may lead to coma and death (Foran 
and Ãbel, 2003). Biochemical detection of AIP includes identification of the 
porphyrin precursor porphobilinogen (PBG) in the urine as the PBG level has been 
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found to be increased by more than 50-fold compared with controls (Kauppinen and 
von und zu Fraunberg, 2002). Factors including high alcohol consumption, reduced 
carbohydrate intake, or hormones increase the frequency of acute attacks in AIP 
(Poblete-Gutiérrez et al., 2006). 
 
1.7.3. TREATME&T OF PORPHYRIAS 
 
In United Kingdom, patients with acute symptomatic porphyria receive treatment. 
Glucose and heme-based infusion therapy are standard therapies for the treatment of 
porphyrias (Poblete-Gutiérrez et al., 2006), which are discussed below. 
 
1.7.3.1. GLUCOSE ADMI&ISTRATIO& 
 
One of the  therapies for porphyria is administration of glucose as this can decrease 
heme biosynthesis (Foran and Ãbel, 2003).. The glucose-dependent decrease in 
porphyrin synthesis is mediated by the insulin/PGC-1α/ALAS1 axis in liver 
(Handschin et al., 2005). Proliferator-activated receptor γ coactivator 1α (PGC-1α) is 
a coactivator of nuclear receptors and transcription factors (Puigserver and 
Spiegelman, 2003). An increase in gluconeogenesis is mediated by PGC-1α during 
the fasted state. In addition, PGC-1α induces gene expression of ALAS1 (Handschin 
et al., 2005), the rate limiting enzyme in heme biosynthesis (Furuyama et al., 2007). 
Insulin exerts negative control over PGC-1α expression, firstly by reducing glucagon 
release (Bansal and Wang, 2008), and secondly, by inhibiting PGC-1α via Akt 
mediated phosphorylation of FoxO1 (Puigserver et al., 2003). Hence, an increase in 
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insulin secretion following glucose administration can reduce the PGC-1α mediated 
increase in ALAS1 function, resulting in a decrease in heme synthesis (Handschin et 
al., 2005). 
 
1.7.3.2. HEME ARGI&ATE I&FUSIO& 
 
The mainstay of treatment for AIP is administration of a heme preparation (Foran 
and Ãbel, 2003). Heme arginate (HA) is licensed for use in patients with porphyria in 
several countries of Europe including United Kingdom. The recommended dose for 
HA is 3 mg/kg, once daily for 4 consecutive days (Poblete-Gutiérrez et al., 2006). 
The underlying principle for using HA is the ability of the heme component of HA to 
repress ALAS1 by a number of feed-back mechanisms including a reduction in gene 
transcription, mRNA stability and transport of pre-ALAS1 into mitochondria (Figure 
1.18) (Yamamoto et al., 1988). A study using the avian ALAS1 gene promoter in 
Leghorn male hepatoma cells in culture showed that the promoter region of the 
ALAS1 gene had regulatory regions which respond to hemin (Kolluri et al., 2005). 
Hemin has been shown reduce ALAS1 mRNA stability by decreasing the half-life of 
ALAS1 mRNA in chick embryo hepatocytes (Hamilton et al., 1991). Furthermore, 
hemin specifically inhibits transfer of pre-ALAS1 from the cytosol into the 





Figure 1.18 Negative feedback regulation of ALAS1 by heme. An increase in 
intracellular heme concentration leads to negative feedback control of ALAS1 gene 
expression by several mechanisms, including reduction in the transcription, and mRNA 
stability of ALAS1 and inhibition of transportation of pre-ALAS1 from the cytosol into 
mitochondria. Abbreviations. ALAS1: 5-aminolevulinate synthase, CO: Carbon 
monoxide. Picture adapted from Kolluri, S., Sadlon, T.J., May, B.K. and Bonkovsky, 
H.L. 2005. Haem repression of the housekeeping 5-aminolevulinic acid synthase gene 














1.8. AIMS OF THE PROJECT 
 
In the current PhD project entitled ‘The role of heme arginate in modulation of 
inflammation and type 2 diabetes’, three key hypothesises listed below were tested 
 
i. Heme component of heme arginate (HA) has anti-hyperglycaemic effect in the 
db/db mouse model of type 2 diabetes. 
ii. HA induced heme oxygenase (HO) activity potentiates anti-hyperglycaemic 
effect in db/db mouse model of type 2 diabetes. 









































2.1. MATERIALS A&D REAGE&TS 
 
2.1.1. METALLO-PORPHYRI& COMPOU&DS 
 
Heme arginate (HA) was purchased from Orphan Europe (Paris La Défense, France). 
Other metallo-porphyrin compounds, including the HO activity inducer, cobalt (III) 
protoporphyrin IX chloride (CoPP), and the HO activity inhibitors, stannous (IV) 
mesoporphyrin IX dichloride (SM) and chromium (III) mesoporphyrin IX chloride 
(CrMP), were purchased from Frontier scientific (Logan, U.S.A). For in vitro 
studies, 25mg of amorphous CoPP, SM and CrMP were dissolved in 3ml of 
10mmol/l Tris-NaOH solution, pH 14.0. The stock concentration and pH were 
adjusted to 8-12µM and pH 7.4 respectively using 10mmol/l Tris-HCl solution, pH 
7.0 and 0.1N hydrochloric acid (HCl). The aliquots were wrapped in foil and stored 
at 4oC and for a month. 
 
The tetrapyrrole structure of porphyrin molecule enables it to absorb light energy in 
the visible spectrum, particularly in the sorbet (400 nm) band (Poh-Fitzpatrick, 1985, 
Spikes, 1975). This causes transformation of the stable porphyrin molecule into an 
excited state molecule, where it can act as electron donor to facilitate several 
chemical reactions, including formation of reactive oxygen species (Dalton et al., 
1972). Hence, to avoid the unwarranted photosensitive chemical reactions, the 




2.1.2. TISSUE CULTURE REAGE&TS, MATERIALS A&D EQUIPME&TS 
 
Tissue culture reagents and materials, including heat-inactivated fetal calf serum (HI-
FCS), penicillin streptomycin (PS), Corning tissue culture flasks and plates were 
from Sigma Aldrich (Dorset, U.K.). GIBCO Dulbecco’s modified Eagle medium 
[DMEM] from Invitrogen (Paisley, U.K.), Dulbecco’s phosphate buffered saline 
[PBS] from PAA laboratories (Somerset, U.K.) and Falcon conical tubes, syringes 
and needles from Becton, Dickinson (Oxford, U.K.) were also employed.  All other 
chemicals were purchased from Sigma Aldrich (Dorset, U.K.) unless otherwise 
stated in the text. A IEC Micro CL17R microfuge from Thermo Electron Corp. 
(Wilmington, U.S.A) and a Rotina 420R from DJB Labcare (Buckinghamshire, 
U.K.) were used for centrifugation. 
 
2.2. I VIVO STUDIES A&D FU&CTIO&AL TESTS 
 
In vivo studies were carried out in diabetic (C57BL/KsOlaHsd-leprdb/leprdb or, db/db) 
mice, a model of type 2 diabetes. The db/db mice are C57BL/KsJ inbred strain of 
mice with mutation for leptin receptor on chromosome 4. Hence, leptin regulated 
control over appetite is lost leading to hyperphagia that results in obesity and the 
development of insulin resistance and type 2 diabetes (Shafrir et al., 1999). 
Therefore, wild-type C57BL/KsJ mice were used as lean and non-diabetic control for 




2.2.1. COMPOU&D PREPARATIO& FOR I VIVO STUDIES 
 
Dilution of HA and SM was performed in minimal light. HA was available as a 
solution at concentration of 25mg/ml. It was diluted 1:5 in PBS prior to intravenous 
(i.v.) injections. Amorphous SM (25mg) was dissolved in 3ml of 10mmol/l Tris-
NaOH solution, pH 14.0. The concentration and pH were adjusted to 5mg/ml and pH 
7.8 respectively using 10mmol/l Tris-HCl solution, pH 7.0 and 0.1 N HCl. 
 
2.2.2. PROTOCOL FOR I VIVO STUDIES 
 
All in vivo experiments were carried out in accordance with protocols and guidelines 
outlined in project and personal license issued by the Home Office, U.K. Ten week 
old male lean C57BL/KsJ and diabetic db/db (Harlan laboratories, U.K.) mice were 
housed in groups of four per cage in the animal facility of the College of Medicine 
and Veterinary Medicine, University of Edinburgh. The mice were provided with 
water and RM1 feed ad libitum, except when fasted for four hours, to perform 
functional tests. The mice were weight and blood sugar matched on day 1 of the 
experiments for allocation to their treatment groups. The mice were anaesthetized 
using iso-flurane prior to intravenous injections to minimize stress. In vivo 
experiments were carried out for 8 weeks according to the treatment regime outlined 
in table 2.1.  
 
 
At the end of the in vivo study, mice were anaesthetized to collect blood by cardiac 
puncture and organs, including pancreas, fat depots (epididymal, sub-cutaneous, 
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retroperitoneal), liver, spleen and kidneys. Organs were snap-frozen in liquid 
nitrogen and fixed in methyl-Carnoy’s solution (60% methanol, 30% chloroform and 
10% acetic acid) for histological examination.  
 
Study &o. Treatments Dose Injection/
week 
Administration route 
     
01 & 02 PBS 150µl 2 
01 & 02 HA  15 mg/kg 2 
01 L-arginine (LA) 20 mg/kg 2 
Intravenously via tail 
vein 
02 SM 20 mg/kg 3 Intraperitoneal 
02 Tris-NaOH pH 7.8 150µl 3 Intraperitoneal 
 
Table 2.1 Treatments, doses, administration and duration of the in vivo studies. 
 
2.2.3. FU&CTIO&AL TESTS CARRIED OUT DURI&G I VIVO STUDIES 
 
i. Fasting blood glucose: The mice were weighed and fasted for four hours. A 
small tail vein prick was made using a sterile needle and a drop of blood was 
applied to the glucose monitor strip attached to the glucometer (Accu-check 
Aviva glucometer, Roche, U.S.A.) to measure fasting blood glucose 
concentrations. Tail vein blood from each mouse was collected in a microvette 
(CB300 Kalium-EDTA blood collecting vials, SARSTEDT, U.K.) for further 
diagnostic assays to measure insulin, free fatty acids, and triglycerides. 
 
ii. Glucose tolerance test (GTT): The mice were fasted for 4 hours, weighed and 
injected intraperitoneally (i.p.) with glucose solution to achieve a final dose of 2 
gram glucose per kilogram body weight (2g/kg). Tail vein prick was performed 
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to collect blood at 0, 15, 30, 60 and 120 minutes post i.p. glucose injection. 
Microvettes were centrifuged at 7000g for 10 minutes at 4oC. Non-haemolysed 
serum (~20µl) was aspirated and transferred to 0.5ml labelled Eppendorff tubes 
for storage at -80oC. The blood sugar levels were then quantified using a 
hexokinase glucose assay (see 2.4), as blood glucose concentrations during the 
GTT frequently exceeded the upper limit of the quantification range of the 
glucometer.  
 
iii. Insulin tolerance test (ITT): The mice were fasted for 4 hours, weighed and 
injected i.p. with insulin at a concentration of 1 unit insulin per kilogram body 
weight (1 unit/kg). Tail vein prick was performed and blood glucose readings 
were obtained at 0, 15, 30, 60 and 120 minutes post insulin injection using a 
glucometer.  
 
iv. Food intake: Food intake was monitored over six days during week 7 and 8 of 
the in vivo study. The db/db mice were housed in individual cages and each cage 
was provided with 150 grams of RM1 chow. The chow left on each cage was 
weighed at the end of 6 days and mean daily food intake was determined by the 
formula ‘(150-end chow weight)/6’. 
 
2.3. I&SULI& ELISA ASSAY 
 
The kit is based on the sandwich enzyme-linked immuno-sorbent assay (ELISA) 
technique, where an antigen is immobilized between two antigen specific antibodies 
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of which one is conjugated to an enzyme that oxidises the chromogenic substrate to 
produce a blue coloured end-product (Figure 2.1) (Jordan et al., 2005). Absorbance is 
then quantified in each well of the plate using a plate reader. The absorbance signal 
is proportionate to the amount of insulin antigen in the sample and is converted to an 




Figure 2.1 Principle of sandwich enzyme-linked immuno-sorbent assay (ELISA). 
The technique utilizes an enzyme-substrate reaction to convert a colourless chromogen 
into a coloured end product. 96 well-plates (wp) are coated with an antigen specific 
capture antibody to capture and immobilize antigens present in the sample. A second 
biotin or horseradish peroxidase (HRP) conjugated antigen specific detection antibody is 
added to sandwich the antigen between two layers of antibodies for greater specificity. 
At the end, 3, 3’, 5, 5’- tetramethylbenzidine (TMB) which is a substrate for HRP is 
added to catalyze a reaction that produces a blue detectable byproduct. If a biotin-
labeled detection antibody has been used (as in Duoset ELISA kits for cytokine 
measurements unlike Insulin ELISA kit which uses HRP-conjugated detection antibody), 
a streptavidin-HRP conjugated secondary detection antibody is applied prior to reaction 
with TMB.  Biotin-streptavidin is often used for to amplify the signal as (strep)avidin has 





MATERIALS: Ultra sensitive mouse insulin ELISA kit (Crystal Chem Inc, 
Downers Grove, U.S.A.), Synergy HT microplate reader (BioTek, Bad, Germany). 
 
METHOD: To create a standard curve, an insulin standard (12.8ng/ml) underwent 8 
serial 1:2 dilution in reagent diluent. The serum samples were diluted 20x in reagent 
diluent. The diluted samples and standards were pipetted (100µl/well; in duplicates) 
into a microplate pre-coated with guinea pig anti-insulin antibody and incubated for 
2 hours at 4oC The plate was washed 5x with wash buffer (PBS + 0.05% v/v Tween-
20) before incubating with 100µl/well of horse radish peroxidase (HRP) conjugated 
anti-insulin antibody at room temperature for 30 minutes. The plate was washed 7x 
with wash buffer before adding 100µl/well of 3, 3’, 5, 5’- tetramethylbenzidine 
(TMB) substrate solution to facilitate the reaction with HRP to produce a blue-
coloured by-product over a period of 40 minutes at room temperature in the dark. 
The reaction was stopped by addition of 1N sulphuric acid and absorbance was read 
at 450nm on the microplate reader.  The concentration of insulin in serum samples 
were determined based on absorbance readings from the insulin standard curve.  
 
2.4. MEASUREME&T OF SERUM GLUCOSE LEVELS USI&G 
HEXOKI&ASE ‘GLUCOSE’ ASSAY 
 
The hexokinase reagent initiate a two-step breakdown of glucose into 6-
phosphogluconate with glucose-6-phosphate as an intermediate product. The reaction 
results in the reduction of nicotine adenine dinucleotide (NAD+) into NADH whose 
absorbance is measured to quantify the amount of glucose in system.     
 90 
MATERIALS: Infinity glucose hexokinase reagent (Thermo Scientific, 
Wilmington, U.K.), 44.4 mmol/l D-glucose solution, Synergy HT microplate reader. 
 
METHOD: Serum samples from the GTT were thawed on ice. A four point standard 
curve (1:2 serial dilutions) was prepared using a starting concentration of 44.4mmol/l 
D-glucose. 2µl of standards and samples were pipetted into a flat bottom 96 well-
plate kept on ice for 15 minutes. The plate was incubated for 3 minutes at 37oC and 
absorbance was read at 340 nm on a microplate reader set at 37oC. 
 
2.5. &O&-ESTERIFIED FATTY ACIDS (&EFA) ASSAY 
 
The NEFA assay is based on the three-step enzymatic reactions outlined in table 2.2. 
 
Steps Reactant Catalyst Product 
    
01 NEFA Acyl-CoA synthetase (ACS) Acyl-CoA 
02 Acyl-CoA Acyl-CoA oxidase (ACOD) 2, 3-trans-Enoyl-CoA + H202 
03 H202+MEHA+4-AAP Peroxidase Purple coloured product 
 
Table 2.2 Enzymatic reactions catalysed by NEFA reagents. 
Abbreviations. H2O2- Hydrogen peroxide, MEHA- 3-methyl-N-ethyl-N-(β-hydroxyethyl)-




MATERIALS: NEFA-HR2 kit (Wako Chemicals, Neuss, Germany), flat bottom 96 
well plate, Synergy HT microplate reader. 
 
METHOD: 5µl/well of water (blank), standard (1mmol/l) and thawed serum 
samples were pipetted into a 96 well-plate which was cooled on ice for 15 minutes.  
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160µl/well of reagent A (0.53U/ml ACS, 0.31mmol/l CoA, 4.3mmol/l ATP, 
1.5mmol/l 4-AA) was added and incubated at 37oC for 3 minutes to initiate the first 
reaction. Immediately, 80µl/well of reagent B (12U/ml ACOD, 14U/ml HRP, 
2.4mmol/l MEHA) was added and the plate was incubated at 37oC for 4.5 minutes to 
produce purple coloured end-product. Absorbance was read at 546 and 660nm at 
37oC. The absorbance read at 660nm was deducted from the absorbance reading 
taken at 546nm for each sample and standard. Serum NEFA concentration was 
determined based on absorbance reading for the standard. 
 
2.6. TRIGLYCERIDE ASSAY 
 
The enzymatic triglyceride conversion assay is based on the method of Wako and 
modifications by McGowan et al. and Fossati et al. The four-step conversion reaction 
is outlined in table 2.3. 
  
Steps Reactant Catalyst Product 
    
01 Triglyceride Lipase Glycerol +NEFA 
02 Glycerol  Glycerol kinase + ATP Glycerol-3-phosphate  
03 Glycerol-3-phosphate Glycerol phosphate oxidase Di-hydroxyacetone 
phosphate + H202 
04 H202 + 4-AAP + DHBS Peroxidase Red coloured dye 
 
Table 2.3 Enzymatic reactions catalysed by triglyceride reagent. 




MATERIALS: Infinity triglyceride kit (Thermo Scientific, Northumberland, U.K.), 
Synergy HT microplate reader. 
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METHOD: Liver triglyceride content was determined by performing isopropanol 
extraction of lipids. Approximately 100mg of frozen liver was homogenised in 1ml 
of isopropanol. The homogenate was placed on a plate shaker for 45 minutes with a 
vigorous vortex every 10 minutes. The homogenates were centrifuged at 3000g for 
10 minutes and the clear supernatant was collected and stored on ice. In the 
meantime, a 96 well-plate was placed on ice. 2µl of isopropanol (blank), standard 
(2.5mmol/l) and liver samples were pipetted into 96 well-plates. The plate was 
incubated at 37oC for 5 minutes after 200µl/well of triglyceride reagent was added. 
Absorbance was read at 500nm at 37oC. The triglyceride concentration of samples 
was determined based on the absorbance reading for standards and was normalized 
for the mass of liver that was homogenised. 
 
2.7. CULTURI&G A&D STIMULATIO& OF MI&6 β-CELL LI&E 
 
MIN6 is a routinely used mouse β-cell line which was established from the 
insulinoma that developed in a transgenic mouse which had a human insulin 
promoter connected to SV40 T-antigen gene (Inada et al., 1996). The mouse 
insulinoma MIN6 β-cell line was kindly provided by Dr. N.M. Morton (University of 
Edinburgh/Centre for Cardiovascular Science) for the current study. 
 
MATERIALS: Insulinoma MIN6 β-cell line cell at passage number 18, cell culture 
reagents and materials mentioned in section 2.1.2., TNF-α and IL-1β derived from 
E.coli (R&D system, Abingdon, U.K.), TRIZOL reagent (Invitrogen, Paisley, U.K.). 
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METHOD: The MIN6 β-cell line was serially passaged once or twice a week once a 
confluency of approximately 80% was achieved. Serial passaging was performed for 
2-3 weeks prior to performing experiments in DMEM medium containing 5.5mM D-
glucose, 15% heat-inactivated fetal calf serum (HI-FCS), penicillin (100U/ml), 
streptomycin (100µg/ml) and β-mercaptoethanol (5µl/ml) at 37oC, 5% CO2.  
 
The experiments were carried out between cell passage numbers 25-35. MIN6 β-cells 
was plated at cell density of half a million (0.5 x 106) cells per well in 12 well-plates. 
The plates were incubated for 48 hours at 37oC, 5% CO2. Non-adherent cells were 
washed off twice with PBS. The cells were pre-treated in fresh medium with either 
10µl of PBS (vehicle) or the HO activity inhibitor SM (20µM) for 2 hours before 
adding the HO activity inducer HA (20µM). The cells with PBS and HA±SM added 
were either incubated at 37oC, 5% CO2 for 24 hours for western blotting or for 4 
hours prior to stimulation with cytokine mix. The cytokine mix containing IL-1β, 
IFN-γ and TNF-α at final concentration of 5ng/ml, 100ng/ml and 10ng/ml 
respectively was added to the medium and incubated for 20 hours at 37oC, 5% CO2.  
 
Following 20 hours stimulation with cytokine mix, supernatant for each treatment 
was harvested for nitrite determination. The plated cells for each treatment were 
washed twice with PBS and harvested in 1ml of TRIZOL reagent and stored at -80oC 
for subsequent RNA extraction. In some experiments, plated cells for each treatment 
were trypsinised to dislodge them from the surface of the plate and collected by 
centrifugation at 300g for 5 minutes at room temperature to perform cytospin 
preparations (Refer to section-2.20) to determine iNOS expression by immuno-
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fluorescence. Please refer to the section 5.2 of chapter 5 for a flow chart 
representation (Figure 5.1) of the protocol and for the concentration of compounds 
used (Table 5.1). 
 
2.8. PREPARATIO& A&D CULTURI&G OF BO&E MARROW DERIVED 
MACROPHAGES (BMDMs) 
 
Bone marrow derived macrophages (BMDM) are routinely used to characterize the 
anti-inflammatory effect of different compounds.  
 
MATERIALS: DMEM, cell culture reagents and materials mentioned in section 
2.1.2., 70% ethanol, autoclaved teflon pots and forceps, 10ml syringes and 19G and 
25G needles. 
 
METHOD: DMEM medium with 10% HI FCS and 1% PS (DMEM-PS10F) was 
made up in a sterile tissue culture hood. BMDMs were prepared from 6-8 week old 
C57BL/KsJ mice. The mice were sacrificed by cervical dislocation (schedule 1 
procedure). The abdomen and lower limbs were wiped and cleaned with 70% ethanol 
and the lower limbs were exposed by making a midline incision and removing the fur 
coat. The femur was isolated by cutting the lower limbs at the pelvis level and at the 
mid-point of the tibia and transferred to ice-cold DMEM-PS10F. Under aseptic 
conditions in a tissue culture hood, the soft tissues attached to the femur were 
removed using a sterilised scalpel and thoroughly cleaned with a bacteriological 
wipe. The cleaned femurs were surface sterilised by dipping in 70% ethanol and 
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transferred to bijous containing 5ml of DMEM-PS10F. The femur was decapitated at 
both ends, exposing the marrow cavity. Bone marrow from the femur was isolated by 
flushing 10ml of DMEM-PS10F using a 25G needle through the marrow cavity into 
a 60ml teflon pot. Bone marrow cell clumps were broken into a single cell 
suspension by aspirating through a 19G needle five times in the teflon pot. 30ml of 
DMEM-PS10F with 20% (v/v) of L929 medium containing macrophage colony 
stimulating factor (M-CSF) was added to produce a final volume to 40ml in teflon 
pots. Teflon pots were incubated at 37oC, 5% CO2 for 6 days. 10ml of medium from 
the teflon pot was replaced with fresh L929 containing medium on alternate days. At 
the end of 6 days, the entire medium containing BMDM was transferred to a 50ml 
falcon tube and centrifuged at 300g for 5 minutes at room temperature. BMDM 
pellets were re-suspended in DMEM-PS10F containing 20% (v/v) of L929 medium 
and plated in 6 or 12 well plates for terminal differentiation. 
 
2.9. STIMULATIO& OF BMDMs FOR I VITRO STUDIES 
 
The in vitro stimulation of macrophages with either lipopolysaccharide (LPS) or 
interferon (IFN)-γ or both mimics the activation of macrophage in an inflammatory 
micro-environment in vivo. 
 
MATERIALS: LPS (Sigma Aldrich, Dorset, U.K.), DMEM-PS10F, Micro-
centrifuge, trichostatin, metallo-porphyrin compounds listed in section 2.1.1. and 
tissue culture reagents and materials listed in section 2.1.2. 
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METHOD: BMDM were plated in either 6 or 12 well plates at a cell density of 0.5 x 
106 cells/well in 1ml of fresh medium (DMEM-PS10F supplemented with 20% (v/v) 
of L929 medium) and incubated overnight at 37oC, 5% CO2, The medium in each 
well was aspirated off and 1ml of fresh medium was added. BMDMs were pre-
treated with either PBS or HO activity inhibitors or trichostatin (TSA; inhibitor of 
histone deacetylases) for 2-4 hours prior to addition of PBS or HO activity inducers. 
Following incubation for 20 hours, the BMDMs in each well were washed twice with 
warm PBS before being stimulated with LPS for another 24 hours. Each treatment 
was performed in duplicate.  
 
At the end of experiment, the medium from each well was collected, centrifuged at 
10,000g for 2 minutes and the supernatants were aliquoted in 0.5ml Eppendorff tubes 
and stored at -80oC for ELISA and Griess assay. The cells for each treatment were 
either lysed in 1ml of TRIZOL or scraped off and harvested for gene and protein 
expression studies respectively. Refer to section 6.2 of chapter 6 for a flow chart 
representation (Figure 6.2) of the protocol and the concentration of compounds used 
(Table 6.1). 
 
2.10.  ALAMAR BLUE CELL VIABILITY ASSAY 
 
The alamar blue cell viability assay is based on the colorimetric conversion of the 
cell permeable blue coloured dye ‘resazurin’ into the fluorescent red molecule 
‘resorufin’ in response to cellular metabolic reduction. 
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MATERIALS: Flat bottom 96 well-plates, Multi-channel pipette (Thermo 
Scientific, Wilmington, U.K.), Alamar blue (AbD Serotec, Kidlington, U.K.), 
Synergy HT microplate reader. 
 
METHOD: A diluted cell suspension stock of MIN6 β-cells and BMDMs was 
prepared to a density of 25000 cells per 100µl. An automatic multi-tip pipette was 
used to pipette 100µl of cell suspension per well in a 96 well-plate. The plates were 
then incubated in the incubator at 37oC, 5% CO2 for 24 hours. Post incubation, HA 
and other metallo-porphyrin compounds were diluted in PBS at the desired 
concentration (ranged between 1-10µM). The medium in the 96 well-plate was 
aspirated off and plated cells were washed twice with 100µl/well of warm PBS. 
100µl/well of the diluted compounds was added in triplicate to the seeded plates 
which were incubated for 24 hours at 37oC and 5% CO2. After 24 hour, the media 
containing the treatments were aspirated off and the cells were washed twice with 
warm PBS. 100µl/well of 10% (v/v) of Alamar Blue diluted in DMEM medium was 
added and the 96 well-plate was placed back in the incubator for 4 hours.  The 
absorbance was read at excitation 570nm and 600nm.  
 
A&ALYSIS: The percentage reduction in Alamar blue (AB) was calculated based on 
the equation provided [{(O2 x A1) – (O1 x A2)} {(R1 x N2) – (R2 x N1)}-1] x 100 
where, 
 O1: Molar extinction coefficient (E) of oxidised AB at 570nm (E=80586) 
 O2: E of oxidised AB at 600nm (E=117216) 
 A1: Absorbance of test wells at 570nm 
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 A2: Absorbance of test wells at 600nm 
 R1: E of reduced AB at 570nm (E=155677) 
 R2: E of reduced AB at 600nm (E=14652) 
 N1: Absorbance of negative control (medium + Alamar blue - cells) at 570nm 
 N2: Absorbance of negative control at 600nm 
 
Once the percentage of reduction in alamar blue was calculated, the values for test 
samples were normalised to the value of the control (PBS treatment) sample and 
expressed as ‘percentage cell viability’. 
 
2.11.  ELISA ASSAY FOR I&FLAMMATORY MEDIATORS 
 
Activated macrophages release inflammatory mediators, including cytokines, to 
orchestrate different stages of inflammation. In the present study, the levels of pro-
inflammatory mediators including TNF-α and IL-6 as well as IL-10, a potent anti-
inflammatory cytokine release by LPS activated BMDMs with different pre-
treatments were determined using detection kits based on the sandwich ELISA 
methodology (Figure 2.1).  
 
MATERIALS: Duoset ELISA kits for TNF-α, IL-6, IL-10 (R&D system, Abingdon, 
U.K.), RIA flat bottom 96 well-plates, Synergy HT microplate reader. 
 
METHOD: Kits based on the sandwich ELISA technique was used for cytokine 
determination. The cytokine ELISAs were performed according to the 
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manufacturers’ instructions. Briefly, RIA 96 well-plates were coated with 100µl/well 
of capture antibody and left overnight at room temperature. The plates were blocked 
with 1% BSA solution in PBS for an hour. Standards were prepared using 1:2 serial 
dilutions and 100µl/ml of samples (BMDM supernatant) and standards were added 
(duplicate wells/sample) and incubated for 2 hours at room temperature for antigen 
capture. The plate was washed 3x with wash buffer (PBS + 0.05% v/v Tween-20) 
before incubating with 100µl/well of biotin-labeled detection antibody at room 
temperature for 90 minutes. Post incubation with detection antibody, 100µl/well of 
1:200 diluted streptavidin-HRP conjugated secondary detection antibody was added 
once the plate was washed 3x with wash buffer. The plate was incubated at 30 
minutes at room temperature in dark. Post incubation, the plate was washed with 3x 
with wash buffer before adding 100µl/well of TMB substrate which was converted 
by HRP into a blue-coloured byproduct over a period of 10 minutes at room 
temperature in the dark. The reaction was stopped by the addition of 50µl/well of 1N 
sulphuric acid and the absorbance was read at 450nm on the microplate reader. The 
concentration of cytokines in the samples was determined by referencing the 
absorbance of the sample to the absorbance in the standard curve. 
 
2.12.  GRIESS ‘&ITRITE’ ASSAY 
 
The Griess method of nitrite determination is based on the reaction of nitrite with 
sulfanilic acid to form a diazonium salt that reacts with 1-(1-naphthyl) 
ethylenediamine to produce a coloured azo-dye whose absorbance was read 
spectrophotometrically. 
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MATERIALS: Griess reagent, Nitrite standard 0.1M (Promega, Southampton, 
U.K.), flat bottom 96 well-plate, Synergy HT microplate reader. 
 
METHOD: 50µl of 1:2 serially diluted standards and samples (BMDM supernatant) 
and 50µl Griess reagent were pipetted into a 96 well-plate. Each standard and sample 
was in duplicate wells. The plate was placed on a shaker for 20 minutes at room 
temperature and the absorbance was read at 540nm. The concentration of nitrite in 
the samples was determined by referencing the absorbance of the sample to the 
absorbance in the standard curve.   
 
2.13.  R&A EXTRACTIO& FROM CELLS A&D TISSUES 
 
An extraction buffer containing high chaotropic ions and RNase inhibitors is used to 
solubilise macromolecules and prevent RNA degradation respectively during the 
extraction process.  
 
MATERIALS: NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany).  
 
METHOD: Different kits were employed for RNA extractions from cells and 
tissues, hence they are discussed separately. 
 
i. R&A extraction from MI&6 β-cells and BMDMs: RNA extraction from cells 
was carried out according to manufacturer’s guidelines for TRIZOL reagent. 
TRIZOL reagent contains phenol and guanidine isothiocyanate that inhibit RNase 
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activity thereby preventing RNA degradation. TRIZOL lysed cells stored at -
80oC were thawed on the bench for 10 minutes prior to performing a phase 
separation step using chloroform. 200µl of chloroform per ml of TRIZOL was 
added to the Eppendorff tubes, vortexed and incubated at room temperature for 5 
minutes. The Eppendorff tubes were centrifuged at 13,000g for 10 minutes at 
4oC. The clear phase was pipetted into a new Eppendorff tubes and incubated 
with an equal volume of isopropanol for 15 minutes at 4oC. RNA in samples was 
precipitated by centrifuging at 13,000g for 25 minutes at 4oC. The supernatant 
was aspirated and RNA precipitates in the Eppendorff tubes were washed with 
ice-cold 75% ethanol. RNA precipitates were dissolved in 20µl RNase free water 
once ethanol was evaporated and incubated for 10 minutes at 55oC on a hot plate. 
 
ii. R&A extraction from tissues including liver and adipose tissue: RNA 
extraction from tissues of C57BL/KsJ and db/db mice was performed using the 
NucleoSpin RNA II kit. Briefly, tissues were homogenised in 350µl of RA1 
buffer which contained 1% (v/v) β-mercaptoethanol and centrifuged for 1 minute 
at 11,000g in a NucleoSpin filter column. Clear filtrate was mixed with equal 
volume of ice-cold 70% ethanol in RNase free water in a RNA binding column 
and centrifuged at 11,000g for 30 seconds to bind RNA in the filtrate to a silica 
membrane. Silica membrane bound RNA was washed subsequently with 
desalting buffer, DNase for DNA removal and wash buffers. Purified RNA was 




2.14.  cD&A SY&THESIS BY REVERSE TRA&SCRIPTIO& 
 
Prior to performing real time PCR, RNA must be reverse transcribed into 
complementary DNA (cDNA). RNA-directed DNA polymerase enzyme initiates 
cDNA synthesis using mRNA as a template in the presence of deoxy-ribonucleotide 
triphosphates (dNTP) and random primers to produce short pieces of cDNA from 
different regions of the mRNA template. 
 
MATERIALS: High capacity cDNA reverse transcription (RT) kit (Applied 
Biosystems, Warrington, U.K.), PTC-100 Thermal controller (MJ Research Inc., 
Reno, U.S.A.), NanoDrop ND-1000 spectrophotometer (Thermo Scientific, 
Wilmington, U.K.). 
 
S.&o. Constituent Volume/Reaction (µl) Final concentration 
    
01 10x RT Buffer 2 1x 
02 25x dNTP mix (100mM) 0.8 4mM 
03 10x RT Random primers 2 1x 
04 Reverse transcriptase (50U/µl) 1 50U 
05 RNase inhibitor 1  
06 Nuclease free water 3.2  
 
Table 2.4 Reverse transcription master mix constituent. 




METHOD: RNA was quantified in samples by reading the absorbance at 340nm on 
a NanoDrop spectrophotometer. The cDNA synthesis from mRNA was performed 
according to the RT kit instruction manual. Briefly, 1µg of mRNA was adjusted to a 
volume of 10µl using RNase free water and mixed with 10µl reverse transcription 
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master mix (table 2.4).  Reverse transcription was carried out at 37oC for 2 hours and 
the reaction was terminated by raising the temperature to 85oC for 5 minutes on a 
programmed thermal controller. The cDNA samples were then stored at -80oC. 
 
2.15.  REAL TIME POLYMERASE CHAI& REACTIO& (RT PCR) 
 
In RT PCR, the amount of cDNA present at the end of each PCR cycle is determined 
by the use of fluorescent probes. Oligonucleotide probes are designed to be 
complementary to a short sequence of the target cDNA and primers are 
complementary to the target cDNA on either side of the probe, thus amplifying the 
DNA region containing the probe binding site.  
 
The oligonucleotide probes contain a fluorophore at 5’end and a quencher at 3’ end. 
The quencher inhibits the fluorophore activity as long as they are in association by 
proximity (Figure 2.2). The nuclease activity of DNA polymerase (polymerase 
isolated from thermophilic bacterium Thermus aquaticus also known as Taq 
polymerase) initiates synthesis of the strand in a 5’→3’ direction and cleaves the 
fluorophore molecule attached to the 5’ end of the primer. The level of fluorescence 
of the cleaved fluorophore is proportional to the amount of target DNA present at 
end of each PCR cycle. 
 
 
MATERIALS: TaqMan inventoried primers and TaqMan Universal PCR master 




Figure 2.2 Diagrammatic representation of the Taq polymerase based detection 
system for quantitative analysis of DNA synthesis. An oligonucleotide probe 
complementary to the target cDNA contains a fluorophore at the 5’end and a quencher 
at the 3’ end. The quencher (Q) inhibits the fluorophore (F) activity while they are in 
close proximity. Once the amplification process i.e. synthesis of the nascent strand from 
the primers annealed to the cDNA strand by the activity begins, the 5’→3’ exonuclease 
activity of Taq polymerase cleaves the probe from the 5’ end releasing the fluorophore 
from the proximity of quencher to allow the fluorophore to fluorescence. The 
fluorescence is then proportional to the amount of DNA. 
 
 
METHOD: 1µl of 20x TaqMan inventoried primers and probe of interest and 9µl of 
2x PCR master mixes was added to 5ng cDNA in a total volume of 20µl in a fast 96 
well reaction plate. Polymerase chain reaction was performed for 40 cycles on an 
Applied Biosystems Fast Real time 7500 PCR machine using the automated program 




S. &o Steps Duration Temperature 
    
01 DNA polymerase activation 10 minutes 95oC 
02 Melting (per cycle) 15 seconds 95oC 
03 Annealing & extension (per cycle) 1 minute 60oC 
 




A&ALYSIS: Analysis was performed on SDS Software 1.3.1. The baseline 
amplification plot was adjusted such that the threshold was located in the linear 
phase of the exponential fluorescence curve, above the background noise. The 
software generated a threshold cycle (CT) value for each sample that represented the 
cycle number at which the fluorescence passed the threshold.   
 
 
Figure 2.3 Representative amplification plot for 18S gene in the BMDMs. The 
baseline was set to capture the exponential phase of fluorescence and discount the 
background. The cycle number at which fluorescence level crosses threshold limit 
represents the threshold cycle (CT) value. In the above representative figure, the red 
arrows represent the CT values. The cycle numbers between which the fluorescence for 
the 18S gene reached threshold. 
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The gene expression is expressed relative to a house-keeping gene expression. 
Hence, the ∆CT value was calculated based on the difference of the CT values 
between the target gene and house-keeping gene such as 18S. The gene expression 
needs to be normalized to the control group of the experiment too. Thus, calibrator 
value was calculated by averaging the ∆CT value of the control group (Eg: PBS 
treatment) of the experiment. Then, the ∆∆CT value for each sample was calculated 
by subtracting the mean ∆CT value of the calibrator from the ∆CT value for each 
sample.  Finally, the relative expression was determined by raising 2 to the power of 
the ∆∆CT value which is known as the RQ value (see table 2.6).  
 
S. &o. Determinant Equation 
   
01 ∆CT CT (Target gene) - CT (House-keeping gene) 
02 Calibrator Av (∆CT of control group) 
03 ∆∆CT ∆CT - Calibrator 
04 RQ Power (2, ∆∆CT
-1) 
 
Table 2.6 Equations to determine relative gene expression.  
 
 
VALIDATIO& OF E&DOGE&OUS CO&TROL GE&E: Relative gene expression 
studies require an endogenous control (reference) gene, such as house-keeping genes, to 
enable normalisation for differences in the amount of total cDNA in each sample. 
(VanGuilder et al., 2008). It’s important to determine that variability in gene expression of 
reference gene is minimal across different treatment samples, to achieve a robust relative 
difference in expression of target genes between different treatment regimes.  
 
Two endogenous control genes, 18S and tata-box binding protein (TBP), were used for 
validating endogenous control gene. The degree of variation between the animals across 
different treatments groups, as assessed by the standard deviation, was comparable between 
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18S and TBP. Hence, either of the two was used as the endogenous control gene for further 








































Figure 2.4 Validation of endogenous control gene in epididymal fat. 18S and TBP 
were endogenous control (reference) genes in mice treated with PBS or HA±SM.. 
Variability in CT values as assessed by standard deviation in sample size (N=25) 
showed comparable variability between 18S and TBP. Abbreviations.  TBP: Tata box-
binding protein, HO-1: Heme oxygenase-1, S.D.: Standard deviation. 
 
2.16.  BCA PROTEI& DETERMI&ATIO& ASSAY 
 
The peptide bonds present in protein reduce cupric sulphate from the Cu2+ to the 
Cu1+ state at 37oC. Bicinchoninic acid (BCA) molecules chelate Cu1+ to form a 
purple coloured end-product whose absorbance is measured.  
 
MATERIALS: Pierce BCA kit (Thermo scientific, Wilmington, U.K.), flat bottom 
96 well-plate, Synergy HT microplate reader. 
 
METHOD: Tissue or cell samples were homogenised in a small volume (100-
200µl) of homogenisation buffer. Standards using 1:2 serial dilutions of 1.5mg/ml 
 108 
BSA were made up. 25µl/well of standards and 20x diluted samples were pipetted in 
flat bottom 96 well-plate. 50 volume of BCA reagent A (bicinchoninic acid, sodium 
carbonate, sodium bicarbonate, sodium tartate) was mixed with 1 volume of BCA 
reagent B (4% cupric sulphate) and 250µl/well was added to the 96 well-plate. The 
plate was incubated at 37oC for 30 minutes and absorbance was read at 565nm. 
Protein concentrations in samples were determined based on the BSA standard curve.  
 
2.17.  WESTER& BLOTTI&G FOR PROTEI& EXPRESSIO& 
 
A gel electrophoresis system was used to separate proteins present in the sample 
based on the difference in molecular size of proteins under the influence of an 
electric field. The fractionalised proteins are transferred onto a porous membrane and 
probed with antibodies conjugated to an enzyme that cleaves a chemoluminescent 
substrate.  
 
MATERIALS: List of antibodies and dilutions in table 2.7, Mini protean tetra gel 
electrophoresis system and power pac 300 (Bio-Rad, U.K.), Pierce ECL western 
blotting detection reagent (Thermo scientific, Wilmington, U.K.), Hybond ECL 
nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, U.K.), CL-
Xposure film (Thermo scientific, Wilmington, U.K.), ColorBurst electrophoresis 
marker (Sigma Aldrich, Dorset, U.K.). 
 
METHOD: Tissues including liver and fat were homogenised in ice-cold buffer A 
(50mM HEPES, pH 7.0, containing 20mM NaCl, 1mM DTT, 10mM sodium 
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pyrophosphate, 10mM sodium fluoride, 1mM sodium orthovanadate and 1x 
Complete protease inhibitors cocktail) using a mixer mill MM200 tissue 
homogeniser. MIN6 β-cells and BMDM plated in 6 well plates were lifted in buffer 
A and underwent 3 freeze-thaw cycles. Homogenised tissue or cell lysates were left 
on ice for 30 minutes before being centrifuged at 10,000g for 15 minutes at 4oC. 
Supernatant were transferred into pre-chilled Eppendorff tubess and protein 
quantification was carried out using the BCA assay. Samples of equal protein content 
were prepared in 5x laemmli sample buffer (60mM Tris-HCl pH 6.8, 2% SDS, 10% 
glycerol, 0.01% bromophenol blue) containing 5% (v/v) β-mercaptoethanol and 
boiled at 95oC for 10 minutes.  
 
10% Tris-acrylamide gels were cast (also known as sodium dodecyl sulphate 
polyacrylamide gel electrophoresis, SDS-PAGE) and loaded onto a vertical 
electrophoresis system. The inner chamber of the electrophoresis unit was filled with 
cathode buffer (50mM Tris, pH 8.6 containing 383.5mM glycine and 0.1% (w/v) 
SDS) and the tank with anode buffer (50mM Tris, pH 8.6 containing 0.1% (w/v) 
SDS). Samples containing 30µg protein and protein standard (ColorBurst 
electrophoresis marker) were resolved by running the gel at 70 volts. The resulting 
fractionated samples on the gel were transferred onto the nitrocellulose membrane 
cushioned on both sides with a sheet of wet  filter paper and sponge at 90 volts for an 
hour in transfer buffer (50mM TRIS, 383.5mM glycine, 20% (v/v) methanol). The 
nitrocellulose membrane containing the transferred proteins was washed twice for 5 
minutes each in TBST (50mM TRIS pH 7.5, 150mM NaCl, 0.05% (v/v) Tween-20). 
The membranes were stained with 0.2% ponceau’s solution to check for equal 
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loading of the samples. The membranes were washed twice in TBST for five minutes 
before being blocked in 5% (w/v) non-fat milk solution in TBST for an hour. The 
membranes were incubated with primary antibodies in 3% milk or 5% BSA solution 
in TBST overnight at 4oC. The next morning the membranes were given 3x washes 
with TBST for 10 minutes each, before being incubated with a species appropriate 
secondary HRP conjugated antibody diluted in 3% milk in TBST for an hour at room 
temperature. The membranes were washed 3x for 10 minutes each in TBST. 
Membranes were drained and placed on saran wrap and 3 ml of freshly prepared 
ECL western blotting detection reagent was added to the surface of each membrane 
for three minute. The ECL solution was removed with the tissues and the membranes 
were wrapped in saran wrap and transferred to a film cassette. The membranes were 
exposed to x-ray film in the dark for the appropriate time (between 5 seconds and 10 
minutes) to develop the film. 
 
S. &o Primary (1
o
) antibody Dilution Secondary (2
o
) antibody Dilution 
 (Rabbit anti-mouse)    
     
01 HO-1  
(Stressgen, U.K.) 
1:5000 1:5000 
02 HO-2  
(Stressgen, U.K.) 
1:1000 1:5000 
03 β-Actin  
(Sigma Aldrich, U.K.) 
1:10000 









2.18.  HEME OXYGE&ASE BIOACTIVITY ASSAY 
 
The heme oxygenase (HO) activity assay is a paired enzyme reaction that catalyses 
the conversion of heme into bilirubin as shown in Figure 2.5. The bilirubin levels are 
measured spectrophotometrically by determining the difference in absorption at 454 
and 530nm. If the heme, NADPH and biliverdin reductase are all present in excess, 
HO is the rate-limiting enzyme and hence the concentration of bilirubin will be 
proportional to the HO activity. The method was first described by Tenhunen et al. in 
1968 and with minor modifications has been used over the years and found to be 




Figure 2.5 The principle of the paired enzyme assay for determination of heme 




MATERIALS: Mixer mill MM200 (Retch, Yorkshire, U.K.), Master mix 
constituents listed in table 2.7 were from Sigma Aldrich (Dorset, U.K.), HA, Quartz 
cuvette, Biomate 3 spectrophotometer (Thermo scientific, Wilmington, U.K.). 
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METHOD: Liver lysates were prepared by homogenizing liver samples in 250µl of 
phosphate buffer (0.1M di-potassium phosphate, 2mM magnesium chloride, pH 7.4) 
using a mixer mill MM200 tissue homogeniser. For cell culture experiments, MIN6 
β-cells were plated in 10mm petri-dishes at a cell density of 5 x 106 cells per plate in 
10ml of medium. The BMDMs were plated in 6 well plates at a cell density of 2 x 
106 cells per well in 4ml of medium and were pooled later. Following treatment with 
the compound of interest, the plated MIN6 β-cells and BMDMs were washed twice 
with 3ml of PBS and scrapped off in 300µl of phosphate buffer. The cell lysates 
under-went 3 freeze-thaw cycles. 
 
Liver and cell lysates were centrifuged at 10,000g for 10 minutes at 4oC and the 
supernatant was transferred into pre-chilled Eppendorff tubess. Protein 
concentrations in the lysates were determined by the BCA assay and adjusted to a 
concentration of 5µg/µl using phosphate buffer. Master mix was prepared as outlined 
in table 2.8 and 200µl (1mg protein) of lysate was added to an equal volume of 
master mix in an Eppendorff tubes. Samples were incubated in the dark for an hour 
at 37oC in a water bath. An additional sample was incubated on ice as a negative 
control for the experiment.  
 
Chloroform extraction of bilirubin was performed by adding an equal volume 
(400µl) of chloroform to each sample to terminate the reaction at the end of the one 
hour incubation. Samples were mixed by vortexing for 30 seconds and centrifuged at 
10,000g for 2 minutes at room temperature. The clear chloroform fraction (~400µl) 
at the bottom of the Eppendorff tubes was transferred to a new 1.5ml Eppendorff 
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tubes. The absorbance at 454 and 530nm (extinction coefficient, ɛ=40Mm-1cm-1) was 
measured using a quartz curvette in a Biomate 3 spectrophotometer. Result was 
expressed as ‘pmol bilirubin/mg protein/hour’ (McNally et al., 2004). 
 






     µl 
01 Glucose-6-phosphate 
dehydrogenase (G-6-P-D) 
To maintain NADPH  200U 
 
0.2U 1 
02 d-glucose-6-phosphate Substrate for G-6-P-D  1.13M 4mM 3.5 
03 Heme arginate (HA)  Substrate for HO 
enzyme  
31.53mM 100µM 3.2 
04 Bilirubin reductase-A 
Activity: ~700 unit/mg 
Rate limiting enzyme  425µg/ml 0.4 nmol 6.5 
05 NADPH  100mM 2.5mM 25 
06 Phosphate buffer    960.8 
 
Table 2.8 Master mix constituents for heme oxygenase activity assay. 
 
2.19.  IMMU&O-HISTOCHEMISTRY (IHC) 
 
IHC is based on the principle that an antibody will bind specifically to a target 
antigen of interest. In general, the primary antibody will be raised against the antigen 
of interest in a different species to that of the target species. A secondary antibody 
that binds to the FC portion of antibodies from the species that the primary antibody 
was raised in is then applied. To visualize the bound antibody the avidin and biotin 
conjugated horseradish peroxidase macro-molecule complex (ABC) is the most 
widely used enzyme system. It exploits the high affinity binding of strept(avidin) to 
the biotinylated secondary antibody to form a irreversible complex. Binding of  
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strept(avidin) to additional biotin molecules result in signal amplification. Colourless 
chromogen substrate which is a good electron donor is then oxidised by the 
peroxidase enzyme system which is conjugated to the avidin molecule to produce 
coloured ‘detectable’ end-product (Figure 2.6).  
 
MATERIALS: A list of antibodies used and their source is provided in table 2.9. 
Biotinylated secondary antibodies, Avidin/Biotin blocking kit and RTU (ABC) 
vectastain (Vector laboratories, Peterborough, U.K.). Serum free protein block, 
antibody diluent, liquid diaminobenzidine (DAB) and substrate chromogen (Dako, 





Figure 2.6 Principle for the detection of antigen by immuno-histochemistry (IHC) 
staining. ABC (Avidin and Biotin conjugated horseradish peroxidase macro-molecular 
Complex) technology was used for the detection of target antigen where a secondary 
antibody conjugated to biotin undergoes an irreversible binding to ABC reagent which is 
later detected by applying a chromogen substrate of horseradish peroxidase.  
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METHOD: 5µm sections/slides of methyl-Carnoy fixed organs embedded in 
paraffin were employed. For islet studies, sections at least 75µm apart were used. 
The sections were deparaffinised for 15 minutes in xylene and serially rehydrated 
through 100, 90, 75 and 50% ethanol. The endogenous tissue peroxidase activity was 
blocked by incubating sections in 3% hydrogen peroxide on a shaker for 15 minutes 
at room temperature. Endogenous tissue avidin and biotin were blocked using 
100µl/slide of blocking kit for ten minutes each at room temperature with 2x PBS 
wash in between blocking steps. The slides were then blocked with 3 drops of serum-
free protein block for 30 minutes at room temperature before incubating overnight 
with primary antibodies (F4/80, iNOS, 4-HNE or HO-1) at 4oC. Antibody treated 
sections were incubated with a species-specific biotin labeled secondary antibody for 
2 hours at room temperature. After 2x PBS washes, sections were incubated for 2 
hours at room temperature with 3 drops/slide of ABC reagent. Lastly, sections were 
stained with 125µl/slide of chromogen DAB for 1-7 minutes to obtain brown staining 
localized to the region of primary antibody binding. PBS wash x2 was performed 
between each step to remove unbound material. For double staining, the process was 
repeated from the endogenous tissue avidin and biotin blocking step to stain for 
insulin. Lastly, sections were stained for 10 minutes with HistoGreen chromogen for 
detection of insulin producing islet β-cells. The sections were then counterstained in 
Meyer’s haematoxylin and Scott’s tap water for 15 seconds each with washes in tap-
water in between before being dehydrated serially in 50, 75, 90, 100% ethanol and 















     
Rabbit anti-mouse i&OS Type II 
250 µg/ml 
Polyclonal / IgG 























Guinea pig anti-mouse Insulin  
Not determined 
Polyclonal / IgG 
Abcam (U.K.) 
#ab7842 
















IMAGI&G A&D A&ALYSIS: The staining on sections was visualised on a Zeiss 
Axioskop microscope (Zeiss, Germany). Images of pancreatic islets were captured at 
200x magnification using QCapture Pro imaging software. Minor adjustment for 
brightness and contrast were performed on images using Adobe Photoshop. ImageJ 
is a publically available, Java-based image processing program developed by the 
U.S. National Institute of Health and was used to count the number of cells which 
stained positively for a particular antigen using the ‘cell counter’ plugin. The islet 
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area was calculated in pixels by drawing a circle around the periphery of the islet 
using the ‘Free hand selection’ on ImageJ (Figure 2.7). The area in pixels was 
converted into ‘µm2’, based on a measurement taken using a graticule at the same 
magnification. As the islet area was different between treatments, it was standardized 














Figure 2.7 IHC staining specimen. Pancreatic islet stained for insulin (green) and 
iNOS (brown). Black boundary shows ‘free hand selection’ performed to measure islet 
area based on the distance measured using a graticule (shown in red). Yellow dots 
represent manual counting performed using the ‘cell counter’ plugin to count the number 
of positively stained cells.  
 
2.20.  I&DIRECT IMMU&O-FLUORESCE&CE (IF) 
 
An indirect method of detection of antigen of interest using fluorescent dye labeled 
antibodies. The fluorescent dye is excited and the emission spectrum at the 
wavelength specified for the dye is viewed using a fluorescent microscope.   
100 µm = 570 pixel
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Availability of fluorescent dyes that are excited and emit light at different 
wavelengths aid co-localization of two or more markers. 
 
MATERIALS: Refer to table 2.10 for antibody list and source. Vectashield 
mounting medium with DAPI (Vector laboratories, Peterborough, U.K.), Molecular 
probe tertiary antibody streptavidin conjugated 488 and 555 (Invitrogen, Paisley, 
U.K.) serum free protein block and antibody diluent (Dako, Cambridgeshire, U.K.).  
 
METHOD: Paraffin embedded methyl-Carnoy fixed section, cryostat cut frozen 
sections or cytospin sections were used for the indirect immuno-fluorescence study. 
Paraffin embedded sections were deparaffinised and rehydrated (similar to IHC 
protocol) in graded ethanol. Frozen and cytospin sections were fixed for 3 minutes in 
90% acetone+10% methanol solution. The sections were the blocked for endogenous 
biotin and avidin for ten minutes each with PBS washes in between steps. The 
sections were treated with 125µl/section of serum-free protein block for 30 minutes 
before being incubated overnight with 125µl/section of diluted primary antibody at 
4oC. Next morning, sections were treated with biotinylated secondary antibody 
(125µl/section) and incubated in dark at room temperature for 2 hours. Then, 
sections were incubated with streptavidin conjugated tertiary antibody attached to a 
fluorescent dye (125µl/section) for an hour at room temperature in the dark. 
Unbound materials on sections were washed off with PBS at the end of each 
incubation step. Sections were mounted with mounting medium containing DAPI 
and stored in the dark at 4oC for single label IF. For double-labelling IF, steps from 
avidin and biotin blocking were repeated for detecting a second antigen on same 
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section. Ideally, a tertiary antibody conjugated to a fluorochrome with an 
excitation/emission spectrum that does not overlap that of previous fluorochrome is 
used to localise the second antigen of interest. The flurochromes were visualised 
using a Zeiss Axioskop 2 MOT PLUS fluorescent microscope (Zeiss, Germany) and 















   
Rabbit anti-mouse i&OS Type II 
1:100 
BD Transduction Lab (U.K.) 
Goat anti-rabbit 
1:300 
Vector laboratories (U.K.) 
Alexa Fluor 595 conjugate 
1:500 
Invitrogen (U.K.) 




guinea pig  
1:500 
Abcam (U.K.) 
Streptavidin Alexa Fluor 




Table 2.10 List of antibodies and dilutions used for indirect immuno-fluorescence 
staining. 
 
2.21.  STATISTICAL A&ALYSIS 
 
Non-parametric statistical tests were employed to assess for significant differences 
between different treatment regimes. A Two-tailed Mann-Whitney test, the non-
parametric equivalent of the non-paired t-test was employed to compare two 
treatment groups, whereas the Kruskal-Wallis test, the non-parametric test equivalent 
to one-way analysis of variance, was used to compare multiple treatment groups. The 
Friedman test, the non-parametric equivalent of the repeated measures one-way 
analysis of variance, was used for data analysis where multiple treatment groups 
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were compared across serial time-points. For data with serial time-points, either the 
area under the curve using the trapezoid method or, the relative difference to baseline 
level was calculated and tested for statistical significance using the Kruskal-Wallis 
test.Dunn’s multiple comparison post-test was performed to derive P-values between 
treatment groups, when P<0.05 by either Friedman or Kruskal-Wallis test, with 
confidence interval set at 95%. All data are expressed as mean ± standard error mean 
(s.e.m.). All statistical analysis was performed using GraphPad Prism version 4.0 


















3. CHAPTER 3: I VIVO STUDY 1: DETERMI&I&G THE A&TI-DIABETIC 
EFFECT OF HEME ARGI&ATE I& LEPTI& RECEPTOR DEFICIE&T 






















Inducers of heme oxygenase (HO) activity have been reported to reduce obesity and 
hyperglycaemia in experimental models of type 2 diabetes. A HO activity-dependent 
increase in circulatory adiponectin has been postulated to promote a protective 
phenotype that included weight loss, reduced insulin resistance and suppressed levels 
of circulatory cytokines and mediators of oxidative stress (Li et al., 2008, Weisberg 
et al., 2008). In addition, hemin treatment in diabetic rats restores muscle AMPK 
levels (Ndisang et al., 2009a). 
 
Heme arginate (HA) is a potent inducer of HO activity in vitro and in vivo 
(Ferenbach et al., 2011) and is licensed for use in humans to treat acute intermittent 
porphyria. An in vivo experiment was designed to test the hypothesis that the heme 
component of HA ameliorates hyperglycaemia in the leptin receptor deficient 











3.2. A& OVERVIEW OF THE DIABETIC (db/db) MOUSE MODEL OF 
TYPE 2 DIABETES 
 
The diabetic (db/db) mouse is a genetic model of type 2 diabetes, first discovered at 
Jackson Laboratory, when an autosomal recessive mutation occurred in the leptin 
receptor gene (Leprdb) on chromosome 4 in the C57BL/KsJ inbred strain of mice 
(Panchal and Brown, 2010).  
 
Leptin is an adipokine hormone and acts as part of a negative feedback loop to 
maintain body fat. Circulatory leptin levels increase in adiposity. Leptin interacts 
with leptin receptors present in hypothalamic nuclei of the brain to suppress appetite 
(Friedman and Halaas, 1998). Interaction of leptin with its receptor in the 
hypothalamic nuclei counteracts the effect of feeding stimulants such as 
neuropeptide Y (Friedman, 1997). Melanocyte-stimulating hormone (MSH) is an 
appetite suppressant and is required for the biological response of leptin (Erickson et 
al., 1996).   
 
The Leprdb mutation in the C57BL/KsJ strain of mice (db/db mouse) prevents leptin 
interacting with leptin receptors in hypothalamic nuclei thereby resulting in loss of 
control over appetite. This leads to an unregulated increase in food intake 
(hyperphagia) resulting in obesity and severe hyperglycaemia (Hummel et al., 1966). 
Profound weight gain can be observed by 6 weeks of age, followed by development 
of glucose intolerance, hyperinsulinemia and islet hyperplasia and hypertrophy 
between 8 and 12 weeks of age. A drop in the plasma insulin level coincides with 
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islet β-cell loss and a further increase in hyperglycaemia between 16 and 24 weeks of 
age (Coleman and Hummel, 1967, Coleman, 1978). The Leprdb mutation in the 
C57BL/6J inbred strain of mice also causes hyperphagia and obesity; however 
hyperglycaemia is transient due to the compensatory effect of hyperinsulinaemia 
because C57BL/6J mice are resistant to islet atrophy (Davis et al., 2012).  
 
The db/db mouse was used for in vivo experiments to test the following hypotheses: 
 Chapter 3: Heme component of HA ameliorate hyperglycaemia. 
 Chapter 4: Anti-hyperglycaemic effect of HA is dependent on HA’s ability to 
induce HO activity. 
 














3.3. DETERMI&ATIO& OF THE OPTIMAL HA DOSE FOR SUSTAI&ED 
I&DUCTIO& OF HO ACTIVITY 
 
C57BL/KsJ mice were intravenously administered either PBS or HA at 3 different 
concentrations, 5, 15, and 30mg/kg. Livers from PBS and HA-treated C57BL/KsJ 
mice were isolated 24 hours after intravenous administration. Western blotting 
performed on liver lysates demonstrated that all three concentrations of HA induced 
HO-1 protein (Figure 3.1A). 
 
As 15mg/kg of HA significantly induced HO-1 protein in the liver of C57BL/KsJ 
mice, this dose was chosen to assess the time course of HO-1 induction. Western 
blotting showed that a single dose of 15mg/kg of HA induced HO-1 protein levels 
for up to 72 hours (Figure 3.1B). 
 
A HO activity assay was performed to determine whether 15mg/kg of HA increased 
HO activity relative to PBS-treated mice. Hepatic HO activity was significantly 
increased 24 and 48 after HA administration, compared with that observed in PBS-
treated mice (Figure 3.1C). Hence, twice weekly administration of 15mg/kg HA was 








Figure 3.1 Optimisation of dose and frequency of administration of HA in 
C57BL/KsJ mice. Sustained induction of hepatic HO-1 protein and activity levels in 
C57BL/KsJ mice were the parameters used to select the optimal HA concentration and 
frequency of administration A. HA treatment at 5, 15 and 30mg/kg for 24 hours induced 
HO-1 protein levels, relative to PBS-treated mice. The western blot is a representative 
blot of n=1 mice/treatment. B. A single dose of 15mg/kg of HA induced HO-1 protein 
levels for up to 72 hours relative to PBS-treatment. The western blot is a representative 
blot of n=1 mice/treatment. C. A significant increase in HO activity relative to PBS-
treated mice was observed 24 and 48 hours after a single intravenous administration of 
HA, * P<0.05, P-value derived from Dunn’s multiple comparison post-test when P<0.05 







3.4. I VIVO EXPERIME&T DESIG& 
 
HA contains 25 mg/ml of hemin and 26.6 mg/ml of L-arginine in a glycerol solution. 
L-arginine has been reported to stimulate islet β-cells to secrete insulin (Henningsson 
and Lundquist, 1998). Hence, the in vivo experiment required an L-arginine control 
group in addition to PBS to reliably assess the specific effect of the ‘heme’ 
component of HA. L-arginine (LA) was administered at a concentration (16mg/kg) 
that replicated the LA concentration in 15mg/kg of HA (Levere et al., 1990). The 
experiment was conducted over a period of 8 weeks with twice weekly intravenous 
administration of PBS, LA and HA as outlined in Figure 3.2. Readouts included 












Figure 3.2 In vivo experiment design to determine HA efficacy in the db/db mouse 
model of type 2 diabetes. Ten week old db/db diabetic mice and non-diabetic 
C57BL/KsJ (lean) mice were intravenously injected with PBS, LA, and HA at the stated 
doses twice weekly for 8 weeks. Weight and fasting (4 hour) blood glucose were 
monitored during the study and functional tests including food intake, ITT and urine 
collection in metabolic cage were performed. Mice were culled at 18 weeks of age and 
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3.5. DIABETIC PHE&OTYPE OF db/db MICE AT THE BEGI&&I&G OF  
THE STUDY 
 
The treatment groups for db/db mice were determined by matching for the body 
weight (Table 3.1) at the beginning of the study. Ten week old db/db mice were 
significantly obese, hyperglycaemic and hyperinsulinaemic compared to lean 
C57BL/KsJ mice (Table 3.1).  
 
 
Read-outs Lean db/db 
 PBS PBS LA HA 
& number 3 4 4 3 
Weight (gram) 27.4±0.3 44.8±1.3* 43.7±1.3 44.8±1.2 
Fasting glucose (mmol/l) 6.1±0.7 18.0±2.0* 17.9±2.6 16.9±0.8 
Fasting insulin (ng/ml) 0.8±0.1 5.1±0.6* 4.9±0.6 3.9±0.3 
   
 
Table 3.1 Metabolic parameters at the beginning of the in vivo study. Statistically 
significant differences in metabolic parameters, including weight, fasting blood glucose 
and insulin levels were observed between lean (C57BL/KsJ) and db/db mice at the 
beginning of the in vivo study. *P<0.05, P-values derived from two-tailed Mann Whitney 
test for comparison between Lean PBS and db/db PBS-treated mice. There were no 
significant differences in metabolic parameters, including weight, fasting blood glucose 
and insulin levels between the different treatment groups of db/db mice. P>0.05 by 


















3.6. HA BUT &OT L-ARGI&I&E REDUCED HYPERGLYCAEMIA 
 
The mice were fasted for 4 hours prior to tail vein bleeding to measure fasting blood 
glucose concentration. A progressive increase in fasting blood glucose was observed 
in PBS-treated db/db mice. Non-parametric Friedman test along with Dunn’s 
multiple comparison post-test demonstrated that HA treatment significantly reduced 
(P<0.01) fasting blood glucose levels relative to PBS-treated db/db mice (Figure 
3.3.A). In contrast, twice weekly treatment of LA did not reduce hyperglycaemia. 
This strongly suggested that the anti-diabetic effect of HA was independent of the 
LA present in the HA solution.  
 
Furthermore, area under the curve analysis suggested that hyperglycaemia was 
significantly reduced with HA treatment specifically between 6 and 8 weeks (P<0.05, 
Figure 3.3.B).  
 
Additionally, the terminal glycosylated haemoglobin level (HbA1C%), a measure of 
long-term blood glucose control, was significantly reduced with HA treatment 
(P<0.05, Figure 3.4.A). HA had no effect on haemoglobin levels (Figure 3.4.B).    




Figure 3.3 Fasting blood glucose and HbA1C%. A. HA-treated db/db mice had 
significantly reduced levels of fasting blood glucose levels, relative to PBS-treated db/db 
mice. **P<0.01 (highlighted in figure), P-value derived from Dunn’s multiple comparison 
post-test when P<0.05 with Friedman test. B. Area under curve (AUC) for fasting blood 
glucose levels between consecutive weeks (0-2, 2-4, 4-6, 6-8 week) showed that HA 
treatment significantly reduced fasting glucose levels between 6 and 8 weeks when 
compared to PBS-treated db/db mice. *P<0.05, P-value derived from Dunn’s multiple 
comparison post-test when P<0.05 with Kruskal-Wallis test at the specified time-point. 
C. HA treatment led to a significant reduction in terminal HbA1C% relative to PBS-treated 
db/db mice. *P<0.05, P-value derived from Dunn’s multiple comparison post-test when 
P<0.05 with Kruskal-Wallis test. D. None of the treatments resulted in any significant 
change in terminal haemoglobin level. P>0.05 (non-significant) by Kruskal-Wallis test. A, 
B, C, D: The data are mean ± s.e.m. from n=3-4 mice/treatment group. a. unit2: arbitrary 
unit2. 
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3.7. HA BUT &OT LA PROMOTED BODY WEIGHT GAI& DESPITE &O 
DIFFERE&CE I& FOOD I&TAKE 
 
There was a significant difference in body weight between treatment groups in db/db 
mice (Figure 3.4.A, P=0.009 by Friedman test). Body weight at each consecutive 
time-points were normalised to baseline (week 0) weight to assess weight gain 
(Figure 3.4.B). Significant increase in weight gain was noted for HA treatment 
(P<0.05) after 6 and 8 weeks of the in vivo study, relative to PBS-treated db/db mice 
(Figure 3.4.B). No significant differences in the weight of liver and fat pads, 
including subcutaneous (SFP), retroperitoneal (RFP) and epididymal (EFP) fat pads 
were observed between the different treatment groups (Figure 3.4.C). 
 
Food intake was monitored over a period of 5 days during week 6 and 7 of the study. 
There was no significant difference in food intake between the treatment groups over 





Figure 3.4 Body weight, weight gain, tissue/organ weights and food intake. A. 
Significant difference in body weight between treatment groups in db/db mice. P<0.05 
(highlighted in figure) by Friedman test. B. Significant weight gain (body weight 
normalised to baseline weight) noted for HA treatment at 6 and 8 weeks, relative to 
PBS-treated db/db mice. *P<0.05, P-value derived from Dunn’s multiple comparison 
post-test when P<0.05 with Kruskal-Wallis test at the specified time-point. C. No 
significant difference in either liver weight or fat pad weights, including epididymal fat 
pad (EFP), retroperitoneal fat pad (RFP) and sub-cutaneous fat pad (SFP), was 
observed between HA-treated and PBS-treated db/db mice (P>0.05). *P<0.05, P-value 
derived with Dunn’s multiple comparison post-test when P<0.05 by Kruskal-Wallis test 
for specified tissue/organ type. D. None of the treatments had a significant impact on 
food intake in the db/db mice. P>0.05 (non-significant) by Kruskal-Wallis test. A, B, C, 
D: The data are mean ± s.e.m. from n=3-4 mice/treatment group. 
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3.8. HA A&D LA HAD &O EFFECT O& I&SULI& RESISTA&CE 
 
An insulin tolerance test (ITT) was performed during week 8 of the in vivo study. 
The db/db mice were fasted for 4 hours prior to intraperitoneal administration of 
insulin at a concentration of 1unit insulin/kg body weight of mouse. The blood 
glucose level was monitored at 0, 15, 30 and 60 minutes post insulin injection.  
 
A significant difference in absolute blood glucose levels during the ITT was 
observed between different treatment groups in db/db mice (P<0.05 by Friedman 
test, Figure 3.5.A). However, an ITT is primarily performed to determine the rate of 
glucose disposal as an assessment of degree of insulin resistance. The baseline (0) 
glucose levels were different between the treatment groups in db/db mice (Figure 
3.5.A). Hence, the glucose concentration at consequent time points (0, 15, 30 and 60 
minutes) during ITT (Figure 3.5.A) were divided by baseline glucose concentration 
to express the ITT curve as fold change in glucose level relative to baseline (Figure 
3.5.B).  
 
No significant difference in the relative change in glucose levels was noted between 
treatment groups in db/db mice (P>0.05 by Friedman test, Figure 3.5.B). Area under 
the curve (AUC) for the relative change in glucose levels during the ITT 
demonstrated that none of the treatment regimes had a significant impact on the 






Figure 3.5 Insulin resistance as assessed by the insulin tolerance test (ITT). A. 
Glucose concentration was determined at 0, 15, 30 and 60 minutes post exogenous 
insulin (1 unit/kg body weight) administration during the ITT in db/db mice. *P<0.05 
(highlighted in figure) between db/db LA and db/db HA, P-value derived from Dunn’s 
multiple comparison post-test when P<0.05 with Friedman test. B. ITT curve 
represented as fold change in blood glucose relative to baseline (0 minute) level. None 
of the treatment regimes significantly lowered the relative change in glucose level during 
ITT. P>0.05 (non-significant) by Friedman test. C. None of the treatment regimes 
significantly reduced relative change in glucose level between consecutive time-points 
(0-15, 15-30, 30-60 minutes) during the ITT, as assessed by area under the curve 
analysis (AUC). P>0.05 (non-significant) was noted for each time-point by Kruskal-
Wallis test. A, B, C: The data are means ± s.e.m. from n=3-4 mice/treatment group. a 
unit2: arbitrary unit2. 
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3.9. HA I&CREASED HEME OXYGE&ASE ACTIVITY A&D 
EXPRESSIO& 
 
Liver lysates from db/db mice were used to perform the heme oxygenase (HO) 
paired enzyme assay to determine the effect of HA on HO activity. HA treatment led 
to a significant increase (P<0.01) in HO activity compared to PBS-treated db/db mice 
(Figure 3.6.A). The increase in HO activity with HA treatment was concurrent with 
increase in HO-1 protein expression as detected by immuno-blotting (Figure 3.6.B). 





Figure 3.6 Terminal HO activity and HO-1 protein levels in the liver of db/db mice. 
A. HA treatment resulted in a significant increase in HO activity relative to PBS-treated 
db/db mice. **P<0.01, P-value derived from Dunn’s multiple comparison post-test when 
P<0.05 with Kruskal-Wallis test. The data are mean ± s.e.m. from n=3-4 mice/treatment 
group. B. HO-1 protein was undetectable in PBS and LA-treated db/db mice. HA 
treatment increased HO-1 protein level. The western blot is a representative blot in 
which n=2 mice/treatment. β-actin was used as a control for loading equal concentration 
of protein. 
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3.10.  HA TREATME&T HAD &O EFFECT O& ADIPO&ECTI& LEVELS 
 
The end-point fasting serum high molecular weight (HMW) form of adiponectin was 
quantified to assess whether HA administration modulated the adiponectin 
concentration in the serum. No significant difference in serum adiponectin 
concentration was observed either between PBS-treated lean and db/db mice or 




Figure 3.7 Terminal fasting serum HMW adiponectin. No significant difference in 
serum concentration of the high molecular weight (HMW) form of adiponectin was noted 
either between PBS-treated lean (C57BL/KsJ) and db/db mice or, between PBS and 
HA-treated db/db mice at the end of the 8-week study. P>0.05, P-value derived from 










3.11.  &O SIG&IFICA&T DIFFERE&CE I& I&SULI& LEVELS BETWEE& 
PBS A&D HA-TREATED db/db MICE 
 
Over the full 8wk period, no significant difference in serial fasting serum insulin 
levels was observed between different treatment groups in db/db mice (Figure 3.8.A, 
P=0.3 by Friedman test). However, Area under the curve (AUC) for fasting insulin 
levels between consecutive weeks (0-2, 2-4, 4-6 and 6-8 weeks) showed that HA-
treated db/db mice had significantly higher fasting insulin levels (P<0.05) 




Figure 3.8 Fasting serum Insulin levels. A. No statistically significant difference in 
serial fasting insulin levels was observed between different treatment groups in db/db 
mice. P>0.05 (highlighted in figure) by Friedman test. B. Area under the curve (AUC) 
analysis for fasting insulin levels showed a significant increase in insulin levels with HA 
treatment between 6 and 8 weeks, relative to LA but not PBS-treated db/db mice. 
*P<0.05, P-values derived from Dunn’s multiple comparison post-post when P<0.05 by 
Kruskal-Wallis test at the specified time-point. A, B: The data are means ± s.e.m. from 









3.12.  HA TREATME&T REDUCED ISLET i&OS EXPRESSIO& 
 
There was an increase in iNOS expression in PBS-treated but not HA-treated db/db 
mice relative to lean mice (Figure 3.9.A). Importantly, a proportion of the iNOS-
stained cells, particularly the cells at the centre of the islet, showed co-localisation 
with insulin, suggesting that the iNOS-stained cells were in part β-cells (Figure 
3.9.B). However, iNOS-stained cells at the periphery region of the islet did not 
exhibit insulin staining, suggesting that some iNOS-staining cells were not β-cells, 






Figure 3.9 Immuno-fluorescence staining for insulin and iNOS in islets. Methacarn 
fixed tissues were stained with insulin/fluorophore 488 (green) and iNOS/fluorophore 
594 (Red) whereas DAPI (4',6-diamidino-2-phenylindole, blue) was used for nuclear 
staining. A. An increase in iNOS staining was observed in pancreatic islets of PBS, but 
not HA-treated db/db mice, when compared to PBS-treated lean (C57BL/KsJ) mice. B. 
A proportion of iNOS-stained islet cells co-localised with insulin producing islet β-cells as 
highlighted by orange staining in the rectangular white box. Whereas, a cluster of iNOS-
stained islet cells, particularly at the periphery of the islet as highlighted by oval box, did 
not co-localise with insulin-stained cells suggesting that other cell-types in the islet 










3.13.  CHAPTER DISCUSSIO& 
 
3.13.1. HA TREATME&T DISPLAYED A&TI-HYPERGLYCAEMIC 
EFFECT I& db/db MODEL OF TYPE 2 DIABETES 
 
The preliminary 8-week in vivo study showed heme arginate (HA) treatment to be 
efficient at reducing the time-dependent increase in fasting hyperglycaemia, which 
was observed in db/db mice who were treated with PBS or L-arginine (LA) (Figure 
3.3.A). The HA-mediated reduction in fasting hyperglycaemia was particularly 
significant towards the end of the in vivo study, between 6 and 8 weeks (Figure 
3.3.B). Furthermore, the beneficial effect of HA treatment on hyperglycaemia was 
further confirmed by the significant reduction in glycosylated haemoglobin level 
(HbA1C%, Figure 3.3.C). HbA1C% reflects glycaemic status over a longer duration 
than fasting glucose because the half-life of erythrocytes in mice is believed to be 2-3 
weeks (Magnani et al., 1988). Hence, two reliable and independent methods of 
quantifying the degree of hyperglycaemia demonstrated that intravenous 
administration of 15mg/kg of HA, twice weekly for 8 weeks, ameliorated 
hyperglycaemia in the db/db mice.   
 
The reduction in hyperglycaemia by HA treatment coincided with a significant 
increase in HO activity and HO-1 protein levels in the liver of db/db mice (Figure 
3.6). This is in agreement to previously published studies, where hemin therapy has 
been reported to induce HO activity and ameliorate hyperglycaemia in insulin-
resistant Goto-Kakizaki (GK) and Zucker diabetic fatty (ZDF) rats (Ndisang et al., 
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2009a, Ndisang et al., 2009b). Therefore, an additional in vivo study is required, 
where a pharmacological inhibitor of HO activity, such as stannous (IV) 
mesoporphyrin IX dichloride (SM) or chromium (III) mesoporphyrin IX chloride 
(CrMP), is employed to determine whether an increase in HO activity is responsible 
for anti-hyperglycaemic effect of HA in the db/db mouse model of type 2 diabetes. 
 
3.13.2. HA TREATME&T PROMOTED WEIGHT GAI& 
 
Previously, Li et al had reported that intraperitoneal administration of cobalt (III) 
protoporphyrin IX chloride (CoPP) induced HO activity, HO-1 protein and prevented 
weight gain by reducing visceral fat mass in the ob/ob mouse model of type 2 
diabetes (Li et al., 2008). An identical phenotype has been reported by Kim et al in 
Zucker fatty rats (Kim et al., 2008). However, in the current study, an increase in HO 
activity and HO-1 protein with HA treatment coincided with a progressive increase 
in body weight in db/db mice (Figure 3.4.A), despite no significant increase in food 
intake (Figure 3.4.D). Consequently, a significant increase in weight gain was noted 
with HA treatment, when compared to PBS-treated db/db mice (Figure 3.4.B). 
Hence, the weight gain associated with HA treatment in db/db mice is in contrast to 
the prevention of weight gain observed with CoPP treatment in ob/ob mice.  
 
The discrepancy in the body weights observed with HA and CoPP may be due to 
differences in the mouse models used for the studies. ob/ob mice are primarily used 
as a model of obesity and insulin resistance because compensatory islet hypertrophy 
and hyperinsulinaemia prevents profound increases in hyperglycaemia and promotes 
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weight gain (Genuth et al., 1971, Li et al., 2008). Whereas, the db/db mice are more 
often employed as a model of type 2 diabetes, where an initial increase in insulin 
resistance and hyperinsulinaemia is succeeded by loss of β-cell mass, an increase in 
hyperglycaemia and consequent weight loss in the later stage of life (Hummel et al., 
1966, Coleman, 1978). Further support for this observation is provided by comparing 
the results from the current and Li et al studies. Vehicle (Tris-HCl pH 7.8 solution) 
treatment led to a progressive increase in body weight in ob/ob mice (Li et al., 2008). 
Whereas, PBS-treated db/db mice showed an initial rise in body weight followed by 
slight decrease during the latter half of the current in vivo study (Figure 3.4.A). An 
alternative explanation for the differing effects of HA- and CoPP-therapy on body 
weight is that the compounds themselves have different properties. For example,  
CoPP but not hemin may regulate the central nervous system to promote loss of 
appetite and body weight (Galbraith and Kappas, 1989) Although the reduction in 
food intake during CoPP treatment in the ob/ob mice (Li et al., 2008) did not reach 
statistical significance, the 10% reduction observed may still be biologically 
important.  
 
A key question is: whether the weight gain promoted by HA treatment is key to its 
anti-diabetic properties or, a side effect. A simple experiment to answer this question 
is to test whether HA treatment can promote weight gain in non-diabetic mice. If so, 
then the weight gain with HA can be attributed to be a side effect rather than a key 




3.13.3. THE A&TI-HYPERGLYCEMIC EFFECT OF HA IS I&DEPE&DE&T 
OF I&SULI& SE&SITIVITY 
 
An important approach to reduce hyperglycaemia is to reduce insulin resistance in 
peripheral organs to facilitate insulin-dependent regulation of hepatic glucose 
production and glucose disposal in muscles. The insulin tolerance test is a crude 
functional test of insulin sensitivity but not specific to a particular organ. Insulin has 
a suppressive effect on glycogenolysis and gluconeogenesis (Barthel and Schmoll, 
2003) and mediates glucose uptake mainly in skeletal muscle by up-regulating 
GLUT4 (Dugani and Klip, 2005). Therefore, the ITT largely reflects the degree of 
insulin resistance in muscle and liver.  
 
The similar relative reduction in glucose levels during the ITT observed in all three 
groups suggested that HA and LA treatment, both failed to significantly reduce 
insulin resistance, relative to PBS-treated db/db mice (Figure 3.5.B, C). This 
observation is in contrast to the increase in insulin sensitivity reported by hemin and 
CoPP in different murine models of obesity and type 2 diabetes (Li et al., 2008, 
Ndisang et al., 2009b, Ndisang and Jadhav, 2009). However, these studies used 
absolute glucose levels rather than relative reductions in glucose levels at specified 
time-points during the ITT, to measure insulin resistance. Therefore, the reduction in 
blood glucose levels observed throughout the course of the ITT may simply reflect 
lower baseline levels, rather than an increase in insulin sensitivity. Hence, the effect 
of HA, hemin or CoPP may be largely independent of improvements in insulin 
sensitivity in all three models. 
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Adiponectin is an adipose tissue derived adipokine that increases insulin sensitivity 
in the peripheral organs by promoting fatty acid oxidation in the liver and muscle and 
thereby reducing ectopic deposition of triglycerides in these organs (Yamauchi et al., 
2001, Kadowaki et al., 2006). Induction of the HO activity-adiponectin axis has been 
reported to be a key mechanism for reducing insulin resistance with hemin and CoPP 
treatment in GK rats and ob/ob mice respectively. However, HA treatment for 8 
weeks failed to significantly modulate serum adiponectin levels in db/db mice 
(Figure 3.7). Hence, the combined results of the ITT and the terminal adiponectin 
level demonstrate that the anti-hyperglycaemic effect of HA is independent of an 
effect on insulin-sensitivity either directly or via adiponectin. 
 
3.13.4. &O SIG&IFICA&T I&CREASE I& I&SULI& SECRETIO& WITH HA 
TREATME&T 
 
In PBS-treated db/db mice there was a steady decrease in fasting insulin levels 
during the first 4 weeks of the in vivo study, indicating reduced capability of islet β-
cells to secrete insulin as the diabetic state progressed (Figure 3.8.A). This may be 
due to the deleterious effects of hyperglycaemia, which include a decrease in the islet 
β-cell mass and secretory function (Donath et al., 2008) along with dedifferentiation 
of β-cells in the db/db mice (Kjorholt et al., 2005).  Additionally, a proportion of β-
cells in the islet of PBS-treated db/db mice expressed iNOS as determined by 
immuno-fluorescence (Figure 3.9). It has been reported that increased iNOS 
expression in pancreatic islet cells may contribute to the pathogenesis of islet β-cell 
dysfunction in an experimental model of type 2 diabetes (Salehi et al., 2008).  
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There was an increase in serum insulin levels in db/db mice after between 6 to 8 
weeks of HA compared with LA-therapy (Figure 3.8.B). A similar difference was 
observed between HA and PBS-treated mice, however this did not meet statistical 
significance, possibly due to the small sample size (n=3-4 mice/group) in this pilot 
study. The reduction in iNOS, partly in β-cells, in the islets, suggests a possible 
mechanism for preserved insulin secretion (Figure 3.9.A, B) as iNOS may impair β-
cell function. Furthermore, the increase in insulin secretion may be responsible for 
the weight gain observed with HA treatment. However, further experiments, 
employing larger numbers of mice, will be required to conclusively determine 
whether the anti-diabetic effect of HA was in part due to an increase in insulin 
secretion. 
 
3.13.5. A&TI-HYPERGLYCEMIC EFFECT OF HA IS I&DEPE&DE&T OF 
L-ARGI&I&E COMPO&E&T OF HA 
 
HA is soluble composition of human blood-derived hemin and L-arginine (LA) in a 
solution mixture containing propylene glycol, ethanol and water (Tenhunen et al., 
1987). LA at millimolar concentration has been reported to stimulate islet β-cell 
insulin secretion in vitro  (Henningsson and Lundquist, 1998). Hence, an LA control 
group at a concentration identical to that present in HA was used to reliably assess 
the specific effect of the ‘heme’ component of HA. No improvement in glycaemic 
control or serum insulin levels was observed in LA-treated db/db mice, 
demonstrating the effect of HA to be independent of the effect of LA. Hemin alone 
was not included in the study due to its relative poor solubility and the tendency to 
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form aggregates in the solution, which became apparent while performing in vitro 
studies to characterise the effect of hemin in primary macrophages. 
 
3.13.6. CO&CLUDI&G REMARK 
 
To conclude, HA treatment led to a significant induction of HO activity and an 
increase in HO-1 protein in db/db mice. Eight weeks of HA but not LA treatment, 
significantly reduced the progressive increase in hyperglycaemia observed in PBS-
treated db/db mice, demonstrating that the anti-hyperglycaemic effect of HA was 
mediated by its ‘heme’ rather than LA component. HA ameliorated hyperglycaemia 
despite no improvement in relative insulin sensitivity in peripheral organs. The anti-
hyperglycaemic effect of HA may have been due to an increased adipogenic capacity 
to store excess lipids and divert them away from key metabolic tissues such as liver 
and muscles. Alternatively, HA did increase blood insulin levels compared with LA 
but not PBS in the latter stages of the model, but whether this was responsible for its 
anti-diabetic effect needs to be confirmed with studies that employ larger numbers of 
mice.  
 
Finally, the phenotype observed with HA, in particular the increase in body weight, 
was different to that observed with other inducers of HO-1, such as CoPP and hemin. 
This raises the possibility that the anti-diabetic properties of HA may be independent 
of its ability to induce HO activity and additional experiments, which include 
inhibitors of HO activity, are require to address this important question. 
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4. CHAPTER 4: I VIVO STUDY 2: ROLE OF HEME ARGI&ATE 
I&DUCED HEME OXYGE&ASE (HO) ACTIVITY I& THE LEPTI& 

























The preliminary in vivo study with heme arginate (HA) in the db/db mice model of 
type 2 diabetes demonstrated that HA therapy ameliorated hyperglycemia (chapter 
3). Equivalent doses of L-arginine had no effect on blood glucose levels suggesting 
that the anti-diabetic effect of HA is dependent on the heme component. Heme is a 
potent inducer of heme oxygenase-1 (HO-1) and previous studies employing other 
inducers of HO-1, such as hemin or cobalt (III) protoporphyrin IX chloride (CoPP) 
have also demonstrated an anti-diabetic effect (Ndisang and Jadhav, 2009, Ndisang 
et al., 2009b, Ndisang et al., 2009a, Kim et al., 2008, Li et al., 2008).  
 
Published studies have employed HO activity inhibitors such as chromium (III) 
mesoporphyrin IX chloride (CrMP) or stannous (IV) mesoporphyrin IX dichloride 
(SnPP/SM) (Ndisang and Jadhav, 2009, Li et al., 2008) to determine that the anti-
diabetic effect of CoPP or hemin was mediated via increased HO activity.  
 
An in vivo experiment was designed to include an inhibitor of HO activity SM to test 
the hypothesis that the anti-hyperglycaemic effect of HA was dependent on its 







4.2. OPTIMISATIO& OF THE DOSE OF STA&&OUS (IV) 
MESOPORPHYRI& IX DICHLORIDE (SM), A& I&HIBITOR OF HO 
ACTIVITY 
 
Li et al employed SM as an HO activity inhibitor to determine whether the anti-
diabetic effect of CoPP was dependent on HO activity in the ob/ob mouse model of 
type 2 diabetes (Li et al., 2008). They administered 20mg/kg of SM intraperitoneally 
(i.p.) thrice weekly in the ob/ob mice (Li et al., 2008) and determined that this 
effectively inhibited HO activity. Hence, a concentration of 20mg/kg of SM was 
selected to determine if SM reduced HA-induced HO activity in non-diabetic 
C57BL/KsJ mice.  
 
The SM solution was prepared in TRIS-HCl pH 7.8 buffer. 10-12 week old 
C57BL/KsJ mice were divided into three groups, including PBS, HA and HA+SM 
(n=3/group). The mice in the PBS and HA groups were administered i.p. with TRIS-
HCl pH 7.8, whereas the HA+SM group was administered i.p. 20 mg/kg of SM. 
After 24 hours of TRIS-HCl pH 7.8 or SM administration, PBS was administered 
intravenously (i.v.) to the PBS group, whereas the HA and HA+SM group were 
administered i.v. 15 mg/kg of HA. The livers were harvested from all treatment 
groups after 24 hours of PBS or HA administration to determine HO activity.  
 
A significant increase (P<0.05) in HO activity was noted following injection of 15 
mg/kg HA when compared to PBS-treated mice (Figure 4.1). In contrast, a single i.p. 
administration of SM abrogated the HA-induced increase in HO activity (Figure 4.1). 
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Hence, 20 mg/kg of SM was selected as the concentration to be used for 
administration in the db/db mice. The treatment regime for SM (thrice i.p. 
administration of SM per week) was as employed previously in ob/ob mice (Li et al., 
2008).   
 
 
Figure 4.1 Optimisation of the dose of SM required to inhibit HA-induced HO 
activity in C57BL/KsJ mice. The significant increase in HO activity following a single 
intravenous administration of 15mg/kg of HA was abrogated by pre-treating with a single 
intraperitoneal administration of 20mg/kg SM in non-diabetic C57BL/KsJ mice. The data 
are means ± s.e.m. from n=3 mice/treatment group. * P<0.05, P-value derived from 










4.3. I VIVO EXPERIME&T DESIG& 
 
The in vivo experiment was conducted over a period of 8 weeks and was comprised 
of four groups of db/db mice who received either PBS (n=4), HA (n=4), SM (n=5) or 
HA+SM (n=8) (Figure 4.2). PBS and 15mg/kg HA were administered intravenously 
(i.v.) twice weekly whereas 20mg/kg SM was administered intraperitoneally (i.p.) 
thrice weekly. The SM solution was prepared in TRIS-HCl buffer, hence db/db mice 
on PBS and HA single treatments were injected intraperitoneally with TRIS-HCl, pH 
7.8 solution as a control. C57BL/KsJ non diabetic (lean) mice acted as controls and 
were given either PBS or 15mg/kg HA intravenously twice weekly. The in vivo study 












Figure 4.2 In vivo experiment design to investigate whether the anti-diabetic effect 
of HA is dependent on HO activity. Ten week old db/db diabetic mice along with non-
diabetic C57BL/KsJ (lean) mice were injected with PBS, HA, SM or HA+SM for 8 weeks. 
Weight, fasting (4 hour) blood glucose, food intake, GTT and ITT were performed. Mice 
were culled at 18 weeks of age and organs collected for HO activity assay, quantification 
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4.4. DIABETIC PHE&OTYPE OF db/db MICE AT THE BEGI&&I&G OF 
THE STUDY 
 
The treatment groups for db/db mice were formed by matching their body weight 
(Table 4.1) taken at the beginning of the study. Ten week old db/db mice were 
significantly obese, hyperglycaemic and hyperinsulinaemic in comparison to lean 
C57BL/KsJ mice (Table 4.1). There were no significant differences in any of the 
metabolic parameters between the db/db mice treatment groups. 
 
Parameters Lean db/db 
 PBS PBS HA SM HA+SM 
& number 4 4 4 5 8 
Weight (gram) 25.4±1.0 42.3±1.2** 42.9±1.1 41.6±0.8 41.2±0.7 
Fasting glucose (mmol/l) 6.7±0.4 16.9±2.6** 16.1±1.7 17.6±1.8 15.2±2.2 
Fasting insulin (ng/ml) 0.8±0.1 8.6±1.4* 7.1±0.8 8.0±2.1 8.7±0.9 
   
 
Table 4.1 Metabolic parameters at the beginning of the in vivo study. Statistically 
significant differences in metabolic parameters, including weight, fasting glucose and 
insulin levels were observed between lean (C57BL/KsJ) and db/db mice at the 
beginning of the in vivo study. *P<0.05, **P<0.01, P-values derived from one-tailed 
Mann Whitney test for comparison between lean and db/db mice on PBS treatment. 
There were no significant differences in metabolic parameters, including weight, fasting 
blood glucose and insulin levels between different treatment groups in db/db mice 









4.5. HA TREATME&T HAD &O SIG&IFICA&T EFFECT O& BODY 
WEIGHT A&D FASTI&G BLOOD GLUCOSE I& THE LEA& MICE 
 
HA treatment produced a progressive increase in body weight in db/db mice in the 
previous in vivo study (chapter 3). Hence, it was important to determine whether HA 
induced weight gain per se, or whether this is a directly related to its anti-diabetic 
effects. Therefore, C57BL/KsJ (lean) mice were administered either PBS or HA over 
an 8 week period.  
 
No significant differences were observed between the two treatment groups. (Table 




Parameter Week Lean PBS Lean HA P-value 
& number  4 5  
0 25.4±1.0 24.7±0.9 >0.05 Body weight (gram) 
8 28.1±0.6 27.4±0.9 >0.05 
0 6.7±0.4 6.7±0.5 >0.05 Fasting blood glucose 
(mmol/l) 8 6.6±0.4 7.0±0.1 >0.05 
 
 
Table 4.2 Effect of HA treatment on body weight and fasting blood glucose in non-
diabetic C57BL/KsJ (lean) mice. No significant changes in body weight and fasting 
glucose levels were observed with HA treatment in lean mice, when compared to PBS-
treated lean mice. P>0.05 by two-tailed Mann Whitney test for comparison between PBS 





4.6. EFFICIE&T I&HIBITIO& OF HO ACTIVITY BUT &OT PROTEI& 
LEVEL WITH SM TREATME&T 
 
At the end of the experiment, liver lysates from db/db mice were used to determine 
HO activity by the HO paired enzyme assay. HA treatment led to a significant 
increase (P<0.05) in hepatic HO activity compared to PBS treated db/db mice 
(Figure 4.3.A). No significant change in HO activity was observed with SM 
treatment alone, when compared to PBS-treated db/db mice. The concurrent 
treatment of SM with HA (will be referred as HA+SM from this point forward in the 
text) significantly reduced (P<0.05) the HA-mediated increase in HO activity (Figure 
4.3.A). The HO activity with HA+SM treatment was comparable to the HO activity 
level observed with PBS treatment in db/db mice. 
 
Quantification of heme was an alternative method to confirm inhibition of HO 
activity in the in vivo study. A significant suppression of HO activity with SM 
treatment would reduce heme degradation into carbon monoxide, bilirubin and 
ferritin and should increase the intracellular heme content when supplied with 
exogenous HA.  
 
HA+SM treatment resulted in a significant increase in hepatic heme content (P<0.01) 
compared to PBS treatment (Figure 4.3.B) in db/db mice. The HO activity and heme 
concentration data together demonstrated that SM treatment efficiently blocked the 
HA mediated increase in HO activity and intracellular heme degradation.  
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Immuno-blotting in liver lysates detected no basal HO-1 protein expression in PBS-
treated db/db mice. An increase in HO-1 protein expression was observed with HA 
but not SM single agent treatment. HA+SM treatment led to a profound and 
synergistic increase in HO-1 protein expression (Figure 4.3.C). A comparable level 
of protein expression of the constitutively expressed HO-2 isoform was observed 





Figure 4.3 Terminal HO activity, heme concentration and HO-1 protein expression 
in liver lysates of the db/db mice. A. Concurrent SM treatment significantly 
suppressed the HA-mediated increase in HO activity. *P<0.05, P-value derived from 
Dunn’s multiple comparison post-test when P<0.05 with Kruskal-Wallis test. NS: Non-
significant (P>0.05) between PBS and SM by Dunn’s post-test. B. HA+SM treatment led 
to an increase in the hepatic heme concentration. **P<0.01, P-value derived from 
Dunn’s multiple comparison post-test when P<0.05 with Kruskal-Wallis test. C. A 
synergistic increase in HO-1 protein expression was observed with HA+SM treatment. 
No difference in HO-2 protein expression was observed between the different treatment 
groups. The western blot is a representative blot in which n=2 mice/treatment. β-actin 
was used as a control for loading equal concentrations of protein. A, B: The data are 
mean ± s.e.m. from n=4-8 mice/treatment group. 
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4.7. HA A&D SM I& COMBI&ATIO& DRAMATICALLY AMELIORATED 
HYPERGLYCAEMIA I& db/db MICE 
 
Ten week old db/db mice were hyperglycaemic comparative to age-matched non-
diabetic lean mice (Table 4.1). PBS-treated db/db mice showed a progressive 
increase in the mean fasting blood glucose from 18mmol/l to 36mmol/l (Figure 
4.4.A) during the 8-week study. 
 
Area under the curve (AUC) for fasting glucose levels showed that HA treatment 
significantly reduced (P<0.05) hyperglycaemia between 6 and 8 weeks when 
compared to PBS-treated db/db mice (Figure 4.4.B). SM treatment did not lead to a 
significant reduction in fasting glucose concentration in db/db mice. HA+SM 
treatment markedly reduced fasting glucose levels (Figure 4.4.A, P<0.01 by Dunn’s 
multiple post-test when P<0.05 by Friedman test) in db/db mice. HA+SM, unlike HA 
treatment, resulted in a significant reduction in fasting glucose levels at early time-
points including 2-4 (P<0.01), 4-6 (P<0.01) and 6-8 (P<0.001) weeks (Figure 4.4.B). 
 
Glycosylated haemoglobin (HbA1C%) was used as an alternative marker of 
glycaemic control. PBS-treated db/db mice had significantly higher HbA1C% than 
lean mice (Figure 4.4.C, P<0.001). HA+SM, but not single agent treatment with HA 





Figure 4.4 Fasting blood glucose and HbA1C%. A. HA+SM-treated db/db mice had 
significantly reduced (P<0.05) levels of fasting glucose levels, relative to PBS-treated 
db/db mice. *P<0.05, **P<0.01 (highlighted in figure legends), P-value derived from 
Dunn’s multiple comparison post-test when P<0.05 with Friedman test. B. Area under 
the curve (AUC) for fasting glucose levels between consecutive weeks (0-2, 2-4, 4-6, 6-
8 week) demonstrated that HA+SM treatment significantly reduced fasting glucose 
levels at 2-4, 4-6 and 6-8 weeks, as opposed to only 6-8 weeks with HA treatment. 
*P<0.05, **P<0.01, ***P<0.001. P-value derived from Dunn’s multiple comparison post-
test when P<0.05 with Kruskal-Wallis test at the specified time-point. C. HA+SM but not 
HA treatment led to a significant reduction in terminal (week 8) HbA1C% relative to PBS-
treated db/db mice. **P<0.01, ***P<0.001. P-value derived from Dunn’s multiple 
comparison post-test when P<0.05 with Kruskal-Wallis test. A, B, C: The data are mean 
± s.e.m. from n=4-8 mice/treatment group. a. unit2: arbitrary unit2. 
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4.8. HA A&D HA+SM TREATME&T LED TO COMPARABLE WEIGHT 
GAI& 
 
The body weight of the PBS-treated db/db mice remained constant during the course 
of the 8-week in vivo study (Figure 4.5.A). Significant weight gain with HA 
treatment was particularly evident after 6 and 8 weeks of the in vivo study (Figure 
4.5.B., P<0.05). However, the greatest increase in body weight was observed with 
HA+SM treatment as these mice gained an average of 16.5 grams during the 8 week 
study (Figure 4.5.A). Significant weight gain with HA+SM treatment was evident 
after 2 weeks, which progressively increased till 8 weeks of the in vivo study, when 
compared to PBS-treated db/db mice (Figure 4.5.B., P<0.001).    
 
The increase in body weight with HA (P<0.01) and HA+SM (P<0.001) was in part 
due to a significant increase in the weights of the epididymal fat pads (EFD) but not 
liver (Figure 4.5.C). Food intake was monitored over a period of 6 days during week 
5 and 6 of the study. The increase in weight gain with HA and HA+SM was despite 







Figure 4.5 Body weight, weight gain, organ/tissue weight and food intake. A. A 
significant difference was noted for body weight between different treatment groups in 
db/db mice P<0.05 with Friedman test. B. Significant weight gain (body weight 
normalised to baseline weight) was observed after 6 and 8 weeks of HA treatment in 
db/db mice. Weight gain with HA+SM treatment was noted after 2 weeks, which 
significantly increased till 8 weeks of the in vivo study. *P<0.05, ***P<0.001. P-value 
derived from Dunn’s multiple comparison post-test when P<0.05 with Kruskal-Wallis test 
at the specified time-point. C. HA and HA+SM significantly increased epididymal fat pad 
(EFP) but not liver weight in db/db mice. **P<0.01, ***P<0.001. P-value derived from 
Dunn’s multiple comparison post-test when P<0.05 with Kruskal-Wallis test for EFP. 
P>0.05 (non-significant) by Kruskal-Wallis test for Liver. D. No significant difference in 
food intake was noted between different treatment groups in db/db mice. P>0.05 with 
Kruskal-Wallis test. A, B, C, D: The data are mean ± s.e.m. from n=4-8/treatment group. 
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4.9. HA±SM TREATME&T FAILED TO IMPROVE GLUCOSE 
TOLERA&CE AS ASSESSED BY GLUCOSE TOLERA&CE TEST 
 
A glucose tolerance test (GTT) was performed to assess the rate of glucose disposal 
by endogenously produced insulin during week 7 of the in vivo study. The db/db 
mice were fasted for 4 hours before intraperitoneal administration of 2 grams of 
glucose per kilogram body weight and the serum glucose concentration at the 
indicated time points was determined by the hexokinase glucose assay. 
 
HA+SM-treated db/db mice had significantly lower glucose levels (P<0.05) during 
the GTT when compared to PBS-treated db/db mice (Figure 4.6). However, baseline 
(0 minute) fasting glucose levels were different for various treatment groups in db/db 
mice (Figure 4.6.A).  
 
The glucose levels increased steeply in the first 10-15 minutes after exogenous 
administration of a glucose bolus during the GTT. Hence, the glucose concentration 
at 15 minutes (1st read-out point after glucose administration) was used to normalise 
glucose levels at consequent time-points during GTT to compare the relative change 
in glucose levels during GTT (Figure 4.6.B).  
 
Area under the curve (AUC) for relative change in glucose levels between 15 and 
120 minutes during the GTT demonstrated no significant difference in serum glucose 
levels between different treatment regimes in db/db mice at 15-30, 30-60 and 60-120 




Figure 4.6 Glucose tolerance as assessed by glucose tolerance test (GTT). A. 
Serum glucose concentrations were determined at 0, 15, 30, 60 and 120 minutes after 
exogenous glucose (2g/kg body weight) was administration during the GTT in db/db 
mice. HA+SM-treated db/db mice had significantly lower levels of serum glucose during 
GTT. *P<0.05, (indicated in the figure). P-value derived by Dunn’s multiple comparison 
post-test when P<0.05 by Friedman test. B. Relative change in glucose levels (glucose 
concentrations at consecutive time-points divided by glucose concentration at 15 
minutes during GTT) during GTT was not significant between the various treatment 
regimes in db/db mice. P>0.05 (indicated in figure) by Friedman test. C. Area under the 
curve (AUC) for relative changes in glucose levels during GTT demonstrated no 
significant change in relative glucose levels between different treatment regimes in 
db/db mice. P>0.05 by Kruskal-Wallis test for specified time-points. A, B, C: The data 
are mean ± s.e.m. from n=4-8 mice/treatment group. a. unit2: arbitrary unit2. 
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4.10. HA±SM TREATME&T HAD &O EFFECT O& I&SULI& 
RESISTA&CE AS ASSESSED BY I&SULI& TOLERAT&CE TEST 
 
An insulin tolerance test (ITT) was performed during week 8 of the in vivo study to 
assess whole body insulin sensitivity. The blood glucose level was monitored for an 
hour after intraperitoneal administration of insulin at a dose of 1 unit insulin per 
kilogram body weight.  
 
HA+SM-treated db/db mice had significantly lower glucose levels (P<0.01) during 
ITT when compared to PBS-treated db/db mice (Figure 4.7.A). However, baseline (0 
minute) fasting glucose levels were different for various treatment groups in db/db 
mice (Figure 4.7.A). Hence, glucose levels at consequent time-points during ITT 
were divided by baseline concentration of glucose to compare relative fold change in 
glucose levels (Figure 4.6.B).  
 
Normalisation of glucose concentrations at consecutive time-points during the ITT 
demonstrated no significant difference in relative changes in glucose levels between 
different treatment groups in db/db mice (Figure 4.7.B). Area under the curve (AUC) 
for relative change in glucose levels during ITT demonstrated that no significant 
change in relative glucose level was evident between various different groups at 









Figure 4.7 Insulin resistance as assessed by insulin tolerance test (ITT). A. 
Glucose concentrations were determined at 0, 15, 30 and 60 minutes, after exogenous 
insulin (1 unit/kg body weight) administration in db/db mice. HA+SM-treated db/db mice 
had significantly lower glucose levels, relative to PBS-treated db/db mice*P<0.05, 
(indicated in the figure). P-value derived by Dunn’s multiple comparison post-test when 
P<0.05 by Friedman test. B. Relative change in glucose levels (normalised by dividing 
with baseline glucose concentration) during ITT was not significant between different 
treatment groups in db/db mice. P>0.05 (indicated in figure) by Friedman test. C. Area 
under the curve (AUC) for relative changes in glucose levels during ITT demonstrated 
no significant difference between treatment groups in db/db mice. P>0.05 by Kruskal-
Wallis test for specified time-points. A, B, C: The data are mean ± s.e.m. from n=4-8 
mice/treatment group. a. unit2: arbitrary unit2. 
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4.11. HA±SM TREATME&T MODULATED TERMI&AL FASTI&G SERUM 
PARAMETERS 
 
The 8-week fasting serum samples were used to determine insulin, non-esterified 
fatty acid (NEFA) and high molecular weight (HMW) adiponectin. PBS-treated 
db/db mice had significantly elevated level of circulatory insulin (Figure 4.8.A, 
P<0.05), NEFA (Figure 4.8.C, P<0.05) and reduced levels of HMW adiponectin 
(Figure 4.8.E, P<0.05), relative to PBS-treated lean (C57BL/KsJ) mice.  
 
Treatment with HA (P<0.05) and HA+SM (P<0.01) for 8 weeks in db/db mice 
resulted in a significant increase in fasting insulin levels when compared to PBS-
treated db/db mice (Figure 4.8.B). However, none of the treatment regimes in db/db 
mice significantly altered fasting NEFA levels (Figure 4.8.D). HA+SM-treated db/db 
mice had significantly improved serum adiponectin levels (Figure 4.8.F), relative to 





Figure 4.8 Terminal fasting serum insulin, non-esterified fatty acid (NEFA) and 
HMW adiponectin levels. PBS-treated db/db mice had significantly increased levels of 
A. Insulin, C. NEFA and reduced levels of E. High molecular weight (HMW) adiponectin, 
relative to PBS-treated lean (C57BL/KsJ) mice.  *P<0.05, P-values derived from one-
tailed Mann Whitney test for comparison between lean and db/db mice on PBS 
treatment. HA and HA+SM treatment for 8-weeks resulted in a significant increase in 
fasting levels of B. Insulin but had no statistically significant effect on D. NEFA. HA+SM 
treatment markedly increased HMW adiponectin levels in db/db mice. B. *P<0.05, 
**P<0.01. P-value derived from Dunn’s multiple comparison post-test when P<0.05 with 
Kruskal-Wallis test. For D, P>0.05 (non-significant) by Kruskal-Wallis test. A, C, E: The 
data are means ± s.e.m. from n=4 mice/treatment group. B, D, F: The data are means ± 
s.e.m. from n=4-8 mice/treatment group. 
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4.12. HA+SM TREATME&T REDUCED ISLET i&OS EXPRESSIO& 
 
In the preliminary in vivo study (chapter 3), prominent iNOS protein expression by 
immuno-fluorescence was observed in the islets of PBS-treated db/db mice (Figure 
3.9.A, B in chapter 3). Hence, quantification of cells expressing iNOS protein was 
performed in the current study to determine whether HA, SM or HA+SM treatment 
had a significant impact on reducing iNOS protein expression within the islets of 
db/db mice.  
 
The number of cells staining positively for iNOS within pancreatic islets was 
quantified by immuno-histochemistry (IHC). The islets were identified by co-
staining with anti-mouse insulin antibody (Figure 4.9). The mean cross-sectional area 
of the islets of db/db mice was significantly larger (P<0.05) than lean mice (Figure 
4.10.A). However, no significant difference in the mean cross-sectional area of the 
islets was observed between db/db mice on different treatment regimes (Figure 
4.10.B). The mean number of iNOS positive cells was corrected for the mean surface 
area per islet. 
 
The number of iNOS-protein expressing cells within the islets of PBS-treated db/db 
mice was significantly greater (Figure 4.10.C P<0.05) than in lean mice. Single agent 
treatment of HA and SM did not result in a significant decrease in number of iNOS 
stained cells in the islets (Fig 4.10.D). However, HA+SM treatment significantly 
reduced (P<0.01) the number of iNOS expressing cells within the islets (Figure 






Figure 4.9 Immuno-histochemical (IHC) staining for iNOS expression in pancreatic 
islets. Co-staining for iNOS (brown) and insulin (green) was performed on methyl-
carbonyl fixed sections of pancreas. A. Staining with insulin antibody only B. Lean mice 
PBS C. db/db PBS D. db/db HA E. db/db SM F. db/db HA+SM. Pictures taken at x 200 





Figure 4.10 Determination of iNOS-protein expression in pancreatic islets. A. Mean 
cross-sectional area of islets of PBS-treated db/db mice was significantly greater than 
lean mice. *P<0.05, P-values derived from two-tailed Mann Whitney test for comparison 
between Lean and db/db mice on PBS treatment. B. No significant difference in mean 
cross-sectional area of islets was observed for various treatment regimes in db/db mice. 
P>0.05 (non-significant) by Kruskal-Wallis test. C. PBS-treated db/db mice had 
significantly higher numbers of iNOS-protein expressing cells compared to lean mice. 
*P<0.05, P-values derived from two-tailed Mann Whitney test for comparison between 
Lean and db/db mice on PBS treatment. D. HA+SM treatment resulted in a significant 
reduction in the number of iNOS-protein expressing cells in the db/db mice. **P<0.01, P-
value derived from Dunn’s multiple comparison post-test when P<0.05 with Kruskal-
Wallis test. A, C: The data are means ± s.e.m. from n=4 mice/treatment group. B, D: 
The data are means ± s.e.m. from n=4-8 mice/treatment group. A minimum of 25 
islets/mouse from cross-sections cut at a minimum difference of 75 micron (to avoid 







4.13. HA A&D HA+SM TREATME&T REDUCED ISLET MACROPHAGE 
I&FILTRATIO& 
 
Macrophage infiltration into pancreatic islets has been observed in both patients with 
type 2 diabetes and in rodent models of type 2 diabetes (Ehses et al., 2007b). Hence, 
F4/80, a pan-macrophage marker was used to stain and quantify islet macrophage 
infiltration (Figure 4.11). Co-staining with insulin was performed to identify islet β-
cells. 
 
The mean cross-sectional area of the islets of PBS-treated db/db mice was 
significantly larger (Fig 4.12.A) than in PBS-treated lean mice. PBS treated db/db 
mice had a significantly greater number (P<0.05) of total (Figure 4.13.C), intra-islet 
(Figure 4.12.E) and peri-islet (Figure 4.12.G) F4/80+ cells compared to PBS-treated 
lean mice.  
 
HA alone led to a significant reduction in the number of intra-islet (Figure 4.12.F) 
F4/80+ cells, relative to PBS-treated db/db mice. No significant reduction in islet 
macrophage infiltration was noted for SM treatment in db/db mice. Importantly, 
HA+SM treatment significantly reduced (P<0.01) macrophage numbers (Figure 
4.12.D) in islets of db/db mice to levels observed in lean mice. This was due to a 
reduction in both intra-islet (Figure 4.12.F, P<0.001) and peri-islet F4/80+ cells 






Figure 4.11 Immuno-histochemical (IHC) staining for macrophage (F4/80) 
infiltration in pancreatic islets. Co-staining for F4/80 (brown) and insulin (green) was 
performed on methyl-carbonyl fixed sections of pancreas. A. Staining with insulin 
antibody only B. Lean mice PBS C. db/db PBS D. db/db HA E. db/db SM F. db/db 





Figure 4.12 Determination of macrophage infiltration in pancreatic islets. A 
significant difference in the mean islet cross-sectional area was noted between A. lean 
and db/db mice on PBS-treatment (P<0.05, two-tailed Mann Whitney test) but not 
between B. various treatment groups in db/db mice (P>0.05, Kruskal-Wallis test). PBS-
treated db/db mice had significantly increased number of C. Total (islet+peri-islet) F4/80, 
E. Islet F4/80 and G. Peri-islet F4/80 cells, relative to lean mice. *P<0.05, P-values 
derived from two-tailed Mann Whitney test for comparison between lean and db/db mice 
on PBS treatment. In HA-treated db/db mice, there was a significant reduction in the 
number of F. Islet F4/80 cells, relative to PBS-treated db/db mice. In HA+SM-treated 
db/db mice, there was a significant reduction in the number of D. Total F4/80, F. Islet 
F4/80 and H. Peri-islet F4/80 cells, relative to PBS-treated db/db mice. D, F, H: *P<0.05, 
**P<0.01, ***P<0.001 by Dunn’s multiple comparison post-test when P<0.05 with 
Kruskal-Wallis test. A, C, E, G: The data are means ± s.e.m. from n=4 mice/treatment 
group. B, D, F, H: The data are means ± s.e.m. from n=4-8 mice/treatment group. A 
minimum of 25 islets/mouse from cross-sections cut at a minimum difference of 75 
micron (to avoid repeated counting of same islet) was used for quantification. 
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4.14. THE MODULATORY EFFECT OF TREATME&T REGIMES O& 
mR&A TRA&SCRIPT LEVELS I& EPIDIDYMAL FAT 
 
The mRNA levels of the pro-inflammatory mediators including cytokines (TNF-α 
and IL-6) and chemokines (MCP-1α and Cxcl-2) along with Pref-1 (an inhibitor of 
adipogenesis), PPAR-γ (marker of adipocyte differentiation) and fatty acid synthase 
(FASN, mediator of lipogenesis) were determined in epididymal fat using RT-PCR. 
 
HA treatment resulted in a significant increase in mRNA level of HO-1 (Figure 
4.13.A, P<0.05) but failed to significantly change the mRNA levels of other listed 
genes in figure 4.13. SM treatment alone failed to significantly increase mRNA level 
of HO-1 but significantly reduced mRNA levels of CD68 (Figure 4.13.B, P<0.01) 
and MCP-1α (Figure 4.13.E, P<0.001). There was a significant increase in the 
mRNA level of HO-1 (Figure 4.13.A, P<0.001) which coincided with a significant 
decrease in mRNA levels of CD68 (Figure 4.13.B, P<0.05) and MCP-1α (Figure 
4.13.E, P<0.05) and a marked increase in Cxcl-2 (Figure 4.13.F, P<0.001) with 
HA+SM treatment in db/db mice. None of the treatment regimes, including HA, SM 
and HA+SM, significantly modulated mRNA levels of pro-inflammatory mediators, 
such as TNF-α and IL-6 (Figure 4.13.C, D). Furthermore, with HA+SM treatment, 
there was a significant reduction in mRNA levels of Pref-1 (P<0.05, Figure 4.13.G) 








Figure 4.13 Gene expressions in the epididymal fat of db/db mice on different 
treatment regimes. Relative mRNA levels of A. HO-1, B. CD68, C. TNF-α, D. IL-6, E. 
MCP-1α, F. Cxcl-1, G. Pref-1, H. PPAR-γ and I. FASN, in the epididymal fat of db/db 
mice receiving PBS, HA, SM and HA+SM treatment. *P<0.05, **P<0.01, ***P<0.001 by 
Dunn’s multiple comparison post-test when P<0.05 with Kruskal-Wallis test. The data 
are mean ± s.e.m. from n=4-8 mice/treatment group. A-F: 18S gene was used as 








4.15. &O SIG&IFICA&T I&CREASE I& LIVER FAT DEPOSITIO& BY ALL 
TREATME&TS 
 
No significant change in either hepatic triglyceride content per unit mass or, hepatic 
total triglyceride (triglyceride/unit mass x liver weight) was observed with any of the 




Figure 4.14 Hepatic triglyceride deposition in db/db mice on different treatment 
regimes. None of the treatment regimes significantly modulated the levels of either A. 
Hepatic triglyceride content per unit mass (mg) or, B. Total hepatic triglyceride content, 
relative to PBS-treated db/db mice. P>0.05 (non-significant) by Kruskal-Wallis test. The 










4.16. &O&E OF THE TREATME&T REGIMES RESULTED I& A 
REDUCTIO& I&  GLUCO&EOGE&IC GE&E EXPRESSIO& 
 
Previously, a study examining the role of the nuclear receptor hormone, Rev-erbα in 
hepatocyte cell culture (HepG2) established heme as a Rev-erbα ligand that 
suppresses expression of key gluconeogenic genes, such as phosphoenol pyruvate 
carboxy kinase (PEPCK) and glucose-6-phosphatase (G-6-P) by recruiting the 
nuclear co-repressor-histone deacetylase 3 (NCoR-HDAC-3) gene repressor complex  
(Yin et al., 2007).  
 
To determine whether the anti-hyperglycaemic effect of HA or HA+SM was 
mediated by suppression of gluconeogenic enzymes, the relative gene expression of 
PEPCK and G-6-P in the liver was determined. Treatment regimes including HA, 
SM and HA+SM did not result in significant modulation of the mRNA levels of 
PEPCK and G-6-P (Figure 4.15). 
 
 
Figure 4.15 Gene expression of gluconeogenic genes in the liver of db/db mice on 
different treatment regimes. Treatment regimes including HA, SM and HA+SM failed 
to significantly modulate mRNA levels of A. PEPCK B. G-6-P (glucose-6-phosphatase) 
in the liver of db/db mice. P>0.05 (non-significant) by Kruskal-Wallis test. The data are 
mean ± s.e.m. from n=4-8 mice/treatment group. 18S gene was used as endogenous 
control gene. 
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4.17. CHAPTER DISCUSSIO& 
 
4.17.1. HO ACTIVITY I&DEPE&DE&T A&TI-HYPERGLYCAEMIC 
EFFECT OF HA 
 
The current in vivo study was performed to test the hypothesis that anti-
hyperglycaemia effect of heme arginate (HA) is dependent on HA’s ability to induce 
heme oxygenase (HO) activity. Consistent with the preliminary in vivo study, a HA-
mediated increase in hepatic HO-activity (Figure 4.3.A) was associated with reduced 
fasting hyperglycaemia between 6 to 8 weeks (Figure 4.4.B) of the in vivo study. 
However, no significant decrease in HbA1C% (glycosylated haemoglobin, Figure 
4.4.C), a marker of sustained hyperglycaemia, was noted for HA treatment. 
Therefore, the two independent measures of hyperglycaemia demonstrated that HA 
was effective at reducing hyperglycaemia during the latter stages of in vivo study, 
only for short period of time, specifically between 6 to 8 weeks. 
 
Stannous (IV) mesoporphyrin IX dichloride (SM) was employed in the current in 
vivo study to inhibit the HA-mediated increase in HO activity. SM treatment alone 
did not significantly modulate the fasting hyperglycaemia and HbA1C% (Figure 
4.4.A-C).  However, the most intriguing result of the current in vivo study was the 
further improvement in glycaemic control (Figure 4.4.A), that was observed when 
SM was co-administered with HA (HA+SM). This occurred despite complete 
abrogation of the HA mediated increase in HO activity (Figure 4.3.A). The anti-
hyperglycaemic effect of HA+SM treatment was confirmed by a significant 
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reduction in the level of glycosylated haemoglobin (Figure 4.4. C). Furthermore, the 
profound improvement in glycaemic control with HA+SM treatment was highlighted 
by the significant reduction in fasting glucose levels from an earlier time-point, 
between 2 and 4 weeks (Figure 4.4.B). The anti-hyperglycemic effect of HA+SM 
treatment is in contrast to a previous study, where chromium (III) mesoporphyrin IX 
chloride (CrMP), an inhibitor of HO activity, reversed the anti-hyperglycaemic effect 
of hemin in non-obese insulin-resistant Goto-Kakizaki (GK) rats (Ndisang and 
Jadhav, 2009). Hence, the current in vivo study demonstrated a novel anti-
hyperglycaemic phenotype, where inhibition of HO activity accentuated the 
ameliorative potential of HA. This observation was in contrast to the hypothesis of 
the present study that the anti-hyperglycaemic effect of HA is dependent on HA’s 
ability to induce HO activity. 
 
4.17.2. I&CREASED OBESITY MAY BE RESPO&SIBLE FOR A&TI-
HYPERGLYCAEMIC EFFECT OF HA±SM 
 
Remarkably, improvement in glycaemic control with HA±SM treatment occurred 
despite a significant gain in weight (Figure 4.5.B). The increase in body weight with 
HA±SM treatment compared to PBS-treated db/db mice was in part due to a 
significant increase in adiposity as reflected by an increase in the weight of the 
epididymal fat pad (Figure 4.5.C). The increase in body weight with HA±SM 
treatment was not due to an increase in food intake (Figure 4.5.D).   
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Both the HA±SM-mediated reduction in fasting hyperglycaemia and increase in 
adiposity in db/db mice occurred from an early point in the study (Figure 4.4.B, 
4.5B). The inverse relationship between weight gain and reduction in fasting glucose 
levels suggests that the two events are related to each other. This is important as the 
elevated adipocyte storage capacity of db/db mice when compared to obesity-
resistant (over-expressing leptin receptor-b) db/db mice, has been reported to be 
critical for delaying the onset and severity of type 2 diabetes (Wang et al., 2008). 
 
HA+SM treatment increased circulatory levels of adiponectin (Figure 4.8.F), an 
insulin-sensitising adipokine (Kadowaki et al., 2006), indicating an improvement in 
the endocrine function of adipose tissue despite profound adiposity. Furthermore, 
HA+SM treatment increased gene expression of PPAR-γ (Figure 4.13.H), a key 
mediator of adipocyte differentiation (Lazar, 1999). The increase in gene expression 
of PPAR-γ and circulatory levels of adiponectin are similar to the effect of PPAR-γ 
agonists, such as thiazolidinedione (TZD) group of compounds, which bind to and 
activate PPAR-γ to promote adipocyte differentiation (Okuno et al., 1998). An 
increase in adipocyte differentiation with HA+SM treatment was further supported 
by the significant decrease in gene expression of Pref-1 (Figure 4.13.G), an inhibitor 
of adipocyte differentiation (Wang et al., 2006). Additionally, HA+SM treatment 
increased the gene expression of FASN (Figure 4.13.I), which facilitates de novo 
lipogenesis, where excess carbohydrate is converted into lipids for storage (Wang et 
al., 2004). Hence, these observations indicate that HA+SM treatment led to a 
metabolically favourable remodelling of visceral fat to improve adipocyte storage 
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capacity, which may have prevented ectopic lipid deposition in the liver of db/db 
mice.  
 
To determine whether the increase in body weight was a generic side-effect of HA 
treatment or a specific phenotype in db/db mice Lean (C57BL/KsJ) mice were 
administered 15mg/kg of HA, twice weekly for 8 weeks. No significant difference in 
fasting glucose and body weight was noted with HA treatment in lean mice (Table 
4.2), indicating weight gain with HA treatment to be a specific phenotype of HA in 
db/db mice. 
 
4.17.3. THE A&TI-HYPERGLYCAEMIC EFFECT OF HA±SM IS 
I&DEPE&DE&T OF I&SULI& SE&SITIVITY 
 
Amelioration of peripheral insulin resistance is a key mechanism for reducing 
hyperglycaemia by promoting insulin mediated glucose disposal (Dugani and Klip, 
2005) and reducing hepatic gluconeogenesis (Barthel and Schmoll, 2003).  
 
In the current in vivo study, significant reduction in fasting hyperglycaemia with 
HA±SM treatment was noted despite no improvement in insulin resistance compared 
to PBS-treated db/db mice (Figure 4.7.B, C). HA+SM-treated db/db mice had 
significantly lower glucose levels during insulin tolerance test (ITT), however this 
was due to the difference in baseline (0 minute) glucose levels (Figure 4.7.A). When 
the glucose levels during the ITT were normalised to determine relative changes in 
glucose levels, there was no significant change in the rate of glucose disappearance 
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between the different treatment groups in db/db mice (Figure 4.7.B, C). The HA+SM 
treatment may have been ineffective in improving insulin sensitivity as it had limited 
efficacy in altering the following key pathogenic pathways that are responsible for 
insulin resistance in type 2 diabetes: 
 
 Ectopic lipid deposition paradigm: Lipid deposition in peripheral organs, such 
as liver reduces the control of insulin on gluconeogenesis (Matsumoto et al., 
2006). In the current in vivo study, HA±SM treatment failed to reduce hepatic 
triglyceride content (Figure 4.14.B) or gene expression of gluconeogenic genes, 
including PEPCK and glucose-6-phosphatase (Figure 4.15), suggesting that the 
glucose output from the liver HA±SM-treated db/db mice was likely to not be 
different to diabetic PBS-treated db/db mice. 
 
 Endocrine function of adipose tissue paradigm: Pro-inflammatory adipokines, 
such as TNF-α and IL-6, has been reported to promote insulin resistance 
(Fontana et al., 2007, Hotamisligil et al., 1995). HA±SM treatment failed to 
significantly reduce mRNA levels of key pro-inflammatory mediators, such as 
TNF-α, IL-6, Cxcl-2 (Figure 4.13.C, D, F). HA+SM treatment selectively 
reduced mRNA levels of CD68 (Figure 4.13.B), a marker for macrophages, and 
MCP-1α, (Figure 4.13.E) monocyte chemo-attractant. However, these changes in 
mRNA levels with HA+SM treatment did not seem to have an impact on 
peripheral insulin sensitivity. 
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It is possible that HA+SM therapy improved insulin sensitivity in the earlier stages 
of the model as the ITT was performed in week 8. However, it seems likely that the 
HA+SM was exerting its anti-diabetic effect primarily via an alternative mechanism 
to actions on insulin sensitivity. 
 
4.17.4. PRESERVATIO& OF ISLET β-CELL FU&CTIO& BY HA±SM 
 
One mechanism by which HA±SM may ameliorate hyperglycaemia is by improving 
islet function as indicated by the increase in fasting terminal insulin levels (Figure 
4.9.B). Several mechanisms by which HA±SM therapy could preserve islet function 
are listed below, 
 
 Firstly, it may simply be a secondary effect of reduced glucotoxicity (Maedler et 
al., 2002) with HA±SM treatment in db/db mice. 
 
 Secondly, HA+SM but not HA treatment resulted in inhibition β-cell iNOS 
expression (Figure 4.10.D) which is important as nitric oxide, the product of 
iNOS has been reported to inhibit glucose-stimulated insulin secretion from islets 
in vitro (Mosen et al., 2006) and iNOS inhibitors have been shown to ameliorate 
hyperglycaemia in rodent models of type 2 diabetes (Shimabukuro et al., 1997).  
 
 Finally, HA±SM may reduce islet inflammation as there was a striking reduction 
in intra-islet macrophage infiltration (Figure 4.12.F), which is pertinent given that 
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strategies that target pro-inflammatory cytokines are efficacious in rodents and 
humans with type 2 diabetes (Ehses et al., 2009).  
 
A separate in vivo study is required to conclusively determine whether preservation 
of islet β-cell function primarily is responsible for anti-hyperglycaemic effect of 
HA+SM treatment in db/db mice or whether it is simply a secondary response to 
reduced β-cell glucotoxicity. The in vivo study should be terminated after 2 to 3 
weeks, the time-point when HA+SM begins to improve glycaemic control, relative to 
PBS treatment in db/db mice. Examining islet histology along with glucose 
stimulated insulin secretion (assessed by the serum insulin level during GTT) at this 
point may shed light whether improved insulin release from β-cells is indeed 
primarily responsible for the anti-hyperglycaemic effect of HA+SM in db/db mice. 
 
4.17.5. THE MODE OF ACTIO& OF HA IS DIFFERE&T TO A&TI-
DIABETIC EFFECT OF PUBLISHED HO ACTIVITY I&DUCERS 
 
The mode of action of HA and heme per se may be different to that reported 
previously. The efficacious phenotype of hemin in GK and Zucker diabetic fatty 
(ZDF) rats and cobalt (III) protoporphyrin IX chloride (CoPP) in ob/ob mice was 
reversed with the HO activity inhibitors CrMP and SM, respectively (Li et al., 2008, 
Ndisang and Jadhav, 2009, Ndisang et al., 2009a). In contrast to published results, 
the current in vivo study demonstrates that pharmacological inhibition of HO activity 
enhances the anti-hyperglycaemic effect of HA. Importantly, the anti-
hyperglycaemic effect of HA±SM coincided with weight gain and preservation of 
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islet function rather than an increase in peripheral insulin sensitivity and weight loss 
as reported with either CoPP or hemin treatment in murine models of type 2 diabetes 
(Li et al., 2008, Ndisang and Jadhav, 2009, Ndisang et al., 2009a).   
 
The discrepancy between the findings of the current and previous studies may due to 
following reasons 
 
 The different models of type 2 diabetes employed (db/db mouse v ob/ob mouse 
(Li et al., 2008) or obese rats (Ndisang and Jadhav, 2009, Ndisang et al., 2009b, 
Ndisang et al., 2009a) 
 
 The different combinations of HO-1 inducers and inhibitors (HA+SM v 
CoPP+SM or (Li et al., 2008) or hemin+CrMP (Ndisang and Jadhav, 2009, 
Ndisang et al., 2009a, Ndisang et al., 2009b). 
 
 The different concentration, treatment regime and administration route of HO 
activity inducers and inhibitors employed in the various studies (Table 1.3, 1.4). 
 
4.17.6. POSSIBLE MECHA&ISM FOR THE A&TI-DIABETIC EFFICACY 
OF HA±SM 
 
The most intriguing question is how concurrent HA and SM interact to dramatically 
improve glycaemic control. It may be that they act via different mechanisms, 
however an alternative possibility is that the effect of HA+SM may be due to an 
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additive dose-dependent effect of either the porphyrin structure per se or HO-1 
protein levels or intracellular heme concentration.  
 
 Additive effect of porphyrin structure per se: HA and SM contain a porphyrin 
ring and it may be that this structure per se that is efficacious. However, earlier 
published studies have also employed different porphyrin based pharmacological 
inducers and inhibitors of HO activity but have not observed an additive to 
synergistic interaction between HO activity modulators (Ndisang and Jadhav, 
2009, Li et al., 2008) suggesting that the porphyrin structure per se is unlikely to 
be the mechanism by which HA and SM interact to ameliorate hyperglycaemia. 
However, to test the hypothesis that porphyrin ring per se has an anti-
hyperglycaemic effect; protoporphyrin IX (without a metal ion and therefore 
unable to modulate HO-1 protein or activity, P8293 from Sigma Aldrich or, 
P562-9 from Frontier scientific) could be employed at different concentrations to 
determine whether protoporphyrin IX has a dose-dependent modulatory effect on 
hyperglycaemia in db/db mice. 
 
 Additive effect of HO-1 protein: HO-1 protein has been reported to translocate 
to the nucleus independently of HO activity and induce expression of anti-
oxidants and protect against oxidative stress (Hori et al., 2002, Lin et al., 2007). 
HA+SM treatment resulted in a synergistic increase in HO-1 protein in the liver 
of db/db mice (Figure 4.3.C). Hence, future work may focus on testing the 
hypothesis that HO-1 protein expression is vital for anti-hyperglycaemic effect of 
HA+SM treatment. To test this hypothesis, either global knock-out or tissue 
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specific homozygous HO-1 knock-out db/db mice will be required. Tissue-
specific knock-out would be the most incisive method as it would provide 
information on the importance of HO-1 in individual organs. It would also help 
overcome the challenges posed by the poor survival rate of homozygous HO-1 
knock-out in mice (Poss and Tonegawa, 1997), which is likely to be further 
reduced in diabetic (db/db) mice.  
 
 Additive effect of heme per se: HA+SM treatment was shown to significantly 
increase the intracellular heme concentration in the liver of db/db mice (Figure 
4.3.B). This was due to administration of a heme-based compound and 
simultaneous inhibition of the major heme degradation pathway with SM 
treatment. Heme is a ligand for the nuclear receptor Rev-erbα and heme 
promotes recruitment and stabilisation of the nuclear receptor corepressor–
histone deacetylase 3 (NCoR-HDAC3) complex to the promoter regions of key 
gluconeogenic enzymes resulting in inhibition of gene expression in hepatocytes 
in vitro (Yin et al., 2007). Furthermore, heme has been reported to promote 
adipocyte differentiation by acting as a ligand for Rev-erbα in the 3T3-L1 cell 
line (Kumar et al., 2010). The majority of the modulatory effects facilitated by 
heme and Rev-erbα interaction are limited to in vitro studies. However, recently 
the focus has shifted to determine the physiological effect of either synthetic 
agonists of Rev-erbα or, organ and tissue specific Rev-erbα knockout in murine 
models of type 2 diabetes (Cho et al., 2012a, Solt et al., 2012a). Hence, HA+SM 
treatment in db/db mice with organ and tissue specific Rev-erb knock-out may 
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help to establish whether the increase in intracellular heme concentration is 




Figure 4.16 Possible mode of actions for the synergism between HA and SM. 
HA+SM which are porphyrin based compounds resulted in a synergistic increase in HO-
1 protein and intracellular heme concentration. Published studies based on in vitro 
studies report that HO-1 protein translocation to the nucleus protects from oxidative 
stress (Lin et al., 2007), increased intracellular heme can repress metabolic genes via 
Rev-erbα (Yin et al., 2010) and porphyrin based pharmacological inhibitors of HO 
activity such as zinc protoporphyrin have the ability to inhibit iNOS activity and 
expression (Grundemar and Ny, 1997). The synergism between HA and SM may be due 
to one or all of these properties. Black arrows represent observations made in either the 
present study or reported earlier in the literature and the dotted arrows represent 
possible interactions that have not been established yet but are of interest for future 
research. 
 
4.17.7. CO&CLUDI&G REMARK 
 
In conclusion, HA treatment in db/db mouse model of type 2 diabetes was found to 
reduce fasting hyperglycaemia during the end of 8-week study. Paradoxical to the 
hypothesis of current in vivo study, concurrent treatment of HA and the HO inhibitor, 
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SM, resulted in a profound improvement in glycaemic control indicating that a HA 
mediated increase in HO activity is not the primary mechanism for the anti-
hyperglycaemic effect of HA±SM. The relatively delayed and an early improvement 
in glycaemic control with HA+SM treatment occurred despite an increase in obesity. 
The anti-hyperglycaemic effect of HA±SM was possibly due to an increase in 
adipocyte storage capacity, preservation of islet β-cell function and reduced islet 
inflammation. It would be of great interest in future to determine the primary 
metabolic event responsible for ameliorative potential of HA±SM in the db/db mouse 
model of type 2 diabetes. Further in vivo studies are also needed to investigate 
whether the anti-hyperglycaemic effect of HA+SM is due to additive increase in HO-
1 protein or heme per se.  
 
Concurrent to the present in vivo study, the anti-inflammatory effects of HA±SM 
were characterized in cell culture models of inflammation including cytokine 
administration to a MIN6 β-cell line (chapter 5) and lipopolysaccharide activation of 










5. CHAPTER 5: CHARACTERISATIO& OF THE EFFECT OF HEME 
OXYGE&ASE ACTIVITY MODULATORS I& CYTOKI&E MIX-

























In vivo studies have demonstrated that increased expression of pro-inflammatory 
cytokines and chemokines in the islets of rodents or humans with type 2 diabetes can 
promote macrophage infiltration and impair islet β-cell function (Ehses et al., 2007, 
Donath et al., 2009). In keeping with this, the in vivo study to determine the anti-
diabetic efficacy of heme arginate (HA) in the db/db model of type 2 diabetes 
(chapter 4) demonstrated increased islet macrophage infiltration and islet iNOS 
protein expression in the db/db mice when compared with non-diabetic C57BL/KsJ 
(lean) mice. There was a marked reduction in islet inflammation with HA and 
HA+SM (SM - Stannous (IV) mesoporphyrin IX dichloride, an inhibitor of heme 
oxygenase activity) treatment in the db/db mice. However, the preservation of islet β-
cells with HA+SM treatment in the db/db mice may be due to either a direct anti-
inflammatory effect of HA and SM on islets or reduced glucotoxicity. Therefore, it 
was important to determine whether HA and SM alone or in combination had a direct 
anti-inflammatory effect on the insulin producing β-cells.  
 
Chronic exposure of pancreatic islet β-cells to pro-inflammatory cytokines (Corbett 
and McDaniel, 1995) and elevated levels of lipids (Shimabukuro et al., 1997) 
promotes islet β-cell destruction (insulitis) mediated in part via increased iNOS 
expression and production of nitric oxide (Thomas et al., 2002).  Ex vivo culture of 
rodent islets with the pro-inflammatory cytokine interleukin-1β (IL-1β) in 
combination with tumor necrosis factor-α (TNF-α) or interferon-γ (IFN-γ) is 
routinely used to mimic the effects of insulitis that occur in rodent models of type 1 
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diabetes (Corbett and McDaniel, 1995). The ex vivo culture of mouse and rat islets in 
the presence of IL-1β inhibits islet insulin release (Southern et al., 1990) and 
coincides with increased iNOS gene and protein expression and production of nitrite 
(Corbett and McDaniel, 1995). Inhibitors of iNOS including NG-monomethyl-L-
arginine (NMMA), aminoguanidine, nitro-L-arginine methylester (L-NAME) and 
ONO-1714 have been reported to reverse the detrimental effects of IL-1β (Southern 
et al., 1990, Corbett et al., 1992, Welsh and Sandler, 1992, Corbett and McDaniel, 
1995, Kato et al., 2003).  
 
In the current in vitro study, MIN6 β-cells were employed to test the hypothesis that 















5.2. I VITRO β-CELL I&FLAMMATIO& MODEL 
 
The MIN6 β-cell is a cell line derived from in vivo immortalized mouse insulin-
secreting pancreatic β-cells. MIN6 β-cells were stimulated with a combination of 
recombinant cytokine proteins including IL-1β, TNF-α and IFN-γ to mimic the pro-
inflammatory stress on β-cells in vivo. The final concentration of HA, SM and 
recombinant pro-inflammatory cytokine proteins applied to the MIN6 β-cells are 
listed in table 5.1. MIN6 β-cells were pre-treated for 2 hours with PBS or SM prior to 
addition of HA for another 4 hours. Post 4 hours incubation with HA±SM, a cytokine 
mix (CM) comprising of IL-1β, IFN-γ and TNF-α at concentrations listed in table 5.1 














Figure 5.1 In vitro experimental protocol in the MIN6 β-cell line. The aim of the 
study was to determine whether HA and SM had anti-inflammatory properties in an in 
vitro model of pro-inflammatory stress on β-cells that are observed in vivo. 
RT PCR for mRNA levels of iNOS, MCP-1α, Cxcl-1, IL-1β 
or cytospin sections stained for iNOS 
or western blotting for HO-1 protein levels 






 20 hr incubation 
 2 hr incubation 
MIN6 β cells treated with PBS or HO activity inhibitor SM 
MIN6 β cells treated with PBS or HA 
Medium harvested for nitrite determination 
 2x PBS wash 
Stimulation MIN6 β cells treated with cytokine mix (CM) 
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Stimulants LA HA SM IL-1β IF&-γ T&F-α 
       
Concentration 100µM 20µM 20µM 5ng/ml 100ng/ml 10ng/ml 
 
Table 5.1 Final concentrations of the heme oxygenase inducer and inhibitor and 
the pro-inflammatory stimulants applied to MIN6 β-cells. LA: L-arginine, HA: Heme 
arginate, SM: Stannous mesoporphyrin, IL-1β: Interleukin-1β, IFN-γ: Interferon-γ, TNF-

























5.3. CO-TREATME&T WITH SM ABROGATED THE HA MEDIATED 
I&CREASE I& HO ACTIVITY BUT &OT HO-1 PROTEI& 
EXPRESSIO& 
 
Treatment with 20µM of HA induced HO-1 protein expression in MIN6 β-cells 
(Figure 5.2.A). Co-treatment with HA and SM, a HO activity inhibitor, 
synergistically increased HO-1 protein levels when employed at the two different 
(10µM and 20µM) concentrations (Figure 5.2.A). A 20µM concentration of HA and 
SM was selected to determine their effect on HO activity as single and concomitant 
treatments. Treatment of MIN6 β-cells with 20µM of HA resulted in a significant 
increase (P<0.05) in HO activity, which was abrogated on co-treatment with 20µM 
of SM (Figure 5.2.B). Based on the HO activity result, HA and SM at 20µM 





Figure 5.2 HO-1 protein levels and HO activity in MIN6 β-cells. A. 20µM of HA-
induced HO-1 protein levels whereas co-treatment of HA and SM (HA+SM) 
synergistically increased HO-1 protein level when compared to single agent treatment. 
This was evident for the two concentrations (10µM and 20µM) of SM employed in the 
study. Representative western-blot from n=2, separate experiments. B. The significant 
increase in HO activity with 20µM of HA treatment was abrogated in MIN6 β-cells when 
co-treated with 24 hour treatment of SM. *P<0.05, P-value derived by Dunn’s multiple 
comparison post-test when P<0.05 by Kruskal-Wallis test. The data given are mean ± 
s.e.m. from n=3 independent cell culture experiments where each ‘n’ was performed in 
duplicates. 
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5.4. THE MI&6 β-CELL LI&E IS &OT A GOOD MODEL OF GLUCOSE-
I&DUCED I&SULI& SECRETIO& 
 
L-arginine (LA) and hemin, both constituents of HA, are reported to induce insulin 
secretion in ex vivo culture of islets from mice (Henningsson and Lundquist, 1998). 
Therefore, the effect of HA and LA on insulin release by MIN6 β-cells was 
determined.  
 
MIN6 β-cells plated in DMEM medium containing either 5mM or 30mM D-glucose, 
were treated with either PBS (vehicle) or 100µM of LA or 20µM of HA (HA), and 
incubated for 24 hours at 37oC. Post incubation, MIN6 β-cells were washed twice 
with warm PBS. MIN6 β-cells were again incubated with DMEM medium 
containing either 5mM or 30mM D-glucose for 30 minutes at 37oC, before collecting 
medium from different treatment wells to determine the insulin concentration. 
 
The incubation of MIN6 β-cells at different concentration of glucose did not result in 
any significant difference in insulin release (Figure 5.3.B). Additionally, LA or HA 
treatment for 24 hours in presence of 5mM (Figure 5.3.C) or 30mM (Figure 5.3.D) 
D-glucose failed to markedly increase insulin release when MIN6 β-cells were re-
incubated with different concentration of glucose for 30 minutes.  
 
The DMEM medium employed in the experiment contained fetal calf serum (FCS), a 
potential source of exogenous insulin, which may have masked the insulin secretion 
induced by glucose in the MIN6 β-cell line., Hence the insulin concentration in FCS 
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was also measured and found to be much lower than that obtained from the MIN6 
cell supernatants (Figure 5.3.A). This demonstrated that the insulin concentrations 
determined for test samples were not due to the presence of exogenous insulin 
contained in the FCS present in the DMEM medium. Fasting serum sample of HA-




Figure 5.3 Insulin released by MIN6 β-cells in response to a low or high 
concentration of glucose. A. No detectable insulin content was measured in FCS. 
Week 8 fasting serum sample from HA-treated mice was used as positive (+ve) control. 
B. No significant difference in insulin release was observed in PBS-treated MIN6 β-cells 
incubated with 5mM (5G) and 30mM (30G) of D-glucose. P>0.05 by two-tailed Mann 
Whitney test. C. No significant difference in insulin release by MIN6 β-cells incubated in 
5G, in presence of PBS (vehicle), 100µM L-arginine (LA) or 20µM heme arginate (HA). 
P>0.05 by Kruskal-Wallis test. D. No significant difference in insulin release by MIN6 β-
cells incubated in 30G, in presence of PBS (vehicle), LA or HA. P>0.05 by Kruskal-
Wallis test. The data given are mean ± s.e.m. from n=3 independent cell culture 
experiments where each ‘n’ was performed in duplicates. 
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5.5. CYTOKI&ES I&DUCED A& I&CREASE I& &ITRITE PRODUCTIO& 
I& MI&6 β-CELLS 
 
A pilot experiment was performed to determine the optimal combination of IL-1β, 
TNF-α and IFN-γ required to stimulate nitrite production in MIN6 β-cells. The 
combination of IL-1β and TNF-α, in the absence or presence of IFN-γ was found to 
significantly increase nitrite release (Figure 5.4) when compared to PBS-treated 
MIN6 cells after 48 hours of treatment. A combination of IL-1β, IFN-γ and TNF-α 
(cytokine mix) was selected to stimulate a pro-inflammatory response in MIN6 β-





































































Figure 5.4 Nitrite produced by MIN6 β-cells following treatment with IL-1β, TNF-α 
and IFN-γ either alone or in different combination for 48 hours. The combination of 
IL-1β and TNF-α, in the absence or presence of IFN-γ resulted in a significant release of 
nitrite after 48 hours. *P<0.05, **P<0.01, P-values derived from Dunn’s multiple 
comparison post-test when P<0.05 by Kruskal-Wallis test. The data given are mean ± 




5.6. CO-TREATME&T OF MI&6 β-CELLS WITH HA REDUCED 
CYTOKI&E MIX-I&DUCED I&CREASE I& i&OS EXPRESSIO& 
 
Treatment of MIN6 β-cells for 24 hours with the cytokine mix led to a substantial 
increase in iNOS protein expression when compared to PBS-treated MIN6 β-cells 
(Figure 5.5). However, co-treatment of MIN6 β-cells with HA and the cytokine mix 
reduced the levels of iNOS protein expression (Figure 5.5) in comparison to cytokine 




Figure 5.5 Immuno-fluorescence staining for iNOS in MIN6 β-cells stimulated with 
a cytokine mix for 24 hours. Incubation of MIN6 β-cells with a cytokine mix for 24 
hours resulted in increased iNOS protein expression. Concurrent treatment with HA 
reduced the cytokine mix induced iNOS protein expression. The figure is representative 
of n=2 separate experiments. Scale bar represents 100 pixels. 
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5.7. HA±SM REDUCED THE PRO-I&FLAMMATORY RESPO&SE TO 
CYTOKI&E MIX I& MI&6 β-CELLS 
 
Treatment of MIN6 β-cells (non-stimulated) for 24 hours with either single or co-
treatment of HA and SM did not result in a significant modulation of mRNA levels 
of iNOS, IL-1β, and monocyte chemo-attractants MCP-1α and Cxcl-1 (also known 
as chemokine KC) (Figure 5.7.A, C, E, G). Cytokine mix (CM) stimulation of MIN6 
β-cells resulted in a significant increase in the relative mRNA levels of iNOS, IL-1β 
and MCP-1α (Figure 5.6, P<0.05). 
 
Co-treatment of CM-stimulated MIN6 β-cells with HA but not SM resulted in a 
significant reduction in mRNA levels of iNOS, IL-1β, MCP-1α and Cxcl-1 (Figure 
5.7.B, D, F, H, P<0.05).  
 
Pre-treatment of MIN6 β-cells with SM prior to co-treatment with HA and CM 
partially inhibited the HA-mediated reduction in mRNA levels of iNOS (Figure 
5.6.B). However, SM pre-treatment of MIN6 β-cells failed to reverse HA-mediated 







Figure 5.6 mRNA levels of pro-inflammatory mediators stimulated by cytokine mix 
in MIN6 β-cells. Cytokine mix stimulation of MIN6 β-cells for 24 hours significantly 
increased relative mRNA levels of iNOS, IL-1β and MCP-1α. The mRNA level of Cxcl-1 
with PBS treatment could not be determined; hence statistical significance could not be 
calculated when compared to the mRNA level induced by cytokine mix. *P<0.05, P-
values derived by two-tailed Mann Whitney test for each specified gene. 18S gene was 
used as endogenous control gene. The data given are mean ± s.e.m. from n=3 





Figure 5.7 Effect of HA and SM on mRNA levels of pro-inflammatory mediators 
stimulated by a cytokine mix in MIN6 β-cells. Relative mRNA levels of A. iNOS, C. 
IL-1β, E. MCP-1α, G. Cxcl-1 observed in non-stimulated MIN6 β-cells. P>0.05 by 
Kruskal-Wallis test. Relative mRNA levels of B. iNOS, D. IL-1β, F. MCP-1α, H. Cxcl-1 in 
cytokine mix stimulated MIN6 β-cells. *P<0.05, P-values derived by Dunn’s multiple 
comparison post-test when P<0.05 by Kruskal-Wallis test. 18S gene was used as 
endogenous control gene. The data given are mean ± s.e.m. from n=3 independent cell 
culture experiments where each ‘n’ was performed in duplicates. ND: Not determined. 
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5.8. CHAPTER DISCUSSIO& 
 
5.8.1. THE A&TI-I&FLAMMATORY EFFECTS OF HA ARE 
I&DEPE&DE&T OF HO ACTIVITY A&D HO-1 PROTEI& 
EXPRESSIO& 
 
Heme arginate (HA) was observed to reduce iNOS expression and markedly reduce 
islet infiltration in the pancreatic islet of db/db mouse model of type 2 diabetes, and 
this was independent of induction of HO activity (chapter 4). However, it could not 
be determined whether this was simply due to a decrease in gluco/lipotoxicity as HA 
reduced hyperglycaemia or a direct effect of HA±SM on β-cells. Therefore, the anti-
inflammatory effect of HA was investigated in cytokine mix (CM; 5ng/ml IL-1β + 
10ng/ml TNF-α + 100ng/ml IFN-γ) stimulated MIN6 β-cells. CM stimulation of 
MIN6 β-cells for 24 hours resulted in a substantial induction in iNOS protein 
expression and a significant increase in expression (mRNA levels) of pro-
inflammatory mediators, such as iNOS, IL-1β,  and chemo-attractants, including 
MCP-1α and Cxcl-1 genes (Figure 5.5, 5.6).  
 
I had initially hypothesised that HA may exert an anti-inflammatory effect in MIN6 
cells via it’s ability to induce HO activity. HA treatment did indeed reduce CM-
stimulated iNOS protein expression and significantly reduce mRNA levels of iNOS 
in MIN6 β-cells. Pre-treatment with SM partially reversed the HA-mediated 
reduction in mRNA levels of iNOS, demonstrating that the effect of HA may be 
partly dependent on its ability to induce HO activity. However, pre-treatment of 
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MIN6 β-cells with SM, prior to co-treatment with HA and CM failed to reverse the 
significant reduction in relative mRNA levels of IL-1β, MCP-1α and Cxcl-1 genes 
despite abrogating the HA-mediated increase in HO activity. Hence, while HA 
treatment did indeed have anti-inflammatory effects in CM-stimulated MIN6 β-cells, 
contrary to the initial hypothesis, this was largely independent of its ability to induce 
HO activity (Figure 5.2.B). 
 
The anti-inflammatory effect of HA in MIN6 β-cells is also unlikely to be due to the 
increase in HO-1 protein levels as HA+SM resulted in a synergistic increase in HO-1 
protein in comparison to HA treatment alone, however, this did not result in a  
significantly greater decrease in mRNA levels of iNOS, IL-1β, MCP-1α and Cxcl-1.  
 
The current study in MIN6 β-cells demonstrates that HA treatment may protect islet 
β-cells from the deleterious effects of islet inflammation, which recently has been 
postulated to be responsible for the loss of β-cell mass and function in type 2 
diabetes (Donath et al., 2009, Ehses et al., 2007b). Furthermore, published ex vivo 
studies have reported that reductions in β-cell iNOS expression per se may restore 
islet insulin release (Kato et al., 2003). 
 
5.8.2. POSSIBLE EXPLA&ATIO& FOR THE MECHA&ISM OF THE 
A&TI-I&FLAMMATORY EFFECTS OF HA±SM I& MI&6 CELLS 
 
A possible explanation for HO activity independent anti-inflammatory effects of HA 
and HA+SM treatment may be the ability of heme to interact with the nuclear 
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hormone receptor Rev-erb (Yin et al., 2010). In a recent study, Vieira et al has 
demonstrated that siRNA knock-down of Rev-erbα in MIN6 β-cells decreased the 
expression of genes which facilitate lipogenesis, insulin exocytosis and β-cell 
proliferation (Vieira et al., 2012). Additionally, Rev-erbα has been demonstrated to 
facilitate repression of pro-inflammatory genes, such as iNOS and MCP-1α in 
murine macrophages (Huang et al., 2011, Pascual et al., 2005). However, the effect 
of the interaction between heme and Rev-erbα on pro-inflammatory genes in 
pancreatic β-cells has not been explored. On the basis of the results from the current 
study and emerging evidence on the role of Rev-erbα in pancreatic β-cells, it will be 
of interest in future to test the hypothesis that the increase in intracellular heme 
concentration with HA±SM treatment exerts anti-inflammatory effects via Rev-erb in 
islet β-cells.    
 
5.8.3. THE MI&6 β-CELL LI&E IS A POOR MODEL TO STUDY THE 
DETRIME&TAL EFFECT OF I&FLAMMATIO& O& I&SULI& 
SECRETIO& 
 
Although a significant reduction in the CM stimulated pro-inflammatory response in 
MIN6 β-cells was observed with HA±SM pre-treatment, it could not be determined 
whether these anti-inflammatory changes could potentially improve β-cell function 
as the insulin secretion in response to low and high concentration of D-glucose was 
found to be indistinguishable. This is a major limitation of using the MIN6 β-cell line 
as a model of β-cells. 
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Collagenase digestion of the pancreas to isolate pancreatic islets is the physiological 
option for β-cell studies. This could not be carried out during the PhD due to time 
constraints. Hence pre-treatment of isolated islets with HA±SM prior to stimulation 
with pro-inflammatory cytokines would be a useful experiment to determine whether 
HA±SM could preserve glucose-stimulated insulin secretion in β-cells. However the 
heterogeneity of cell-types in the pancreatic islets would make it difficult to 
determine whether the anti-inflammatory effect of HA±SM are due to a direct effect 
on β-cells within the islet or to the effect on other cell types including macrophages. 
 
5.8.4. CO&CLUDI&G REMARK 
 
In conclusion, HA was demonstrated to have a direct anti-inflammatory effects in 
cytokine mix stimulated MIN6 β-cells with a reduction in gene expression of pro-
inflammatory mediators, including iNOS and IL-1β. The anti-inflammatory effect of 
HA on insulin secretion could not be demonstrated due to the lack of glucose-
responsive insulin production by MIN6 β-cells. Also, HA significantly reduced the 
mRNA levels of the immune cell chemo-attractants MCP-1α and Cxcl-1 (also known 
as Chemokine KC, a homologue of human IL-8), two chemokines that may promote 
islet macrophage infiltration in rodent models of type 2 diabetes (Ehses et al., 
2007b). This may in part explain the reduction in macrophage infiltration in the islets 
of HA±SM treated db/db mice (chapter 4). The anti-inflammatory effects of HA in 
the MIN6 β-cells were demonstrated to be broadly independent of HO activity, and 
the mechanism by which HA exerts its anti-inflammatory effects remains elusive. In 
addition it is possible that HA may have a role not only in reducing macrophage 
 206 
infiltration, but also in changing the macrophage activation status both in islets and 
adipose tissue. Hence, the effect of HA on macrophage phenotype will be 























6. CHAPTER 6: CHARACTERISATIO& OF THE EFFECT OF HEME 
OXYGE&ASE ACTIVITY MODULATORS I& LIPOPOLYSACCHARIDE 

























Induction of heme oxygenase (HO)-1 has been shown to have anti-inflammatory 
effects on macrophages (Lee and Chau, 2002, Weis et al., 2009) and classical 
activation of macrophages is important in the pathogenesis of type 2 diabetes 
(Lumeng et al., 2007). Therefore, the current study was performed to test the 
hypothesis that the anti-inflammatory effects of HA are due to induction of HO 
activity in primary macrophages.  
 
In the present study, cobalt (III) protoporphyrin IX chloride (CoPP), which like HA, 
is a protoporphyrin based inducer of HO activity, was included to determine whether 
any anti-inflammatory effects of HA are specific to HA or shared by other metallo-
porphyrins, either due to their ability to induce HO activity or due to the 
protoporphyrin ring structure per se.  
 
The anti-inflammatory effects of HA in the db/db mice and pancreatic β-cell line, 
MIN6, were not reversed by treatment with stannous (IV) mesoporphyrin IX 
dichloride (SM), despite SM efficiently inhibiting the HA mediated increase in HO 
activity. To exclude off-target effects of SM, chromium (III) mesoporphyrin IX 
chloride (CrMP) was included in the present study, as it is reported to be a more 
selective inhibitor of HO activity. CrMP has been reported not to inhibit nitric oxide 
synthase activity (Appleton et al., 1999) and it does not induce HO-1 protein 
(Ndisang and Jadhav, 2009). 
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6.2. I VITRO MODEL OF CLASSICALLY ACTIVATED 
MACROPHAGES 
 
Classically activated macrophages are used routinely to screen for anti-inflammatory 
effects of various cytokine proteins, compounds and cell types including IL-10 (Lee 
and Chau, 2002), immune complexes (Gerber and Mosser, 2001) and apoptotic cells 
(Fadok et al., 1998), respectively.  
 
LPS is a cell-wall component of gram-negative bacteria which activates 
macrophages by binding to the cell-surface receptors present on macrophages, 
including TLR-4 (Poltorak et al., 1998) and CD14 (Meng and Lowell, 1997). LPS 
activation of macrophages evokes a pro-inflammatory response that include release 
of nitrite, TNF-α, IL-12 p40 and IL-6 (Gerber and Mosser, 2001, Meng and Lowell, 
1997). Hence, the in vitro model of LPS-activated macrophage was used to 




Figure 6.1 Diagrammatic representation of IFN-γ, LPS or TNF-α mediated classical 
activation (CA) of macrophages (Mϕ). The cell surface receptors such as TLRs, 
CD14 and IFN-receptor 1 present on macrophages facilitate classical activation of 
macrophages by stimulants including TNF-α, LPS and IFN-γ to evoke a pro-
inflammatory response which is characterised by release of IL-1, IL-6, TNF-α and nitric 
oxide. Text in red font and blue font represent stimulants and cell-surface macrophage 
receptors respectively. 
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In the current study, bone marrow derived macrophages (BMDM) from C57BL/KsJ 
mice were pre-treated with either PBS, HO activity inhibitors or trichostatin (TSA; 
an inhibitor of histone deacetylases (HDACs)) for 2-4 hours prior to treatment with 
HO activity inducers for a further 20 hours. BMDM were then washed with PBS 
before being stimulated with LPS for 24 hours (Figure 6.2). 
 
The supernatants harvested were used to determine the concentration of nitrite and 
cytokines released, while cells were then washed with PBS before lysing in TRIZOL 
reagent in order to determine the levels of expression of pro-inflammatory genes by 
real time polymerase chain reaction (RT PCR). The compounds, their action and the 
















Figure 6.2 In vitro experiment protocol in bone marrow derived macrophages 
(BMDMs). The primary objective was to determine the effect of HO activity inducers and 







TRIZOL cell lysis 
20 hr incubation 
2-4 hr incubation 
20 hr incubation, 2x PBS wash 
BMDM treated with PBS or, TSA or, HO activity inhibitors 
BMDM treated with PBS or, HO activity inducers 
BMDM treated with LPS 
RT PCR for mRNA levels of iNOS, MCP-1α, TNF-α 
Medium harvested for nitrite, TNF-α, IL-10, IL-6 determination 
2x PBS wash 
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S.&. Compounds Abr. Function Final 
concentration 
     
01 Heme arginate HA HO activity inducer 10 µM 
02 L-arginine LA Component of HA 50 µM 
03 Cobalt (III) protoporphyrin IX 
chloride 
CoPP HO activity inducer 10 µM 
04 Stannous (IV) mesoporphyrin IX 
dichloride 
SM HO activity inhibitor 10 µM 
05 Chromium (III) mesoporphyrin IX 
chloride 
CrMP HO activity inhibitor 5 µM 
06 Trichostatin TSA Inhibitor of HDACs 10 nM 
07 Lipopolysaccharide LPS BMDM activator 100 ng/ml 
 
 
Table 6.1 List of compounds, their function/purpose and final concentration used 















6.3. LPS STIMULATIO& RESULTED I& A PRO-I&FLAMMATORY 
RESPO&SE I& ACTIVATED BMDM 
 
A time-course experiment was performed to determine the duration of LPS 
stimulation that evoked a substantial pro-inflammatory response. The BMDMs were 
stimulated with either PBS or LPS for 1, 6 and 24 hours. The supernatant was used to 
determine the concentration of nitrite, TNF-α and IL-6 released at the stated time 
points.  
 
LPS stimulation of BMDM led to a time-dependent increase in nitrite, TNF-α and 
IL-6.  LPS stimulation of BMDM significantly increased the release of nitrite, TNF-α 
and IL-6 (P<0.05, Figure 6.3.A-C) after 24 hours of LPS stimulation.  
 
A significant increase in mRNA levels of iNOS and TNF-α (P<0.05, Figure 6.3.D) 
was observed after 24 hour of LPS stimulation. Hence, 24 hours of LPS stimulation 
of BMDMs was selected for future experiments to generate a robust pro-
















Figure 6.3 Time-course of the LPS-stimulated pro-inflammatory response in 
BMDM. LPS stimulation of BMDM for 24 hours resulted in a significant increase in 
release of A. nitrite, B. TNF-α, C. IL-6 protein and in mRNA levels of D. iNOS and TNF-
α. A-C: *P<0.05, P-values derived by two-tailed Mann Whitney test between PBS and 
LPS-treated BMDM for each specified time-points. D. *P<0.05, P-values derived by two-
tailed Mann Whitney test between PBS and LPS-treated BMDM for each specified gene. 
The data given are mean ± s.e.m. from n=3 independent cell culture experiments where 











6.4. EFFECT OF HA A&D METALLO-PORPHYRI& COMPOU&DS O& 
HO ACTIVITY A&D HO-1 PROTEI& LEVELS 
 
The BMDM were pre-treated with either PBS or SM or CrMP for 4 hours prior to 
treatment with the HO activity inducers HA or CoPP for 20 hours. HO activity and 
HO-1 protein levels were determined by the paired enzyme assay and by western 
blotting respectively.  
 
A dose-dependent increase in HO-1 protein level was noted in BMDMs-treated with 
2, 10, 20, 50 and 100µM of HA for 24 hours (Figure 6.4.A). 10µM of HA was 
further tested for its effect on HO activity. HA treatment of BMDMs resulted in a 
significant increase (P<0.05, Figure 6.4.B) in HO activity which was partially 
reduced by pre-treatment with either SM or CrMP (Figure 6.4.B). CoPP treatment 
increased HO activity by approximately 3 fold when compared with PBS-treated 
BMDM however; this increase was not statistically significant (Figure 6.4.C). SM 
pre-treatment reduced CoPP induced HO activity from 3 fold to <2 fold however, 
large variations in the CoPP+CrMP group made it difficult to confidently state that 
CrMP also reduced the CoPP-mediated increase in HO activity (Figure 6.4.C).   
 
HA and CoPP treatment resulted in a substantial induction of HO-1 protein (Figure 
6.4.D). SM and CrMP, the two HO activity inhibitors used in the current study, 
induced HO-1 protein levels. CrMP was more potent at increasing HO-1 protein 
levels when compared to SM. Co-treatment of SM with either CoPP or HA increased 




Figure 6.4 Determination of HO activity and HO-1 protein level with HA and 
metallo-porphyrin compounds in BMDM. A. HA treatment for 24 hours resulted in a 
dose-dependent increase in HO-1 protein level in BMDMs. The western blot is a 
representative figure of n=2 separate experiments. B. 10µM of HA treatment for 20 
hours significantly increased the HO activity in BMDMs which was partially inhibited by 
pre-treatment with the HO activity inhibitors, 10µM SM and 5µM CrMP. *P<0.05, P-value 
derived by Dunn’s multiple comparison post-test when P<0.05 by Kruskal-Wallis test. C. 
10µM of CoPP for 20 hours failed to significantly increase HO activity relative to PBS-
treated BMDMs. 10µM of SM reduced the CoPP-mediated 3 fold increase in HO activity 
however, the large variation within the CrMP (5µM) group precluded a definitive 
analysis. P>0.05 (non-significant) by Kruskal-Wallis test. B, C: The data given are mean 
± s.e.m. from n=3 independent cell culture experiments where each ‘n’ was performed in 
duplicates. D. HA, CoPP, SM and CrMP treatment for 24 hours resulted in an increase 
in HO-1 protein level. The increase in HO-1 protein with SM was comparatively lower 
than that with CrMP. The addition of SM to either CoPP or HA resulted in an additive 
increase in HO-1 protein level. The western blot is a representative figure of n=2 
separate experiments. 
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6.5. HA A&D METALLO-PORPHYRI& COMPOU&DS WERE &OT 
CYTOTOXIC 
 
The effect of HA and other metallo-porphyrins on the viability of BMDMs was 
assessed by the Alamar blue cell viability assay. HA and CoPP in the presence or, 
absence of PBS, SM or CrMP did not result in any significant change in cell viability 
(Figure 6.5) at the concentrations listed in table 6.1. Hence these compounds are not 




Figure 6.5 Cell viability of BMDMs following treatment with various metallo-
porphyrin compounds. BMDMs were treated with HA or CoPP in the presence or 
absence of PBS, SM or CrMP for 24 hours prior to Alamar blue treatment for 4 hours. 
No significant change in % cell viability was noted for different treatments when 
compared to PBS (vehicle)-treated BMDMs. P>0.05 (non-significant) by Kruskal-Wallis 
test. The data given are mean ± s.e.m. from n=4 independent cell culture experiments 







6.6. THE A&TI-I&FLAMMATORY EFFECT OF HA IS I&DEPE&DE&T 
OF THE L-ARGI&I&E COMPO&E&T PRESE&T I& HA 
 
The nitric oxide synthase (NOS) enzyme catalyses the reaction between L-arginine 
(LA) and oxygen to produce nitric oxide and citrulline (Alderton et al., 2001). As 
nitrite release was a vital read-out for determining the effect of HA on the pro-
inflammatory response of LPS activated macrophages and since HA contains both 
heme and LA; an iNOS substrate, the in vitro experiment required an LA control 
group to reliably assess the contribution of LA to the effect of HA. LA was used at a 
concentration (50µM) identical to that present in 10µM HA. 
 
BMDMs were pre-treated with PBS, HA or LA for 24 hours prior to stimulation with 
LPS. LA but not HA pre-treatment, markedly increased the release of TNF-α in non-
stimulated BMDMs (P<0.05, Figure 6.6.E). 
 
In LPS-stimulated BMDMs, HA pre-treatment significantly reduced mRNA levels of 
iNOS (P<0.05, Figure 6.6.G), relative to LA pre-treatment. HA pre-treatment 
markedly reduced mRNA levels of MCP-1α (P<0.05, Figure 6.6.I) but not TNF-α 
(Figure 6.6.H), relative to PBS pre-treatment, in LPS-stimulated BMDMs. HA pre-
treatment resulted in a significant reduction in nitrite release (P<0.05, Figure 6.6.J) 
but had no significant impact on the release of the pro-inflammatory cytokine TNF-α 
(Figure 6.6.K) or the immuno-suppressive cytokine IL-10 (Figure 6.6.L), in LPS-
stimulated BMDMs. LA pre-treatment significantly reduced TNF-α secretion when 
compared to HA pre-treatment, in LPS-stimulated BMDMs (P<0.05, Figure 6.6.K). 
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Figure 6.6 Effect of heme arginate (HA) and L-arginine (LA) pre-treatment on the 
LPS-stimulated pro-inflammatory response in BMDMs. The effect of HA and LA pre-
treatment on mRNA levels of A. iNOS, B. TNF-α, C. MCP-1α and release of D. Nitrite, 
E. TNF-α, F. IL-10, in non-stimulated BMDMs. Effect of HA and LA pre-treatment on 
mRNA levels of G. iNOS, H. TNF-α, I. MCP-1α and release of J. Nitrite, K. TNF-α, L. IL-
10, in LPS-stimulated BMDMs. *P<0.05, P-value derived by Dunn’s multiple comparison 
post-test when P<0.05 by Kruskal-Wallis test. The data given are mean ± s.e.m. from 
n=4 independent cell culture experiments where each ‘n’ was performed in duplicates. 
18S gene was used as endogenous control gene. 
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6.7. THE A&TI-I&FLAMMATORY EFFECT OF HA A&D CoPP WERE 
I&DEPE&DE&T OF HO ACTIVITY 
 
Two pharmacological inhibitors of HO activity, SM and CrMP were used to 
determine whether the anti-inflammatory effects of HA were dependent on HO 
activity. Another protoporphyrin based inducer of HO activity; CoPP was used to 
determine whether the anti-inflammatory effects of HA was mimicked by another 
protoporphyrin based inducer of HO activity.  
 
None of the compounds had any effect on inflammatory cytokines in quiescent 
BMDMs (Figure 6.7.A, D, G and 6.8.A, D) except for a significant increase in 
release of IL-10 with CrMP pre-treatment (P<0.001, Figure 6.8.G). HA pre-treatment 
significantly reduced nitrite release (P<0.01, Figure 6.8.B) and mRNA levels of 
iNOS (P<0.001, Figure 6.7.B) and MCP-1α (P<0.05, Figure 6.7.H) in LPS-
stimulated BMDMs. However, it had no effect on either the mRNA levels or 
secretion of TNF-α (Figure 6.7.E, 6.8.E). CoPP like HA pre-treatment reduced nitrite 
release (P<0.001, Fig 6.8.C) and mRNA levels of iNOS (P<0.001, Fig 6.7.C) and 
MCP-1α (P<0.001; Fig 6.7.I) in LPS-stimulated BMDMs.  
 
Pre-treatment with SM and CrMP, the two inhibitors of HO activity, did not result in 
significant modulation of the LPS-stimulated pro-inflammatory response. Pre-
treatment of BMDM with HO activity inhibitors i.e. SM or, CrMP, failed to reverse 
the significant reduction in nitrite release (Figure 6.8.B, C) and mRNA levels of 
iNOS (Figure 6.7.B, C) and MCP-1α (Figure 6.7.H, I), noted with HA and CoPP 
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treatment in LPS-stimulated BMDMS. Additionally, CoPP+SM pre-treatment 





Figure 6.7 Effect of HA and other metallo-porphyrin compounds on expression of 
pro-inflammatory genes in LPS-activated BMDMs. Effect of the modulators of HO 
activity on mRNA levels of A. iNOS, D. TNF-α, G. MCP-1α in non-stimulated BMDMs. 
The modulatory effects of HA (B, E, H) and CoPP (C, F, I) pre-treatment in the presence 
or absence of HO activity inhibitors, SM and CrMP, on mRNA levels of B, C. iNOS, E, F. 
TNF-α, H, I. MCP-1α in LPS-stimulated BMDMs. *P<0.05, ***P<0.001. P-values derived 
with Dunn’s multiple comparison post-test when P<0.05 by Kruskal-Wallis test. A-I. The 
data given are mean ± s.e.m. from n=4-8 independent cell culture experiments where 




Figure 6.8 Effect of HA and other metallo-porphyrin compounds on the release of 
inflammatory mediators by LPS-activated BMDMs. Effect of the modulators of HO 
activity on release of A. Nitrite, D. TNF-α, G. IL-10 in non-stimulated BMDMs. The 
modulatory effects of HA (B, E, H) and CoPP (C, F, I) pre-treatment in the presence or 
absence of HO activity inhibitors, SM and CrMP, on release of B, C. Nitrite, E, F. TNF-α, 
H, I. IL-10 in LPS-stimulated BMDMs. *P<0.05, **P<0.01, ***P<0.001. P-values derived 
with Dunn’s multiple comparison post-test when P<0.05 by Kruskal-Wallis test. A-I. The 
data given are mean ± s.e.m. from n=4-8 independent cell culture experiments where 






6.8. REDUCTIO& I& &ITRITE RELEASE BY HA I& LPS ACTIVATED 
BMDM IS I&DEPE&DE&T OF HO-1 PROTEI& 
 
BMDMs isolated from C57BL/6J mice with a targeted deletion of the Hmox-1 
(Hmox KO) gene (Poss and Tonegawa, 1997) [a kind gift from A. Agarwal, 
Birmingham, Alabama to University of Edinburgh] were pre-treated with either PBS 
or HA for 24 hours prior to LPS stimulation for another 24 hours. Treatment with 
HA for 24 hours substantially increased HO-1 protein in BMDMs isolated from 
C57BL/6J (Hmox WT, HO WT) mice but failed to do so in HO KO BMDM (Figure 
6.9.I). 
 
BMDMs from HO WT and HO KO treated with PBS for 24 hours showed relatively 
comparable levels of release of nitrite (Figure 6.9.A) and TNF-α (Figure 6.9.E). LPS-
stimulation for 24 hours resulted in significantly higher levels of nitrite (P<0.05, 
Figure 6.9.B) and TNF-α (P<0.05, Figure 6.9.F), in the supernatant of BMDMs from 
HO KO mice compared with WT mice. 
 
HA pre-treatment efficiently abrogated the LPS-mediated increase in the release of 
nitrite by BMDMs from both HO WT (Figure 6.9.C) and HO KO (Figure 6.9.D) 
mice. Additionally, HA pre-treatment failed to significantly modulate the release of 





Figure 6.9 Effect of HA in LPS-activated BMDM from Hmox1 knock-out (KO) and 
wild-type (WT) C57BL/6J mice. Release of A. Nitrite, E. TNF-α by non-stimulated 
BMDMs isolated from Hmox wild type (HO WT) and knockout (HO KO) mice. P>0.05 
(non-significant) by two-tailed Mann Whitney test. Release of B. Nitrite, F. TNF-α in 
LPS-stimulated BMDMs isolated from HO WT and HO KO mice. P<0.05 by two-tailed 
Mann Whitney test. Effect of HA pre-treatment on release of C. Nitrite, G. TNF-α in LPS-
stimulated BMDMs isolated from HO WT mice. Effect of HA pre-treatment on release of 
D. Nitrite, H. TNF-α in LPS-stimulated BMDMs isolated from HO KO mice. C, D, G, H. 
*P<0.05, **P<0.01. P-values derived with Dunn’s multiple comparison post-test when 
P<0.05 by Kruskal-Wallis test. I. The effect of HA on induction of HO-1 protein in 
BMDMs isolated from HO WT and HO KO mice. The western blot is a representative 
figure of n=2 separate experiments. A-H. The data given are mean ± s.e.m. from n=3 
independent cell culture experiments. 
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6.9. I&HIBITIO& OF HISTO&E DEACETYLASES REVERSED THE 
A&TI-I&FLAMMATORY EFFECTS OF HA A&D CoPP 
 
To determine whether the anti-inflammatory effects of HA involved histone 
deacetylase (HDAC), BMDMs were pre-treated for 2 hours with trichostatin (TSA), 
a pharmacological inhibitor of histone deacetylases. TSA pre-treated BMDMs were 
treated with either PBS, HA or CoPP for 20 hours. BMDMs were then washed with 
PBS prior to stimulation with LPS in the presence of TSA for 24 hours. CoPP was 
included to determine whether any effect observed was specific to heme or shared by 
other compounds with a protoporphyrin ring structure.  
 
Pre-treatment with TSA did not led to a significant modulation of mRNA levels of 
iNOS, TNF-α and MCP-1α in non-stimulated (Figure 6.10.A, E, I) and LPS-
stimulated BMDMs (Figure 6.10.B, F, J).  
 
Pre-treatment with HA and CoPP significantly reduced mRNA levels of iNOS and 
MCP-1α (P<0.05, Figure 6.10.C, K) but not TNF-α (Figure 6.10.G) in LPS-
stimulated BMDMs. However, pre-treatment of BMDMs with TSA completely 
abrogated the HA and CoPP mediated reduction in mRNA levels of iNOS (Figure 




Figure 6.10 Effect of histone deacetylases (HDAC) inhibition on anti-inflammatory 
effects of HA and CoPP in LPS-activated BMDMs. Effect of TSA pre-treatment on 
mRNA levels of A. iNOS, E. TNF-α, I. MCP-1α in non-stimulated BMDMs. P>0.05 (non-
significant) by two-tailed Mann Whitney test. Effect of TSA pre-treatment on mRNA 
levels of B. iNOS, F. TNF-α, J. MCP-1α in LPS-stimulated BMDMs. P>0.05 (non-
significant) by two-tailed Mann Whitney test. Effect of treatment with HA and CoPP on 
mRNA levels of C. iNOS, J. TNF-α, K. MCP-1α in LPS-stimulated BMDMs. *P<0.05, 
**P<0.01, P-values derived with Dunn’s multiple comparison post-test when P<0.05 by 
Kruskal-Wallis test. Effect of pre-treatment with TSA prior to treatment with HA and 
CoPP on mRNA levels of D. iNOS, H. TNF-α, L. MCP-1α in LPS-stimulated BMDMs. 
P>0.05 (non-significant) by Kruskal-Wallis test. A-L. The data given are mean ± s.e.m. 
from n=4 independent cell culture experiments where each ‘n’ was performed in 






6.10. CHAPTER DISCUSSIO& 
 
6.10.1. THE A&TI-I&FLAMMATORY EFFECT OF HA IS I&DEPE&DE&T 
OF THE L-ARGI&I&E COMPO&E&T OF HA 
 
A significant induction of iNOS gene and protein expression and an increase in iNOS 
activity and nitric oxide generation are some of the key pro-inflammatory effects 
observed with LPS activation of murine macrophages (Tsang et al., 2000, Pascual et 
al., 2005). As the heme arginate (HA) solution contains L-arginine (LA), which is a 
substrate for nitric oxide production by enzyme nitric oxide synthase (NOS) 
(Alderton et al., 2001), it was important to ensure that the LA component of HA did 
not influence the results.  
 
The initial screening showed that HA pre-treatment had a selective anti-
inflammatory effect in LPS-stimulated BMDMs. HA pre-treatment significantly 
reduced the mRNA levels of iNOS and MCP-1α and the release of nitrite in LPS-
stimulated BMDMs (Figure 6.6.G, I, J). However, HA pre-treatment failed to reduce 
LPS mediated increase in TNF-α gene expression and release in BMDMs (Figure 
6.6.H, K). Also, HA pre-treatment did not affect the production of IL-10 (Figure 
6.6.L), a potent anti-inflammatory cytokine that has been reported to mediate the 
anti-inflammatory effects of HO activity in several studies (Lee and Chau, 2002, Ma 
et al., 2007).  
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None of the changes associated with HA pre-treatment in LPS activated BMDM 
were mimicked by pre-treatment with L-arginine (LA) alone suggesting that heme 
rather than the LA component was responsible for the anti-inflammatory effects of 
HA. Initially, hemin dissolved in 10mM Tris-HCl pH 7.4 solution was included in 
the study. However, the hemin precipitated and formed aggregates on a BMDM 
monolayer, and hence was excluded from further studies. 
 
6.10.2. A&TI-I&FLAMMATORY EFFECTS OF HA IS I&DEPE&DE&T OF 
HO ACTIVITY A&D HO-1 PROTEI& 
 
The anti-inflammatory properties of HA were observed at a concentration at which it 
induces HO-1 protein and HO activity. Previous studies have reported that induction 
of HO activity confers anti-inflammatory effects on murine macrophages (Otterbein 
et al., 2000, Lee and Chau, 2002, Weis et al., 2009, Ma et al., 2007), therefore the 
critical question was whether the anti-inflammatory effects of HA were due to its 
ability to induce HO activity.  
 
The anti-inflammatory effects of pre-treatment with HA included a significant 
reduction in mRNA levels of iNOS, MCP-1α and in the release of nitrite in LPS-
stimulated BMDMs (Figure 6.6, 6.7, 6.8). However, the anti-inflammatory effect of 
HA pre-treatment was selective as no significant change in gene expression and 
release of TNF-α was noted in LPS-stimulated BMDMs. Co-treatment of HA with 
either SM or CrMP, two HO activity inhibitors, failed to reverse the anti-
inflammatory effects of HA (Figure 6.7.B, H, Figure 6.8.B) despite a reduction in 
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HO activity (Figure 6.4.B).  Similarly addition of SM to CoPP pre-treatment reduced 
the extent of increase in HO activity (Figure 6.4.C) but failed to significantly reverse 
the anti-inflammatory effects of CoPP (Figure 6.7.C, I, Figure 6.8.C) which were 
similar to those of HA. Hence, the body of evidence indicates that the anti-
inflammatory effect of HA are independent of its ability to induce HO activity.  
 
SM and CrMP were effective at partially reversing the increase in HO activity but 
they increased HO-1 protein levels (Figure 6.4.D). This was of interest as it has 
recently been reported that HO-1 protein may translocate to the nucleus and activate 
gene expression to facilitate an anti-oxidative effect (Lin et al., 2007). To determine 
whether an increase in HO-1 protein could explain the anti-inflammatory effect of 
HA, BMDMs from Hmox knock-out mice were employed. Interestingly in the 
absence of HA treatment, HO deficiency did increase the production of nitrite and 
TNF-α in response to LPS stimulation in BMDMs (Figure 6.9.B, F), demonstrating 
that HO per se also has some anti-inflammatory effects. However, HA pre-treatment 
remained efficient at significantly reducing the release of nitrite by BMDMs isolated 
from Hmox knock-out C57BL/6J mice on stimulation with LPS (Figure 6.9.C, D), 
demonstrating that up-regulation of HO-1 protein was unlikely to be responsible for 






6.10.3. POSSIBLE ROLE OF HDAC MEDIATED REPRESSIO& FOR A&TI-
I&FLAMMATORY EFFECTS OF HA 
 
Having concluded that the anti-inflammatory effect of HA was dependent on the 
heme component, but independent of HO-1 protein or HO activity. Hence, it was 
important to determine the mechanism by which heme was acting. 
 
In a recent study, Gibbs et al has demonstrated Rev-erbα to be a vital for circadian 
clock-dependent variation in gene expression of inflammatory mediators, including 
IL-6, Cxcl-1, CCL2/MCP-1α, but not TNF-α (Gibbs et al., 2012). The recognition of 
heme as a ligand of the nuclear hormone receptor Rev-erb (Yin et al., 2007) and its 
ability to recruit and stabilise the interaction between the components of the NCoR-
HDAC3 co-repressor complex (Yin et al., 2010) has generated interest in exploring 
the role of heme in the regulation of the circadian clock and inflammatory processes. 
The NCoR-HDAC3 co-repressor complex has been shown to be bound to the iNOS 
promoter region in non-stimulated murine macrophages (Pascual et al., 2005). LPS 
stimulation promotes release of the NCoR-HDAC3 co-repressor complex facilitating 
iNOS gene expression (Pascual et al., 2005). Ligand binding to PPAR-γ stabilises the 
NCoR-HDAC3 co-repressor complex in macrophages in vitro, thereby preventing 
LPS-induced release of NCoR-HDAC3. Interestingly this is observed at the 
promoters of the iNOS and MCP-1 but not TNF-α genes (Pascual et al., 2005, Huang 
et al., 2011). As this pattern of gene repression is very similar to that observed with 
heme it was important to test if the anti-inflammatory effect of HA could be reversed 
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by inhibiting the NCoR-HDAC3 co-repressor complex. To do this, BMDMs were 
pre-treated with the histone deacetylase inhibitor trichostatin (TSA). 
 
Pre-treatment of BMDM with the HDAC inhibitor TSA completely abrogated the 
HA mediated reduction in mRNA levels of iNOS and MCP-1α (Figure 6.10.C, D, K, 
L), suggesting HDAC activity to be an integral component of the mechanism by 
which HA facilitates its anti-inflammatory effects. TSA non-specifically inhibits 
several members of HDAC family. Furthermore it may have anti-inflammatory 
effects per se (Han and Lee, 2009). Although in the current study, TSA pre-treatment 
failed to markedly modulate the mRNA levels of iNOS, TNF-α and MCP-1α in non-
stimulated and LPS-stimulated BMDMs (Figure 6.10.A, B, E, F, I, J ). However, the 
validity of the hypothesis that anti-inflammatory effects of HA are mediated via Rev-
erb interaction with NCoR-HDAC-3 co-repressor complex needs further incisive 
studies. The incisive studies should include either deleting or silencing important 
determinants of the mechanism including Rev-erb, NCoR and HDAC-3 to 
convincingly demonstrate that HA’s anti-inflammatory effects are mediated through 
the interaction between heme and Rev-erb leading to stabilisation of the NCoR-






6.10.4. THE PROTOPORPHYRI& STRUCTURE OF HEME MAY BE 
RESPO&SIBLE FOR THE A&TI-I&FLAMMATORY EFFECT OF 
HA 
 
The anti-inflammatory effects of HA including a marked reduction in nitrite release 
and mRNA levels of iNOS and MCP-1α in LPS activated BMDMs were mimicked 
by administration of CoPP (Figure 6.8, 6.9) which is another protoporphyrin based 
inducer of HO activity like HA. Indeed co-treatment of CoPP with HO activity 
inhibitors failed to reverse the above cited anti-inflammatory effects of CoPP in LPS-
stimulated BMDMs. Pre-treatment of BMDMs with trichostatin reversed the anti-
inflammatory effects of CoPP and HA in LPS-stimulated BMDMs (Figure 6.10). 
Hence, HA and CoPP displayed similar phenotypic effects in LPS-activated BMDMs 
in the absence or presence of the HDAC inhibitor trichostatin suggesting that they 
may share a similar mode of action for their anti-inflammatory effects. As HA and 
CoPP, both have a protoporphyrin ring in their structure, it is possible that their anti-
inflammatory effects in LPS activated BMDMs are imparted by the protoporphyrin 
structure per se. To incisively determine whether the anti-inflammatory effect of HA 
and CoPP in LPS activated BMDMs is due to protoporphyrin structure per se, the 
future experiments should include two definite control groups including 
 
i. Protoporphyrin compound with-out a metal ion attached to it, and hence 
which would not affect the level of HO-1 protein or activity 
ii. A heterocyclic compound such as corrin which is similar but not identical to 
the porphyrin structure of protoporphyrin as a negative control. 
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6.10.5. CO&CLUDI&G REMARK 
 
The characterisation of the anti-inflammatory effects of HA and other metallo-
porphyrin compounds in LPS-activated murine macrophages demonstrated that all 
the compounds exhibited anti-inflammatory properties. This was independent of their 
ability to either induce or inhibit HO activity and increase HO-1 protein. 
Interestingly, TSA pre-treatment completely abrogated the inhibitory effect of HA on 
mRNA levels of iNOS and MCP-1α in LPS activated BMDMs. Further work is 
required to pursue the hypothesis that the heme component of HA facilitates the 
repression of inflammatory genes via recruitment and stabilising the interaction 










































Heme oxygenase (HO) is a rate-limiting enzyme, and consists of two isoforms, 
inducible (HO-1) and constitutive (HO-2), which play an integral role in maintaining 
heme homeostasis (Maines and Gibbs, 2005). Induction of HO activity facilitates 
oxidative breakdown of free heme into equi-molar concentrations of carbon 
monoxide (CO), the bile pigment biliverdin IX and free iron. Consequently biliverdin 
reductase converts biliverdin IX into bilirubin IX and free iron is stored as ferritin 
(Maines, 2005, Abraham and Kappas, 2008). The products of heme catabolism have 
immuno-modulatory and anti-oxidative properties (Wagener et al., 2003). Hence, 
induction of HO enzyme activity is an attractive approach for treatment of diseases 
characterised by low-grade inflammation and oxidative stress, including obesity-
associated insulin resistance and type 2 diabetes. 
 
HO-1 protein levels and carbon monoxide generation are reported to be down-
regulated in murine models of obesity and type 2 diabetes, including obese (ob/ob) 
mice and Zucker diabetic fatty (ZDF) rats (Li et al., 2008, Nicolai et al., 2009). 
Indeed, pharmacological induction of HO activity is reported to reduce obesity, 
adipogenesis and insulin resistance in different murine model of type 2 diabetes 
(Ndisang, 2010, Nicolai et al., 2009, Li et al., 2008). The anti-diabetic effect of 
hemin, a natural substrate for HO enzyme, has been reported to be observed for up to 
3-months after termination of treatment in Goto-kakizaki (GK) and ZDF rat models 
of type 2 diabetes (Ndisang et al., 2009a, Ndisang et al., 2009b). An increase in 
peripheral insulin sensitivity with hemin treatment has been attributed to the HO 
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activity-dependent increase in circulatory levels of adiponectin, restoration of AMPK 
protein level and reduced inflammatory and oxidative mediators in the soleus muscle 
of GK rats (Ndisang and Jadhav, 2009). Cobalt (III) protoporphyrin IX dichloride 
(CoPP), a non-heme protoporphyrin inducer of HO activity, induces the HO activity-
adiponectin axis to reduce peripheral insulin resistance along with a reduction in 
body weight gain, adipogenesis and systemic inflammation in the ob/ob mouse 
model of obesity and type 2 diabetes (Li et al., 2008).  The published studies in 
experimental models of obesity and type 2 diabetes demonstrate that 
pharmacological induction of HO activity is effective for the treatment of systemic 
inflammation and insulin resistance. However, the relative insolubility and instability 
of hemin in solution (Goetsch and Bissell, 1986) and the multiple side-effects of 
CoPP, including weight loss (Galbraith and Kappas, 1989), preclude their use for 
treatment of patients in clinic.  
 
Heme arginate (HA) is a stable and soluble composition of hemin, isolated from 
human blood, and L-arginine in a solution containing propylene glycol, ethanol and 
water (Tenhunen et al., 1987). The induction of HO-1 with HA treatment is reported 
to confer protection against acute kidney injury in vivo (Ferenbach et al., 2011). 
Furthermore, HA is licensed for the treatment of acute porphyria in several European 
countries. Hence, HA has translational potential to be used in clinical trials.  
 
The in vivo studies during my PhD were sought to test the hypothesis that the heme 
component of HA ameliorates hyperglycaemia via induction of HO activity in the 
db/db mouse model of type 2 diabetes. Concurrently, in vitro studies in MIN6 β-cells 
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and primary macrophages from C57BL/KsJ mice were performed to test the 
hypothesis that the anti-inflammatory effects of HA are dependent on the induction 
of HO activity. The LPS-stimulated model of pro-inflammatory response in primary 
macrophages was used to test consequent hypotheses, including that the anti-
inflammatory effects of HA are dependent on induction of HO-1 protein level or on 
gene repression mediated by inhibition of histone deacetylases. The key findings of 



















7.2. I&HIBITIO& OF HO ACTIVITY ACCE&TUATES THE A&TI-
DIABETIC EFFECT OF HA I& THE LEPTI& RECEPTOR 
DEFICIE&T db/db MODEL OF TYPE 2 DIABETES 
 
7.2.1. DISCUSSIO& OF THE RESULTS OF THE I VIVO STUDIES I& 
db/db MICE A&D THE I VITRO STUDY I& MI&6 β-CELL LI&E 
 
The preliminary in vivo study demonstrated that the intravenous (i.v.) administration 
of HA (15mg/kg, twice weekly) for 8 weeks resulted in a significant reduction in 
hyperglycaemia. The anti-hyperglycaemic effect of HA coincided with weight gain, 
an increase in fasting serum insulin levels between 6 and 8 weeks and induction of 
HO activity. These phenotypic changes were not reciprocated by i.v. administration 
of L-arginine (LA, 16mg/kg, twice weekly for 8 weeks), at a concentration 
equivalent to that present in 15mg/kg of HA (Table 7.1). The failure of LA but not 
HA treatment to increase fasting insulin levels is of significance because LA, at 
millimolar concentration has been reported to stimulate islet β-cell insulin secretion 
in mouse islets cultured ex vivo  (Henningsson and Lundquist, 1998). Therefore, it 
can be stated that the anti-hyperglycaemic effect of HA is not due to an increase in 
insulin release stimulated by the LA component of HA. Additionally, none of the 
HA-mediated phenotypic changes were mimicked by treatment with LA, suggesting 
that the hemin/heme component of HA is responsible for the anti-diabetic effect of 
HA. Ideally, a hemin treatment group should have been included in the preliminary 
in vivo study as a comparison with the phenotypic changes achieved with HA 
treatment. However, hemin in solution showed a propensity to precipitate and form 
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aggregates in initial in vitro studies in BMDM. Hence, hemin was excluded from the 
in vivo and in vitro studies. 
 
Parameters Changes relative to PBS-treated db/db mice 
 HA LA 
Terminal HO activity in liver ↑ - 
Terminal HO-1 protein levels in liver ↑ - 
Fasting hyperglycaemia (AUC) ↓ (6-8 wk) - 
Terminal HbAIC% ↓ - 
Weight gain ↑ (6 and 8 wk) - 
Serum insulin level (AUC) ↑ (6-8 wk) - 
Relative glucose level during ITT (AUC) - - 
Terminal serum adiponectin level - - 
Terminal haemoglobin level - - 
Food intake - - 
 
Table 7.1 The effects of HA and LA treatment on the listed parameters in the db/db 
mouse model of type 2 diabetes. ↑ indicates increase, ↓ indicates decrease, - 
indicates no change. Changes listed in the table are relative to PBS-treated db/db mice. 
Relative changes for the listed parameters (except for HO-1 protein levels) are based on 
statistical significance achieved with the appropriate non-parametric test. 
 
Stannous (IV) mesoporphyrin IX dichloride (SM), an inhibitor of HO activity, was 
employed in the next in vivo study to test the hypothesis that the anti-diabetic effect 
of HA is dependent on the HA-mediated increase in HO activity. Paradoxical to this 
hypothesis, concomitant treatment of HA and SM resulted in further improvement in 
glycaemic control despite complete abrogation of the HA-mediated increase in HO 
activity. Hence, this result demonstrates that the HA-mediated increase in HO 
activity is not the primary mechanism for the anti-diabetic effect of HA. This 
observation is in contrast to a published study where chromium (III) mesoporphyrin 
IX chloride (CrMP), an inhibitor of HO activity, reversed the anti-hyperglycaemic 
effect of hemin in non-obese insulin-resistant GK rats (Ndisang and Jadhav, 2009).  
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Parameters Changes relative to PBS-treated db/db 
mice 
 HA SM HA+SM 
Terminal HO activity in liver ↑ - - 
Terminal HO-1 protein levels in liver ↑ - ↑ 
Fasting hyperglycaemia (AUC) ↓ (6-8 wk) - ↓ (2-8 wk) 
Weight gain ↑ (6 and 8 wk) - ↑ (2 to 8 wk) 
Epididymal fat pad weight ↑ - ↑ 
Terminal serum insulin level ↑ - ↑ 
Relative mRNA level of HO-1 in EFP ↑ - ↑ 
Terminal heme levels in liver - - ↑ 
Terminal HbAIC% - - ↓ 
Terminal serum adiponectin level - - ↑ 
Number of islet iNOS expressing cells - - ↓ 
Total number of islet macrophages  - - ↓ 
Relative mRNA level of Pref-1 in EFP - - ↓ 
Relative mRNA level of PPAR-γ in EFP - - ↑ 
Relative mRNA level of FASN in EFP - - ↑ 
Relative mRNA level of CD68 in EFP - ↓ ↓ 
Relative mRNA level of MCP-1α in EFP - ↓ ↓ 
Relative glucose levels during GTT 
(AUC) 
- - - 
Relative glucose levels during ITT (AUC) - - - 
Terminal serum NEFA levels - - - 
Relative mRNA level of TNF-α, IL-6 in 
EFP 
- - - 
Food intake - - - 
Liver weight and triglyceride content - - - 
Relative mRNA level of PEPCK, G-6-P 
in liver 
- - - 
 
Table 7.2 The effects of HA, SM and HA+SM treatment on the listed parameters in 
db/db mouse model of type 2 diabetes. ↑ indicates increase, ↓ indicates decrease, - 
indicates no change. Changes listed in the table are relative to PBS-treated db/db mice. 
Relative changes for listed parameters except for HO-1 protein levels, are based on 
statistical significance achieved with non-parametric tests. Modulatory changes in listed 
parameters were not dependent on HO activity. Changes in listed parameters 
highlighted in red may likely be dependent on HO-1 protein level. Changes in listed 
parameters highlighted in blue may likely be dependent on intracellular heme 
concentration. Abbreviations. G-6-P: Glucose-6-phosphatase, FASN: Fatty acid 
synthase.  
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The improvement in glycaemic control with HA±SM treatment in db/db mice was 
unlikely to be due to an improvement in insulin sensitivity. The relative glucose 
levels between different treatment regimes were not significantly different during 
insulin tolerance test, performed in week 8 of the in vivo study. This is in contrast to 
previously reported studies where pharmacological induction of HO activity with 
CoPP and hemin treatment reduced peripheral insulin resistance in murine models of 
type 2 diabetes (Li et al., 2008, Ndisang et al., 2009b, Ndisang and Jadhav, 2009). 
However, these studies used absolute glucose levels, rather than relative reductions 
in glucose levels at specified time-points during the ITT, to measure insulin 
resistance. Normalisation of the absolute glucose levels during ITT from these 
studies may indicate that the effect of HA, hemin or CoPP treatment is largely 
independent of improvements in insulin sensitivity in all three models.  
 
The improvement in glycemic control with HA±SM treatment in db/db mice is likely 
to be due to a change in adipose tissue phenotype and to preservation of islet β-cell 
function. Wang et al has demonstrated that an increase in adipocyte storage capacity 
is responsible for preserving islet mass and delaying the onset and severity of type 2 
diabetes in normal db/db mice when compared to transgenic obesity resistant db/db 
mice (Wang et al., 2008). Indeed, HA±SM treatment resulted in a progressive body 
weight gain and increase in epididymal fat weight despite no significant difference in 
food intake. Furthermore, HA+SM but not HA alone treatment resulted in a 
significant increase in circulatory adiponectin levels, decrease in mRNA levels of 
Pref-1, a marker of pre-adipocytes (Wang et al., 2006), and an increase in mRNA 
levels of PPAR-γ, a marker of adipocyte differentiation (Lazar, 1999), and fatty acid 
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synthase (FASN), a marker of lipogenesis (Wang et al., 2004). These observations 
suggest that HA+SM treatment promotes a metabolically favourable expansion of 
adipose tissue to accommodate safe storage of excess lipid.  
 
HA±SM-treated db/db mice were hyperinsulinaemic at the end of 8 week study, 
indicating preservation of islet β-cell function. Immuno-histology studies 
demonstrated that the HA±SM treatment markedly reduced islet macrophage 
infiltration which is known to play a key pathogenic role in β-cell dysfunction in 
type 2 diabetes (Ehses et al., 2007a). In addition, HA+SM therapy reduced islet 
iNOS staining to the levels observed in lean mice. This is likely to have improved β-
cell function, given the suppressive effect of nitric oxide on glucose-stimulated 
insulin secretion in vitro (Henningsson et al., 2002) and that NOS inhibitors prevent 
β-cell dysfunction in vivo (Kato et al., 2003). Additionally, HA±SM treatment 
markedly reduced expression of pro-inflammatory genes, such as IL-1β, MCP-1α 
and Cxcl-1, in cytokine mix-stimulated MIN6 β-cells which suggests that the 
HA±SM treatment can directly impart a broader range of anti-inflammatory effects 
on β-cells.  
 
The most intriguing question remains how concurrent treatment with HA and SM 
(HA+SM) interact to dramatically improve glycaemic control. It may be that they act 
via different mechanisms, however an alternative possibility is that the effect of 
HA+SM may be due to an additive increase in either HO-1 protein level or 
intracellular heme concentration. The parameters affected by HA, SM and HA+SM 
treatment in db/db mice (Table 7.2) and in cytokine mix-stimulated MIN6 β-cells 
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(Table 7.3) are grouped on the basis of the changes that mimic hepatic HO-1 protein 
expression (highlighted in red) and hepatic heme concentration (highlighted in blue).  
 
Parameters Changes relative to PBS or cytokine mix-
treated MI&6 β-cells 
 HA SM HA+SM 
HO activity  ↑ - - 
Relative mRNA level of iNOS ↓ - - 
HO-1 protein level ↑ - ↑ 
Relative mRNA level of IL-1β  ↓ - ↓ 
Relative mRNA level of MCP-1α  ↓ - ↓ 
Relative mRNA level of Cxcl-1  ↓ - ↓ 
 
Table 7.3 The effects of HA, SM and HA+SM treatment on the listed parameters in 
cytokine mix-stimulated MIN6 β-cells. ↑ indicates increase, ↓ indicates decrease, - 
indicates no change. Changes listed in the table for HO activity and HO-1 protein are 
relative to PBS (vehicle)-treated MIN6 β-cells. Changes listed in the table for mRNA 
levels of pro-inflammatory genes are relative to cytokine mix-stimulated MIN6 β-cells. 
Relative changes for listed parameters (except for HO-1 protein levels), are based on 
statistical significance achieved with the appropriate non-parametric test. Changes in 
listed parameters highlighted in red follow a similar pattern to the HO-1 protein level. 
Changes in listed parameters highlighted in green are associated with the level of HO 
activity. 
 
The groupings of the affected parameters suggest that an increase in HO-1 protein 
level is associated with a reduction in fasting hyperglycaemia, weight gain and 
terminal hyperinsulinaemia during HA±SM treatment. Whereas, the HA+SM-
mediated modulation of glycosylated haemoglobin levels, mRNA levels of 
adipogenic and lipogenic genes in visceral fat, total macrophage number and iNOS 
positive cells in the islets is associated with an increase in heme concentration in 
db/db mice. The additive increase in HO-1 protein level is less likely to account for 
the ameliorative effect of HA+SM treatment because Li et al in their study have 
demonstrated that an additive increase in HO-1 protein during concomitant treatment 
with CoPP and SM does not lead to an increase in insulin sensitivity in the ob/ob 
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mouse model of obesity and type 2 diabetes (Li et al., 2008). An additive increase in 
the intracellular heme concentration may be a more likely explanation for all the 
phenotypic changes associated with HA±SM treatment in db/db mice. It can be 
debated that all the changes in the listed parameters are not shared by HA and 
HA+SM treatment and that they therefore may be acting via different mechanisms 
(Table 7.2). However, an alternative explanation is that the addition of SM 
accentuated the effect of HA, as similar trends in many phenotypic markers were 
common to both HA and HA+SM treatments. It may be that administration of HA 
resulted in a transient increase in the intracellular heme concentration before it was 
degraded by a subsequent increase in HO activity, thereby limiting the effects of HA 
administration Whereas, concurrent inhibition of HO activity with HA+SM treatment 
resulted in a prolonged increase in the intracellular heme concentration which 
allowed heme to exert its protective effect for a longer duration in db/db mice. This 
may explain why inhibition of HO activity accentuates the anti-diabetic phenotype of 
HA. 
 
A key question is to understand the mechanism by which heme may be responsible 
for the anti-diabetic effects of HA±SM. Heme is a ligand for the nuclear receptor 
Rev-erbα (Yin et al., 2010) and published studies demonstrate that Rev-erbα to 
regulates several metabolic pathways, such as adipocyte differentiation (Kumar et al., 
2010), repression of gluconeogenic genes (Yin et al., 2007), and lipogenesis and 
exocytosis in pancreatic β-cells (Vieira et al., 2012). Recently, two independent 
studies have been published which demonstrate that Rev-erb is vital for the 
maintenance of energy homeostasis (Cho et al., 2012b, Solt et al., 2012b). Rev-erb 
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agonists have been reported to modulate the expression of key metabolic genes in the 
liver, skeletal muscle and adipose tissue, resulting in enhanced energy expenditure, a 
reduction in body weight and an improvement in glycaemic control in the high fat 
diet model of type 2 diabetes (Solt et al., 2012b). In tamoxifen-induced Rev-erb 
double knockout (Rev-erb α-/- and β-/-) in C57BL/6 mice, there was an increase in 
circulatory glucose and triglyceride levels when compared to wild-type mice (Cho et 
al., 2012b). Therefore, refinement of the hypothesis and the experiment design is 
required to deconstruct the mode of action of HA±SM treatment in db/db mice, as 
will be discussed later in the ‘future work’ section.          
 
In conclusion, concurrent administration of HA+SM markedly ameliorates 
hyperglycaemia in the db/db model of type 2 diabetes via metabolically favourable 
expansion of visceral fat and preservation of islet β-cell mass and function. The 
improvement in glycaemic control by HA+SM is not due to an increase in HO 
activity, but may be due to an additive increase in HO-1 protein level or intracellular 










7.2.2. LIMITATIO&S OF THE STUDIES 
 
The key limitations of the in vivo studies, which should be considered while 
designing future in vivo experiments, are listed below, 
 
 Low number of mice employed in the in vivo studies: The in vivo study was 
split into two separate experiments to test the hypothesis that a. the heme 
component of HA has an anti-diabetic effect and b. that this effect is dependent 
on an increase in HO activity. Initially, the plan was to merge the results of the 
PBS and HA treatment groups from the in vivo studies described in chapter 3 and 
chapter 4. However, there was a significant difference in the rate of progression 
and the severity of hyperglycaemia in the db/db mice on PBS-treatment between 
the two cohorts (Figure 7.1), therefore it was inappropriate to merge the results of 
the two studies. This resulted in there being less than 5 db/db mice in each of the 
PBS and HA treatment groups in the in vivo study described in chapter 4. Given 
the small sample size, it could not readily be ascertained as to whether a 
particular variable was normally distributed and therefore non-parametric 
statistical tests were employed. Non-parametric tests with small sample size have 
limited power to reject null hypothesis. This is best illustrated by the results of 
the terminal fasting NEFA levels in the in vivo study described in chapter 4. 
HA+SM treatment reduced the fasting NEFA concentration to levels comparable 
with lean mice, however this reduction was not found to be statistically 
significant. Given the small sample size, it is possible that this result represents a 
type 2 error, that is, declaring that HA+SM therapy had no effect on the fasting 
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NEFA concentration, when in reality it had a major impact on the NEFA 
concentration. If true, this size of effect may have biological significance as 
reduced lipid levels are known to have protective effect in type 2 diabetes. 
Hence, power calculations should be performed during the design of future 
experiments, to ensure that the sample size is adequate to reduce the risk of type 




Figure 7.1 Comparison of the progression and severity of hyperglycaemia in PBS-
treated db/db mice from the two separate in vivo studies. A. Fasting glucose levels 
for PBS-treated db/db mice from the two separate in vivo studies. B. Area under the 
curve for fasting glucose levels demonstrated a significant increase in the severity of 
hyperglycaemia in PBS-treated db/db mice in study 2 as compared to study 1. P=0.03 
(significant) by two-tailed Mann Whitney test. The data given are mean ± s.e.m. from 
n=4/group. a. unit: arbitrary unit. 
 
 
 Single concentration of HA employed in the in vivo studies: The use of 
dose/response curve for HA therapy would have helped to determine the 
pharmacokinetics, pharmacodynamics and toxicological effects, which may have 
proved vital to strengthen the case for it to be tested in humans. However, this 
was beyond the scope of my PhD project as the interest was to determine the 
efficacy and mechanism of action of HA in a mouse model of type 2 diabetes.   
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 Single mouse model of type 2 diabetes employed to study the effects of HA 
and SM: Leptin deficiency is a rare cause of obesity in humans, and therefore 
determining whether HA and SM ameliorated hyperglycaemia in a more 
physiological model of human obesity, such as the high fat diet model, would be 
prudent prior to performing clinical trials in humans. One potential mechanism 
by which HA+SM was acting was by preserving β-cell mass and function. 
C57BL/KsJ mice have approximately 50% less β-cell proliferative capacity along 
with increased β-cell susceptibility to glucotoxicity than C57BL/6J mice (Clee 
and Attie, 2007). Hence, a high fat diet induced model of glucose intolerance was 
performed in C57BL/KsJ mice to test whether HA treatment reduced glucose 
intolerance by preserving islet β-cell function. However, 16 weeks of feeding 
with high fat diet (constituting of 60% fat diet) failed to render the C57BL/KsJ 
mice intolerant to glucose as assessed by glucose tolerance test. Hence, the 
experiment was terminated without further testing of the effect of HA treatment.  
 
 
Figure 7.2 Glucose tolerance test (GTT) in C57BL/KsJ mice on normal chow or 
high fat diet for 16 weeks. A. The glucose levels after intraperitoneal administration of 
a 2g/kg glucose bolus in 4 hour fasted C57BL/KsJ mice which were either on normal 
chow or high fat diet for 16 weeks. B. Area under the curve for glucose concentration 
during the GTT demonstrated no significant difference in glucose levels between 
C57BL/KsJ mice on normal chow and high fat diet chow for 16 weeks. P>0.5 (NS: non-
significant) by two-tailed Mann Whitney test. The data given are mean ± s.e.m. from 
n=5/group. a. unit: arbitrary unit. 
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7.2.3. FUTURE WORK 
 
The current PhD project has suggested that HA may ameliorate hyperglycaemia by a 
novel HO activity independent mechanism and has helped to raise new questions. 
Therefore, the hypotheses tested in the current project need refinement to plan future 
work as they are listed below. 
 
 Hypothesis 1- The HA+SM-mediated anti-diabetic phenotype is dependent 
on prolonged interaction between heme and Rev-erb in the db/db mouse 
model of type 2 diabetes: This hypothesis can be tested by using either 
pharmacological antagonists of Rev-erb or by employing organ-specific Rev-erb 
knock-out on C57BL/KsJ mice with the leptin receptor mutation (db/db) mice. A 
preliminary in vivo experiment should be designed to test whether the 
pharmacological antagonist of Rev-erb is able to reverse the anti-diabetic effect 
of HA+SM treatment in db/db mice. The HA+SM treatment regime should be for 
only 2 to 4 weeks, the time when phenotypic changes such as reduction in fasting 
glucose levels and weight gain begins to occur. An evaluation of insulin release 
during the glucose tolerance test at this time-point along with terminal fasting 
insulin levels and islet histology may help to determine whether the preservation 
of islet β-cell function is primarily responsible for the phenotypic changes 
associated with HA+SM treatment in db/db mice. This study can be followed by 
comparing the effects of HA+SM treatment in db/db mice with or without organ-
specific knock-out of Rev-erb as this would be the most incisive method to 
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provide information on the importance of the interaction between heme and Rev-
erb in individual organs.  
 
 Hypothesis 2- The increase in intracellular heme concentration with HA±SM 
treatment exerts anti-inflammatory effects via interacting with Rev-erb in 
cytokine mix-stimulated MI&6 β-cells: The anti-inflammatory effects of 
HA±SM treatment, including a reduction in the mRNA levels of IL-1β, MCP-1α 
and Cxcl-1 in cytokine mix-stimulated MIN6 β-cells were demonstrated to be 
independent of HO activity. Therefore, pharmacological antagonist of Rev-erb 
should be employed to determine whether Rev-erb antagonist can reverse the 
anti-inflammatory effects of HA±SM treatment in MIN6 β-cells.  
     
 Hypothesis 3- The increase in intracellular heme concentration with HA±SM 
treatment promotes adipogenesis via interaction with Rev-erb in 
differentiated pre-adipocyte cell line 3T3-L1: 3T3-LI is a widely used pre-
adipocyte cell line to study adipocyte differentiation (Green and Meuth, 1974). 
The 3T3-LI cell line can be used to test the hypothesis that HA±SM treatment 
promotes adipogenesis. The read-out can include Oil red staining to determine 
the degree of lipid accumulation and in addition, the level of expression of genes 
which facilitate adipogenesis and lipogenesis may be quantified. Furthermore, a 
modified 3T3-LI cell line with knock-down of Rev-erb by administration of a 
lenti-virus containing shRNA against Rev-erb can be generated to test whether 
the increase in the intracellular heme concentration with HA±SM treatment 
promotes adipogenesis via interaction with Rev-erb. 
 250 
 Hypothesis 4- The anti-diabetic effect of HA is dose-dependent and has 
limited toxicity in mouse models of type 2 diabetes: A dose-response study of 
HA would help to determine the ADME (Absorption, Distribution, Metabolism, 
and Excretion) characteristics for HA. Additionally, a dose-response study would 
help to determine whether the anti-hyperglycaemic effect of HA is observed 
across a wider dose-response curve with minimal toxicity. Elucidation of the 
pharmacokinetic and pharmacodynamic properties of HA across a dose-curve 
would both inform and strengthen the case for a clinical trial in patients with type 
2 diabetes. It would be ideal to perform the dose-response study of HA in 
different genetic and diet-induced model of type 2 diabetes, to enable 















7.2.4. PLACE OF HA AS A LI&E OF TREATME&T FOR TYPE 2 
DIABETES I& THE CLI&IC 
 
At present, the first line of treatment of patients with type 2 diabetes is recommended 
to be physical exercise, eating a healthy diet and  weight loss if obese (Kimmel and 
Inzucchi, 2005). However, if these methods fail to control blood sugar levels anti-
diabetic medications will be required. There are different classes of clinically 
approved drugs (Table 7.4) which either promote insulin sensitivity or stimulate 
insulin secretion (Kimmel and Inzucchi, 2005). These drugs are prescribed either as 
mono-therapy or in combination, based on the severity and duration of type 2 




Class of drugs Drugs in clinic Mode of action 
    
Biguanide Metformin Suppress hepatic glucose 
production, Improves insulin 
sensitivity. 
Second 
Thiazolidinedione Pioglitazone Improves insulin sensitivity, 
Promotes glucose utilisation by 
adipocytes and skeletal muscle. 
Sulphonylurea Gliclazide, 
Glipizide 








Stimulate insulin secretion by β-
cells for a shorter duration of time. 
Fourth Dipeptidyl 




Enhances the effect of incretins by 
blocking the action of incretin 
inhibitor DPP4. 
Insulin  Pleotropic effect on glucose 





Exenatide Stimulate insulin secretion by β-
cells in response to glucose, 
prevents glucagon release after 
meals. 
 
Table 7.4 Line of treatment of type 2 diabetes with medication in clinic. (Chitre and 
Burke, 2006, Kimmel and Inzucchi, 2005, Zhou et al., 2001, Cheng and Fantus, 2005). 
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The results of the in vivo studies in db/db mice demonstrated that HA treatment 
failed to improve peripheral insulin sensitivity but was able to preserve islet β-cell 
function. Hence, if HA were found to be effective in clinical trials, it may be best  
employed from an early point in the natural history of type 2 diabetes as its effect 
may prolong islet β-cell function and reduce the need for the sulphonylureas, which 
stimulate insulin secretion and may promote an effect known as ‘β-cell burnout’ 
(Robertson et al., 2003). Metformin is the preferred second line of treatment for type 
2 diabetes as it restricts hepatic glucose production and promotes insulin sensitivity 
in peripheral organs (Zhou et al., 2001). It may be that dual therapy with metformin 
and HA may be a particularly potent combination as the act via different 
mechanisms.   
 
At present, enrolment is open for the Radboud University Nijmegen Medical Centre 
sponsored clinical trial to test ‘the effect of heme arginate treatment on insulin 
resistance and vascular dysfunction related to obesity’ 
(http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2472 last accessed on 21-
06-2012). Hence, there is already an interest with regards to testing the efficacy of 
HA in patients with metabolic dysfunction. Currently, HA is marketed by the Orphan 
Europe pharmaceutical company and is available as a solution rather than tablets. It 
would be desirable that an oral formulation of HA were to be made available as 
prolonged intravenous infusion is unlikely to be palatable for patients. Furthermore, 
there may be problems with iron overload in chronic use. For this reason it is 
unlikely that chronic administration of HA will ever be used long-term as a treatment 
for type 2 diabetes, but that it will be useful in pilot studies such as the one 
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mentioned above. Hence it is important that the mechanisms by which HA 
























7.3. HISTO&E DEACETYLASES MAY BE RESPO&SIBLE FOR THE HO 
ACTIVITY I&DEPE&DE&T A&TI-I&FLAMMATORY EFFECTS OF 
HA I& BMDMs 
 
7.3.1. DISCUSSIO& OF THE RESULTS OF I VITRO STUDIES I& 
PRIMARY MACROPHAGES (BMDM) 
 
Lipopolysaccharide (LPS) activation of bone marrow derived macrophages 
(BMDMs) was used as an in vitro model of inflammation to develop an 
understanding of the mode of action of HA as an anti-inflammatory agent.   
 
The anti-inflammatory repertoire of HA included a significant reduction in mRNA 
levels of iNOS, MCP-1α and in the release of nitrite in LPS-stimulated BMDMs. HA 
pre-treatment of BMDMs failed to reduce mRNA levels of TNF-α or release of TNF-
α protein. Additionally, HA pre-treatment did not result in an increase in release of 
the anti-inflammatory cytokine IL-10 which has been reported in previous studies to 
be the effector molecule responsible for the heme oxygenase dependent anti-
inflammatory effect of hemin, carbon monoxide and biliverdin reductase in LPS 
stimulated macrophages (Ma et al., 2007, Otterbein et al., 2000, Wegiel et al., 2009). 
Hence, HA pre-treatment of BMDMs resulted in a selective anti-inflammatory effect 
in LPS-activated BMDMs. L-arginine (LA) when used at a concentration that was 
identical to the LA concentration in HA, did not mimic the anti-inflammatory 
phenotype of HA (Table 7.5) demonstrating that the heme component of HA was 
responsible for the anti-inflammatory effect in BMDMs.  
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A similar anti-inflammatory phenotype was observed with cobalt (III) 
protoporphyrin IX chloride (CoPP), a non-heme based modulator of HO activity 
(Table 7.5). This suggests that the anti-inflammatory properties may not be specific 
to heme but also apply to other protoporphyrins. 
 
Two HO activity inhibitors, stannous (IV) mesoporphyrin IX dichloride (SM) and 
chromium (III) mesoporphyrin IX chloride (CrMP), were employed in the in vitro 
studies to investigate whether abrogation of the increase in HO activity reversed the 
anti-inflammatory effect of HA and CoPP. Concurrent treatment with the HO 
activity inhibitors failed to reverse the reduction in nitrite release and mRNA levels 
of iNOS and MCP-1α achieved with HA or CoPP pre-treatment in LPS-activated 
BMDMs (Table 7.5). Hence, the anti-inflammatory effects of HA and CoPP were not 
due to an increase in HO activity.  
 
SM and CrMP are effective inhibitors of HO activity however they increase HO-1 
protein expression in BMDMs. Nuclear localization of HO-1 protein has been 
reported to promote anti-oxidative gene expression in vitro (Lin et al., 2007). 
Therefore to determine whether the anti-inflammatory phenotype of HA was 
dependent on HO-1 protein, BMDMs from Hmox1 knock-out mice were employed. 
The lack of a functional HO-protein accentuated the LPS mediated pro-inflammatory 
response as a significant increase in nitrite and TNF-α release was observed in LPS-
activated BMDMs from Hmox1 knock-out mice compared with wild type mice. 
However HA pre-treatment significantly reduced nitrite release in LPS- activated 
BMDMs from Hmox1 knock-out mice demonstrating that the anti-inflammatory 
effect of HA was independent of HO-1 protein and HO activity (Table 7.5).  
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The anti-inflammatory phenotype of HA and CoPP including a reduction in LPS-
induced expression of iNOS and MCP-1α but not TNF-α closely resembles the anti-
inflammatory effects of the peroxisome proliferator-activated receptor-γ (PPAR-γ) 
agonist ‘rosiglitazone’. Glass and co-workers have demonstrated that PPAR-γ 
agonists mediate transrepression of pro-inflammatory genes such as iNOS and MCP-
1α by targeting PPAR-γ to nuclear receptor co-repressor (NCoR) - histone 
deacetylase-3 (HDAC3) complexes on pro-inflammatory gene promoters (Huang et 
al., 2011, Pascual et al., 2005). Heme is a ligand of the nuclear receptor Rev-erb and 
has been reported to stabilize the interaction between Rev-erb and NCoR-HDAC3 
complexes at the promoter region of gluconeogenic genes including PEPCK and 
glucose-6-phosphatase to repress their expression (Yin et al., 2010, Yin et al., 2007).  
 
A role for heme, Rev-erb and NCoR-HDAC3 in regulating inflammatory response 
has not previously been investigated. In the current PhD project, this area was briefly 
examined by employing trichostatin A (TSA), an inhibitor for the class I and II 
mammalian HDAC family which includes HDAC3. The anti-inflammatory effects of 
HA and CoPP, including a reduction in mRNA levels of iNOS and MCP-1α in LPS-
activated BMDMs, was completely reversed by pre-treatment of BMDMs with TSA 
suggesting that the anti-inflammatory effect of HA and CoPP may be due to Rev-erb-
NCoR-HDAC3 mediated gene repression (Table 7.5). A recently published study has 
demonstrated that the Rev-erbα is vital for the circadian clock-dependent variation in 
gene expression of inflammatory mediators, including IL-6, Cxcl-1, CCL2/MCP-1α, 
but not TNF-α (Gibbs et al., 2012). Furthermore, treatment of the THP-1 human 
macrophage-like cell line with either hemin (natural ligand of Rev-erb) or GSK4112, 
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a synthetic agonist of Rev-erbα, significantly lowered the mRNA levels of IL-6 and 
MCP-1α (Gibbs et al., 2012). Therefore, the evaluation of the anti-inflammatory 
effects of HA and CoPP in Rev-erb knock-out macrophages would be an incisive 
approach to determine the role of interaction between protoporphyrins and Rev-erb 
to mediate anti-inflammatory effects. It’s worthwhile noting that the concept that it is 
the protoporphyrin structure rather than heme per se that acts as a ligand of Rev-erb 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.3.2. LIMITATIO&S OF THE STUDIES 
 
The key limitations of the in vitro studies in primary macrophages from C57BL/KsJ 
mice are mentioned below and should be addressed in future in vitro experiments. 
 
 Low sample size: The terminally differentiated primary macrophages, such as 
BMDMs and peritoneal macrophages are considered a better representation of 
the macrophage phenotype in vivo than macrophage-like cell lines. However, 
extensive studies with large sample sizes require the sacrifice of a large number 
of mice, which is best avoided if possible. The caveat of such an approach is to 
interpret the results based on non-parametric statistical tests which tend to be less 
powerful to rejection a null hypothesis. Therefore, it will be useful to generate a 
pro-inflammatory model using a murine macrophage-like cell line which mimics 
the classical activation of primary macrophages. 
 
 Exclusion of nitrate read-out: In the current PhD project, nitrite (NO2
-) (a stable 
metabolite of nitric oxide, NO) was used as a lone read-out to determine the 
effect of the modulators of HO activity on nitric oxide production in LPS-
stimulated BMDMs, while the release of nitrate (NO3
-) in LPS-stimulated 
BMDMs was not determined. This error resulted in the loss of a key read-out as 
the determination of peroxynitrite (ONOO-), an unstable structural isomer of 
nitrate (Pacher et al., 2007), would have helped to indicate whether HA and 
CoPP had anti-oxidative effects in LPS-stimulated BMDMs. The formation of 
peroxynitrite is largely responsible for mediating the cytotoxic effects of NO 
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(Boccini and Herold, 2004). Hence, the release of nitrite as well as nitrate should 
























7.3.3. FUTURE WORK 
 
The in vitro studies with modulators of HO activity in LPS-activated BMDMs have 
demonstrated a novel HO activity independent anti-inflammatory phenotype of 
protoporphyrin-based compounds, including HA and CoPP. Therefore, the re-defined 
hypotheses to determine the mode of action of HA and CoPP in LPS-stimulated 
BMDMs are listed below. 
 
 Hypothesis 1- Rev-erb-mediated recruitment of &CoR-HDAC co-repressor 
complex is responsible for the anti-inflammatory effects of HA and CoPP in 
LPS-activated BMDMs: The preliminary test with TSA has demonstrated that 
inhibition of histone deacetylase activity reverses the selective anti-inflammatory 
effects of HA and CoPP in LPS-activated BMDMs. In the light of the knowledge 
that LPS activation of macrophages releases the NCoR-HDAC co-repressor 
complex from the promoter region of the iNOS and MCP-1α genes, it is possible 
that HA and CoPP may exert their anti-inflammatory effects by stabilising the 
NCoR-HDAC co-repressor complex on the promoter region of iNOS (Pascual et 
al., 2005). Furthermore, interaction of Rev-erbα with it’s natural ligand, heme, 
has been reported to reduce expression of gluconeogenic genes in the hepatic 
(HepG2) cell line via stabilisation of the NCoR-HDAC co-repressor complex at 
the promoter region of PEPCK and glucose-6-phosphatase (Yin et al., 2007). 
Therefore, to test whether heme interaction with Rev-erb also facilitates 
recruitment of the NCoR-HDAC co-repressor complex at the promoter region of 
iNOS and MCP-1α to mediate anti-inflammatory effects of HA, isoforms of Rev-
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erb (α and β), NCoR and HDAC should be knocked down independently in 
primary macrophages to incisively determine the role of Rev-erb along with the 
NCoR-HDAC co-repressor complex in exerting the inflammatory effects of HA 
(Figure 7.3). To explore whether the protoporphyrin structure per se, shared by 
HA and CoPP, interacts with Rev-erb to facilitate repression of iNOS and MCP-
1α genes, the future experiments should include a protoporphyrin compound 
without a metal ion as a positive control, along with a heterocyclic compound 
such as corrin, which is similar but not identical to the porphyrin structure of 




Figure 7.3 Working hypothesis for HA facilitating Rev-erb-NCoR-HDAC3 mediated 
repression of the iNOS gene in BMDMs. A. It is known that LPS stimulation of 
macrophages releases the NCoR-HDAC3 complex from the promoter region of the 
iNOS gene (Pascual et al., 2005). B. Working hypothesis: HA represses iNOS gene 
expression by stabilising Rev-erb-NCoR-HDAC3 binding on the promoter region of iNOS 
gene thereby preventing its degradation in response to LPS. C. An incisive way to test 
the working hypothesis is to perform si-RNA knockdown of either Rev-erb or NCoR or 
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